

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

### **Bassam Abdulkarim**

1. Tsakiridis T, Pond GR, Wright J, Ellis PM, Ahmed N, **Abdulkarim B**, Roa W, Robinson A, Swaminath A, Okawara G, Wierzbicki M, Valdes M, Levine M. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. *JAMA Oncol.* 2021 Sep 1;7(9):1333-1341. doi: 10.1001/jamaoncol.2021.2328. PMID: 34323924; PMCID: PMC8323053.

### **Sharon Abish**

1. Jain A, Huang R, Lee J, Jawa N, Lim YJ, Guron M, **Abish S**, Boutros PC, Brudno M, Carleton B, Cuvelier GDE, Gunaratnam L, Ho C, Adeli K, Kuruvilla S, Lajoie G, Liu G, Nathan PC, Rod Rassekh S, Rieder M, Waikar SS, Welch SA, Weir MA, Winqvist E, Wishart DS, Zorzi AP, Blydt-Hansen T, Zappitelli M, Urquhart B. A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. *Can J Kidney Health Dis.* 2021 Nov 17;8:20543581211057708. doi: 10.1177/20543581211057708. PMID: 34820133; PMCID: PMC8606978.

### **Jason Agulnik**

1. Desilets A, Blanc-Durand F, Lau S, Hakozaiki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, **Agulnik J**, Cohen V, Charbonneau C, Marcoux N, Blais N, Leighl NB, Bradbury PA, Liu G, Shepherd FA, Bahig H, Routy B, Sacher A, Elkrief A. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer.* 2021 Jan;142:83-91. doi: 10.1016/j.ejca.2020.10.008. Epub 2020 Nov 24. PMID: 33242835.
2. Kasymjanova G, Anwar A, Cohen V, Sultanem K, Pepe C, Sakr L, Friedmann J, **Agulnik JS**. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. *Curr Oncol.* 2021 Oct 20;28(6):4247-4255. doi: 10.3390/curroncol28060360. PMID: 34898542; PMCID: PMC8544580.
3. **Agulnik JS**, Kasymjanova G, Pepe C, Hurry M, Walton RN, Sakr L, Cohen V, Small D. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. *Curr Oncol.* 2021 Dec 7;28(6):5179-5191. doi: 10.3390/curroncol28060434. PMID: 34940073; PMCID: PMC8700535.

### **Moulay Alaoui-Jamali**

1. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, **Alaoui-Jamali MA**, Alberti S, Alcocer-Gómez E, Alessandri C, et. al.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>. *Autophagy*. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8. PMID: 33634751; PMCID: PMC7996087.

2. de Lima JM, Castellano LRC, Bonan PRF, de Medeiros ES, Hier M, Bijian K, **Alaoui-Jamali MA**, da Cruz Perez DE, da Silva SD. Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation. *Int J Biochem Cell Biol*. 2021 May;134:105964. doi: 10.1016/j.biocel.2021.105964. Epub 2021 Mar 2. PMID: 33667680.
3. da Silva SD, Marchi FA, Su J, Yang L, Valverde L, Hier J, Bijian K, Hier M, Mlynarek A, Kowalski LP, **Alaoui-Jamali MA**. Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype. *Cancers (Basel)*. 2021 Jan 5;13(1):153. doi: 10.3390/cancers13010153. PMID: 33466385; PMCID: PMC7795342.
4. Hier J, Vachon O, Bernstein A, Ibrahim I, Mlynarek A, Hier M, **Alaoui-Jamali MA**, Maschietto M, da Silva SD. Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy. *Sci Rep*. 2021 May 11;11(1):10012. doi: 10.1038/s41598-021-89476-x. PMID: 33976322; PMCID: PMC8113272.

**Thierry Alcindor**

1. Gotfrit J, Goodwin R, Asmis T, Hyde AJ, **Alcindor T**, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, Thirlwell M, Valdes M, Welch S, Vickers M. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. *Curr Oncol*. 2021 May 26;28(3):1988-2006. doi: 10.3390/curroncol28030185. PMID: 34073199; PMCID: PMC8161825.
2. **Alcindor T**. Cancer and Neurofibromatosis Type 1-Confirming What We Knew and Telling Us Something New. *JAMA Netw Open*. 2021 Mar 1;4(3):e211061. doi: 10.1001/jamanetworkopen.2021.1061. PMID: 33734408.
3. **Alcindor T**, Dumitra S, Albritton K, Thomas DM. Disparities in Cancer Care: The Example of Sarcoma-In Search of Solutions for a Global Issue. *Am Soc Clin Oncol Educ Book*. 2021 Mar;41:1-7. doi: 10.1200/EDBK\_320463. PMID: 33770458.
4. Elkrief A, Kazandjian S, **Alcindor T**. Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series. *Curr Oncol*. 2021 Feb 5;28(1):813-817. doi: 10.3390/curroncol28010078. PMID: 33562486; PMCID: PMC7985763.
5. Hassani M, Jung S, Garzia L, Ghodsi E, **Alcindor T**, Turcotte RE. Aggressive Behavior Predictors in Solitary Fibrous Tumor: Demographic, Clinical, and Histopathologic Characteristics of 81 Cases. *Ann Surg Oncol*. 2021 Oct;28(11):6861-6867. doi: 10.1245/s10434-021-09592-w. Epub 2021 Jan 29. PMID: 33512676.
6. **Alcindor T**, Jung S, Gilbert L. Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report. *Curr Oncol*. 2021 Jun 10;28(3):2146-2149. doi: 10.3390/curroncol28030199. PMID: 34200874; PMCID: PMC8293099.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

7. Elkrief A, Redstone G, Petruccelli L, Ali A, Thomas D, Fernandez M, Rousseau C, Aleynikova O, Anderson D, Ghitulescu G, Vasilevsky CA, Dalfen R, Langleben A, Liberman S, Kavan P, **Alcindor T**. Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. *BMJ Open Qual.* 2021 Mar;10(1):e000934. doi: 10.1136/bmjopen-2020-000934. PMID: 33685857; PMCID: PMC7942255.
8. Van De Sande M, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, Stacchiotti S, Desai J, Wagner AJ, **Alcindor T**, Ganjoo K, Martín-Broto J, Wang Q, Shuster D, Gelderblom H, Healey JH. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. *Acta Orthop.* 2021 Aug;92(4):493-499. doi: 10.1080/17453674.2021.1922161. Epub 2021 May 12. PMID: 33977825; PMCID: PMC8382018.

**Joanne Alfieri**

1. Kang S, Caissie A, Kassam Z, Ingledeu PA, **Alfieri J**, Parliament M, Bezjak A, Giuliani M. In Reply to Wang and Rallis. *Int J Radiat Oncol Biol Phys.* 2021 Jan 1;109(1):299-300. doi: 10.1016/j.ijrobp.2020.08.052. PMID: 33308697.
2. Gerard IJ, Bernier M, Hijal T, Kopek N, Pater P, Stosky J, Stroian G, Toscani B, **Alfieri J**. Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experiences. *Adv Radiat Oncol.* 2021 Apr 20;6(4):100702. doi: 10.1016/j.adro.2021.100702. PMID: 34095614; PMCID: PMC8165547.
3. Di Lalla V, Patrick H, Siriani-Ayoub N, Kildea J, Hijal T, **Alfieri J**. Satisfaction among Cancer Patients Undergoing Radiotherapy during the COVID-19 Pandemic: An Institutional Experience. *Curr Oncol.* 2021 Apr 10;28(2):1507-1517. doi: 10.3390/currenocol28020142. PMID: 33920247; PMCID: PMC8167586.
4. Da-Ano R, Lucia F, Masson I, Abgral R, **Alfieri J**, Rousseau C, Mervoyer A, Reinhold C, Pradier O, Schick U, Visvikis D, Hatt M. A transfer learning approach to facilitate ComBat-based harmonization of multicentre radiomic features in new datasets. *PLoS One.* 2021 Jul 1;16(7):e0253653. doi: 10.1371/journal.pone.0253653. PMID: 34197503; PMCID: PMC8248970.
5. Iantsen A, Ferreira M, Lucia F, Jaouen V, Reinhold C, Bonaffini P, **Alfieri J**, Rovira R, Masson I, Robin P, Mervoyer A, Rousseau C, Kridelka F, Decuypere M, Lovinfosse P, Pradier O, Hustinx R, Schick U, Visvikis D, Hatt M. Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting. *Eur J Nucl Med Mol Imaging.* 2021 Oct;48(11):3444-3456. doi: 10.1007/s00259-021-05244-z. Epub 2021 Mar 27. PMID: 33772335; PMCID: PMC8440243.

**Dawn Anderson**

1. Elkrief A, Redstone G, Petruccelli L, Ali A, Thomas D, Fernandez M, Rousseau C, Aleynikova O, **Anderson D**, Ghitulescu G, Vasilevsky CA, Dalfen R, Langleben A, Liberman S, Kavan P, Alcindor T. Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. *BMJ Open Qual.* 2021 Mar;10(1):e000934. doi: 10.1136/bmjopen-2020-000934. PMID: 33685857; PMCID: PMC7942255.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Armen Aprikian**

1. Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, **Aprikian A**, Rendon RA. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. *Can Urol Assoc J.* 2021 Jun;15(6):E307-E322. doi: 10.5489/cuaj.7355. Erratum in: *Can Urol Assoc J.* 2021 Jul;15(7):E383. PMID: 34127184; PMCID: PMC8195588.
2. Bhindi B, Kool R, Kulkarni GS, Siemens DR, **Aprikian AG**, Breau RH, Brimo F, Fairey A, French C, Hanna N, Izawa JI, Lacombe L, McPherson V, Rendon RA, Shayegan B, So AI, Zlotta AR, Black PC, Kassouf W. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. *Can Urol Assoc J.* 2021 Aug;15(8):E424-E460. doi: 10.5489/cuaj.7367. PMID: 33938798; PMCID: PMC8418246.
3. Bhindi B, Kool R, Kulkarni GS, Siemens DR, **Aprikian AG**, Breau RH, Brimo F, Fairey A, French C, Hanna N, Izawa JI, Lacombe L, McPherson V, Rendon RA, Shayegan B, So AI, Zlotta AR, Black PC, Kassouf W. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version. *Can Urol Assoc J.* 2021 Aug;15(8):230-239. doi: 10.5489/cuaj.7487. PMID: 35099374; PMCID: PMC8418252.
4. Emond JP, Lacombe L, Caron P, Turcotte V, Simonyan D, **Aprikian A**, Saad F, Carmel M, Chevalier S, Guillemette C, Lévesque E. Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. *Br J Cancer.* 2021 Jul;125(1):78-84. doi: 10.1038/s41416-021-01376-z. Epub 2021 Apr 7. PMID: 33828256; PMCID: PMC8257651.
5. Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, **Aprikian A**, Rendon RA. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary. *Can Urol Assoc J.* 2021 Jun;15(6):159-161. doi: 10.5489/cuaj.7357. PMID: 34127181; PMCID: PMC8195584.
6. Saad F, **Aprikian A**, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J.* 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074. Erratum in: *Can Urol Assoc J.* 2021 May;15(5):E304. PMID: 33556313; PMCID: PMC7864710.
7. Minnella EM, Awasthi R, Bousquet-Dion G, Ferreira V, Austin B, Audi C, Tanguay S, **Aprikian A**, Carli F, Kassouf W. Multimodal Prehabilitation to Enhance Functional Capacity Following Radical Cystectomy: A Randomized Controlled Trial. *Eur Urol Focus.* 2021 Jan;7(1):132-138. doi: 10.1016/j.euf.2019.05.016. Epub 2019 Jun 8. PMID: 31186173.
8. Marcq G, Souhami L, Cury FL, Salimi A, **Aprikian A**, Tanguay S, Vanhuysse M, Rajan R, Brimo F, Mansure JJ, Kassouf W. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. *Int J Radiat Oncol Biol Phys.* 2021 Jul 1;110(3):738-741. doi: 10.1016/j.ijrobp.2020.12.033. Epub 2021 Jan 6. PMID: 33421558.
9. Kool R, Marcq G, El-Achkar A, Mansure JJ, Vanhuysse M, **Aprikian A**, Tanguay S, Cury FL, Brimo F, Souhami L, Kassouf W. Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- necessary? Urol Oncol. 2021 May;39(5):299.e7-299.e14. doi: 10.1016/j.urolonc.2020.10.001. Epub 2020 Oct 23. PMID: 33283758.
10. Wissing MD, O'Flaherty A, Dragomir A, Tanguay S, Kassouf W, **Aprikian AG**. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada. Clin Genitourin Cancer. 2021 Aug;19(4):371-371.e9. doi: 10.1016/j.clgc.2021.01.007. Epub 2021 Feb 6. PMID: 33676834.
  11. Khriguian J, Patrocinio H, Andonian S, **Aprikian A**, Kassouf W, Tanguay S, Cury FL. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. Pract Radiat Oncol. 2022 Jan-Feb;12(1):e34-e39. doi: 10.1016/j.prro.2021.07.006. Epub 2021 Sep 13. PMID: 34530170.
  12. Hu J, **Aprikian AG**, Vanhuyse M, Dragomir A. Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. Clin Genitourin Cancer. 2022 Feb;20(1):17-24. doi: 10.1016/j.clgc.2021.08.009. Epub 2021 Sep 15. PMID: 34706850.
  13. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, Rajan R, **Aprikian A**, Tanguay S, Cury FL, Brimo F, Souhami L, Kassouf W. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. Eur Urol Open Sci. 2021 Dec 23;36:26-33. doi: 10.1016/j.euros.2021.11.011. PMID: 35098169; PMCID: PMC8783035.

**Robert Archambault**

1. Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, Bahoric B, **Archambault R**, Vincent F, Bettahar R, Wilke D, Souhami L. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):732-740. doi: 10.1016/j.ijrobp.2021.04.013. Epub 2021 Apr 24. PMID: 33901566.
2. Khriguian J, Tsui JMG, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, **Archambault R**, Villeneuve H, Mohiuddin M, Niazi T. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. J Urol. 2021 Jun;205(6):1648-1654. doi: 10.1097/JU.0000000000001646. Epub 2021 Feb 12. PMID: 33577365.
3. Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, Bahoric B, **Archambault R**, Vincent F, Bettahar R, Wilke D, Souhami L. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. Eur J Cancer. 2021 Jan;143:64-74. doi: 10.1016/j.ejca.2020.10.023. Epub 2020 Dec 3. PMID: 33279855.

**Krum Asiev**

1. Lecavalier-Barsoum M, Khosrow-Khavar F, **Asiev K**, Popovic M, Vuong T, Enger SA. Utilization of brachytherapy in Quebec, Canada. Brachytherapy. 2021 Nov-Dec;20(6):1282-1288. doi: 10.1016/j.brachy.2021.07.002. Epub 2021 Aug 20. PMID: 34420860.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Jamil Asselah**

1. Chu D, Schuster T, Lessard D, Mate K, Engler K, Ma Y, Abulkhir A, Arora A, Long S, de Pokomandy A, Lacombe K, Rougier H, Cox J, Kronfli N, Hijal T, Kildea J, Routy JP, **Asselah J**, Lebouché B. Acceptability of a Patient Portal (Opal) in HIV Clinical Care: A Feasibility Study. *J Pers Med*. 2021 Feb 16;11(2):134. doi: 10.3390/jpm11020134. PMID: 33669439; PMCID: PMC7920437.
2. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, **Asselah J**, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet*. 2021 Sep 23;jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print. PMID: 34556502.

**Laurent Azoulay**

1. Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, **Azoulay L**. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. *Gut*. 2022 Jan;71(1):16-24. doi: 10.1136/gutjnl-2021-325097. Epub 2021 Jul 5. PMID: 34226290.
2. Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, **Azoulay L**. Proton pump inhibitors and risk of colorectal cancer. *Gut*. 2022 Jan;71(1):111-118. doi: 10.1136/gutjnl-2021-325096. Epub 2021 Jul 1. PMID: 34210775.
3. Suissa K, Schneeweiss S, Douros A, Filion KB, Yin H, Paterno E, **Azoulay L**. The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. *Diabetes Obes Metab*. 2021 Nov;23(11):2502-2512. doi: 10.1111/dom.14494. Epub 2021 Aug 3. PMID: 34251086.
4. Abrahami D, McDonald EG, Schnitzer M, **Azoulay L**. Trends in prescribing patterns of proton pump inhibitors surrounding new guidelines. *Ann Epidemiol*. 2021 Mar;55:24-26. doi: 10.1016/j.annepidem.2020.12.002. Epub 2020 Dec 16. PMID: 33338647.
5. Douros A, Santella C, Dell'Aniello S, **Azoulay L**, Renoux C, Suissa S, Brassard P. Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study. *J Alzheimers Dis*. 2021;81(1):329-338. doi: 10.3233/JAD-201534. PMID: 33780369.
6. Rouette J, Yin H, Pottegård A, Nirantharakumar K, **Azoulay L**. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. *Drug Saf*. 2021 Feb;44(2):245-254. doi: 10.1007/s40264-020-01015-1. Epub 2020 Oct 26. PMID: 33104975.
7. **Azoulay L**. Elucidating the association between antihypertensive drugs and cancer: a need for real-world studies. *Lancet Oncol*. 2021 Apr;22(4):421-422. doi: 10.1016/S1470-2045(21)00085-1. PMID: 33794202.
8. Cragg JJ, **Azoulay L**, Collins G, De Vera MA, Etminan M, Lalji F, Gershon AS, Guyatt G, Harrison M, Jutzeler C, Kassam R, Kendzerska T, Lynd L, Mansournia MA, Sadatsafavi M, Tong B, Warner FM, Tremlett H. The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. *Expert Opin Drug Saf*. 2021 Jan;20(1):1-8. doi: 10.1080/14740338.2021.1849134. Epub 2020 Dec 21. PMID: 33170749.
9. Rouette J, Elfassy N, Bouganim N, Yin H, Lasry N, **Azoulay L**. Evaluation of the quality of mammographic breast positioning: a quality improvement study. *CMAJ Open*. 2021 Jun

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 4;9(2):E607-E612. doi: 10.9778/cmajo.20200211. PMID: 34088731; PMCID: PMC8191588.
10. Renoux C, **Azoulay L**, Suissa S. Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. *Am J Epidemiol*. 2021 Aug 1;190(8):1452-1456. doi: 10.1093/aje/kwab028. PMID: 33564823; PMCID: PMC7929453.
  11. Kristensen KB, Hicks B, **Azoulay L**, Pottegård A. Use of ACE (Angiotensin-Converting Enzyme) Inhibitors and Risk of Lung Cancer: A Nationwide Nested Case-Control Study. *Circ Cardiovasc Qual Outcomes*. 2021 Jan;14(1):e006687. doi: 10.1161/CIRCOUTCOMES.120.006687. Epub 2021 Jan 13. PMID: 33435729.
  12. Brunetti VC, Reynier P, **Azoulay L**, Yu OHY, Ernst P, Platt RW, Filion KB. SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study. *Pharmacoepidemiol Drug Saf*. 2021 Jun;30(6):740-748. doi: 10.1002/pds.5192. Epub 2021 Jan 25. PMID: 33428309.
  13. Cao TXD, Fraga LFC, Fergusson E, Michaud J, Dell'Aniello S, Yin H, Rej S, **Azoulay L**, Renoux C. Prescribing Trends of Antidepressants and Psychotropic Coprescription for Youths in UK Primary Care, 2000-2018. *J Affect Disord*. 2021 May 15;287:19-25. doi: 10.1016/j.jad.2021.03.022. Epub 2021 Mar 11. PMID: 33765538.
  14. Douros A, Filliter C, **Azoulay L**, Tagalakis V. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. *Thromb Res*. 2021 Jun;202:128-133. doi: 10.1016/j.thromres.2021.03.026. Epub 2021 Mar 29. PMID: 33836492.
  15. Suissa M, Yin H, Yu OHY, Wong SM, **Azoulay L**. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes. *Diabetes Care*. 2021 Jan;44(1):e9-e11. doi: 10.2337/dc20-1073. Epub 2020 Nov 6. PMID: 33158946.
  16. Abrahami D, **Azoulay L**. Response by Abrahami et al to letter regarding article 'Proton pump inhibitors and risk of colorectal cancer'. *Gut*. 2021 Dec 2;gutjnl-2021-326544. doi: 10.1136/gutjnl-2021-326544. Epub ahead of print. PMID: 34857614.
  17. Ayele HT, Reynier P, **Azoulay L**, Platt RW, Cabaussel J, Benayoun S, Filion KB. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. *World J Urol*. 2021 Jun;39(6):2019-2028. doi: 10.1007/s00345-020-03429-z. Epub 2020 Sep 9. PMID: 32909173.
  18. Kumarendran B, O'Reilly MW, Subramanian A, Šumilo D, Toulis K, Gokhale KM, Wijeratne CN, Coomarasamy A, Tahrani AA, **Azoulay L**, Arlt W, Nirantharakumar K. Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study. *Diabetes Care*. 2021 Dec;44(12):2758-2766. doi: 10.2337/dc21-0437. Epub 2021 Oct 14. PMID: 34649997; PMCID: PMC8669537.
  19. Garant A, Kavan P, Martin AG, **Azoulay L**, Vendrely V, Lavoie C, Vasilevsky CA, Boutros M, Faria J, Nguyen TN, Ferland E, Des Groseilliers S, Cloutier AS, Diec H, Drolet S, Richard C, Batist G, Vuong T. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. *Radiother Oncol*. 2021 Feb;155:237-245. doi: 10.1016/j.radonc.2020.11.008. Epub 2020 Nov 19. PMID: 33220397.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

20. Abrahami D, Pradhan R, Yin H, Honig P, Baumfeld Andre E, **Azoulay L**. Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment. *Clin Pharmacol Ther*. 2021 Feb;109(2):452-461. doi: 10.1002/cpt.2012. Epub 2020 Sep 19. PMID: 32767673.
21. Pradhan R, Abrahami D, Yin H, Yu OHY, Sahasrabudhe V, Baumfeld Andre E, **Azoulay L**. Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials. *Clin Pharmacol Ther*. 2021 May;109(5):1219-1223. doi: 10.1002/cpt.2213. Epub 2021 Mar 16. PMID: 33615445.
22. Mah J, Lieu A, Palayew M, Alipour P, Kong LY, Song S, Palayew A, Tutt-Gu ette MA, Yang SS, Wilchesky M, Lipes J, **Azoulay L**, Greenaway C. Comparison of hospitalized patients with COVID-19 who did and did not live in residential care facilities in Montr al: a retrospective case series. *CMAJ Open*. 2021 Jul 13;9(3):E718-E727. doi: 10.9778/cmajo.20200244. PMID: 34257090; PMCID: PMC8313094.
23. Greenaway C, Greenwald ZR, Akaberi A, Song S, Passos-Castilho AM, Abou Chakra CN, Palayew A, Alabdulkarim B, Platt R, **Azoulay L**, Brisson M, Quach C. Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study. *Lancet Infect Dis*. 2021 Jan;21(1):116-126. doi: 10.1016/S1473-3099(20)30277-2. Epub 2020 Jul 23. PMID: 32711690.
24. Eberle A, Czuzoj-Shulman N, **Azoulay L**, Abenhaim HA. Induction of labor at 39 weeks and risk of cesarean delivery among obese women: a retrospective propensity score matched study. *J Perinat Med*. 2021 Feb 25;49(7):791-796. doi: 10.1515/jpm-2021-0043. PMID: 33650388.
25. Yap TA, Jacobs I, Baumfeld Andre E, Lee LJ, Beaupre D, **Azoulay L**. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. *Front Oncol*. 2022 Jan 6;11:695936. doi: 10.3389/fonc.2021.695936. PMID: 35070951; PMCID: PMC8771908.
26. Rouette J, Yin H, McDonald EG, Barkun A, **Azoulay L**. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. *Drug Saf*. 2022 Jan;45(1):65-74. doi: 10.1007/s40264-021-01128-1. Epub 2021 Oct 29. PMID: 34714528.
27. Kuramoto LK, Sobolev BG, Rosner J, Brasher PMA, **Azoulay L**, Cragg JJ. A systematic, concept-based method of developing the exposure measure for drug safety and effectiveness studies. *Pharmacoepidemiol Drug Saf*. 2022 Jan;31(1):13-21. doi: 10.1002/pds.5372. Epub 2021 Oct 29. PMID: 34657356.
28. Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, **Azoulay L**. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. *Clin Pharmacol Ther*. 2022 Jan;111(1):272-282. doi: 10.1002/cpt.2430. Epub 2021 Oct 16. PMID: 34587280.
29. Ou LB, **Azoulay L**, Reynier P, Platt RW, Yoon S, Grad R, Filion KB. Tramadol versus codeine and the short-term risk of cardiovascular events in patients with non-cancer pain: A population-based cohort study. *Br J Clin Pharmacol*. 2022 Feb;88(4):1824-1834. doi: 10.1111/bcp.15099. Epub 2021 Nov 13. PMID: 34599613.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Melissa Azoulay**

1. Rais F, Tsui JMG, Daianska A, Faye MD, Lambert C, David M, Panet-Raymond V, **Azoulay M**, Saidi A, Hijal T. Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. *Radiother Oncol.* 2021 Sep;162:156-161. doi: 10.1016/j.radonc.2021.07.008. Epub 2021 Jul 15. PMID: 34273468.

**Boris Bahoric**

1. Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, **Bahoric B**, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. *Eur J Cancer.* 2021 Jan;143:64-74. doi: 10.1016/j.ejca.2020.10.023. Epub 2020 Dec 3. PMID: 33279855.
2. Chaddad A, Kucharczyk MJ, Cheddad A, Clarke SE, Hassan L, Ding S, Rathore S, Zhang M, Katib Y, **Bahoric B**, Abikhzer G, Probst S, Niazi T. Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. *Cancers (Basel).* 2021 Feb 1;13(3):552. doi: 10.3390/cancers13030552. PMID: 33535569; PMCID: PMC7867056.
3. Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, **Bahoric B**, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. *Int J Radiat Oncol Biol Phys.* 2021 Nov 1;111(3):732-740. doi: 10.1016/j.ijrobp.2021.04.013. Epub 2021 Apr 24. PMID: 33901566.
4. Khriguian J, Tsui JMG, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, **Bahoric B**, Archambault R, Villeneuve H, Mohiuddin M, Niazi T. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. *J Urol.* 2021 Jun;205(6):1648-1654. doi: 10.1097/JU.0000000000001646. Epub 2021 Feb 12. PMID: 33577365.

**Mark Basik**

1. Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, Ahn R, Lewis K, Lebeau B, La Selva R, Sabourin V, Martínez C, Savage P, Kuasne H, Avizonis D, Santos Martínez N, Chabot C, Aguilar-Mahecha A, Goulet ML, Dankner M, Witcher M, Petrecca K, **Basik M**, Pollak M, Topisirovic I, Lin R, Siegel PM, Kleinman CL, Park M, St-Pierre J, Ursini-Siegel J. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. *Nat Commun.* 2021 Jun 3;12(1):3299. doi: 10.1038/s41467-021-23396-2. PMID: 34083537; PMCID: PMC8175605.
2. Wong SM, **Basik M**, Florianova L, Margolese R, Dumitra S, Muanza T, Carbonneau A, Ferrario C, Boileau JF. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol.* 2021 May;28(5):2621-2629. doi: 10.1245/s10434-020-09211-0. Epub 2020 Oct 23. PMID: 33095362.
3. Tejera D, Rana M, **Basik M**, Boileau JF, Margolese R, Prakash I, Meguerditchian AN, Muanza T, Monette J, Wong SM. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat.* 2021 Dec;190(3):491-501. doi: 10.1007/s10549-021-06393-3. Epub 2021 Sep 20. PMID: 34542772.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

4. Guo Q, Bartish M, Gonçalves C, Huang F, Smith-Voudouris J, Krisna SS, Preston SEJ, Emond A, Li VZ, Duerr CU, Gui Y, Cleret-Buhot A, Thebault P, Lefrère H, Lenaerts L, Plourde D, Su J, Mindt BC, Hewgill SA, Cotechini T, Hindmarch CCT, Yang W, Khoury E, Zhan Y, Narykina V, Wei Y, Floris G, **Basik M**, Amant F, Quail DF, Lapointe R, Fritz JH, Del Rincon SV, Miller WH Jr. The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. *Cancer Res.* 2021 Jul 15;81(14):3876-3889. doi: 10.1158/0008-5472.CAN-20-3143. Epub 2021 May 11. PMID: 33975880.
5. Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc A, Mohammed Y, Buchanan M, Aguilar-Mahecha A, Pötz O, Chen MX, Spatz A, **Basik M**, Batist G, Zahedi RP, Borchers CH. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 $\alpha$  in cell lines and tumor tissues. *Analyst.* 2021 Oct 25;146(21):6566-6575. doi: 10.1039/d1an00165e. PMID: 34585690.
6. Aguilar-Mahecha A, Lafleur J, Brousse S, Savichtcheva O, Holden KA, Faulkner N, McLennan G, Jensen TJ, **Basik M**. Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients. *Cancers (Basel).* 2021 Mar 16;13(6):1331. doi: 10.3390/cancers13061331. PMID: 33809567; PMCID: PMC7999382.
7. Ibrahim S, Lan C, Chabot C, Mitsa G, Buchanan M, Aguilar-Mahecha A, Elchebly M, Poetz O, Spatz A, **Basik M**, Batist G, Zahedi RP, Borchers CH. Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. *Anal Chem.* 2021 Aug 10;93(31):10816-10824. doi: 10.1021/acs.analchem.1c00975. Epub 2021 Jul 29. PMID: 34324311.
8. Gharzai LA, Szczygiel LA, Shumway DA, Bandos H, Julian TB, Mamounas EP, White J, De Los Santos JF, **Basik M**, Ganz PA, Jagsi R. A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006). *Breast Cancer Res Treat.* 2021 Jun;187(3):777-784. doi: 10.1007/s10549-021-06172-0. Epub 2021 Mar 19. PMID: 33740205; PMCID: PMC8648089.
9. Cambrosio A, Campbell J, Keating P, Polk JB, Aguilar-Mahecha A, **Basik M**. Healthcare policy by other means: Cancer clinical research as "oncopolity". *Soc Sci Med.* 2022 Jan;292:114576. doi: 10.1016/j.socscimed.2021.114576. Epub 2021 Nov 18. PMID: 34826765.
10. Wong SM, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, Pollak MN, **Basik M**. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer.* 2022 Apr 1;128(7):1365-1372. doi: 10.1002/cncr.34065. Epub 2021 Dec 17. PMID: 34919263.

**Gerald Batist**

1. Sundquist S, **Batist G**, Brodeur-Robb K, Dyck K, Eigl BJ, Lee DK, Limoges J, Longstaff H, Pankovich J, Sadura A, Sullivan P, Dancey JE. CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada. *Curr Oncol.* 2021 Sep 30;28(5):3857-3865. doi: 10.3390/currncol28050329. PMID: 34677247; PMCID: PMC8534531.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Khare SR, Madathil SA, **Batist G**, Peter Brojde Lung Cancer Group, Vedel I. Lung Cancer Pre-Diagnostic Pathways from First Presentation to Specialist Referral. *Curr Oncol*. 2021 Jan 11;28(1):378-389. doi: 10.3390/currenol28010040. PMID: 33440696; PMCID: PMC7903286.
3. Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc A, Mohammed Y, Buchanan M, Aguilar-Mahecha A, Pötz O, Chen MX, Spatz A, Basik M, **Batist G**, Zahedi RP, Borchers CH. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 $\alpha$  in cell lines and tumor tissues. *Analyst*. 2021 Oct 25;146(21):6566-6575. doi: 10.1039/d1an00165e. PMID: 34585690.
4. Ibrahim S, Lan C, Chabot C, Mitsa G, Buchanan M, Aguilar-Mahecha A, Elchebly M, Poetz O, Spatz A, Basik M, **Batist G**, Zahedi RP, Borchers CH. Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. *Anal Chem*. 2021 Aug 10;93(31):10816-10824. doi: 10.1021/acs.analchem.1c00975. Epub 2021 Jul 29. PMID: 34324311.
5. Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, Vasilevsky CA, Boutros M, Faria J, Nguyen TN, Ferland E, Des Groseilliers S, Cloutier AS, Diec H, Drolet S, Richard C, **Batist G**, Vuong T. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. *Radiother Oncol*. 2021 Feb;155:237-245. doi: 10.1016/j.radonc.2020.11.008. Epub 2020 Nov 19. PMID: 33220397.
6. Gottlieb B, Trifiro M, **Batist G**. Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment. *Trends Cancer*. 2021 May;7(5):400-409. doi: 10.1016/j.trecan.2020.10.013. Epub 2020 Nov 23. PMID: 33243702.
7. Smyth LM, **Batist G**, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. *NPJ Breast Cancer*. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7. PMID: 33863913; PMCID: PMC8052445.
8. Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, Srivastava A, Hébert S, Samson B, Lespérance B, Ko YJ, Dalfen R, St-Hilaire E, Sideris L, Couture F, Burkes R, Harb M, Camlioglu E, Gologan A, Pelsser V, Constantin A, Greenwood CMT, Tejpar S, Kavan P, Kleinman CL, **Batist G**. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. *Clin Transl Med*. 2021 Apr;11(4):e401. doi: 10.1002/ctm2.401. PMID: 33931971; PMCID: PMC8087915.
9. Nagi K, Gupta I, Jurdi N, Jabeen A, Yasmeen A, **Batist G**, Vranic S, Al-Moustafa AE. High-risk human papillomaviruses and Epstein-Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study. *Cancer Cell Int*. 2021 Jun 10;21(1):308. doi: 10.1186/s12935-021-02009-4. PMID: 34112166; PMCID: PMC8194154.
10. Chu QS, Bouganim N, Fortier C, Zaknoen S, Stille JR, Kremer JD, Yuen E, Hui YH, de la Peña A, Lithio A, Smith PS, **Batist G**. Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

- tumors. *Invest New Drugs*. 2021 Aug;39(4):1001-1010. doi: 10.1007/s10637-020-01049-3. Epub 2021 Jan 22. PMID: 33479856.
11. Nagi K, Gupta I, Jurdi N, Yasmeen A, Vranic S, **Batist G**, Moustafa AA. Copresence of High-Risk Human Papillomaviruses and Epstein-Barr Virus in Colorectal Cancer: A Tissue Microarray and Molecular Study from Lebanon. *Int J Mol Sci*. 2021 Jul 29;22(15):8118. doi: 10.3390/ijms22158118. PMID: 34360884; PMCID: PMC8347509.
  12. Liu X, Maleki F, Muthukrishnan N, Ovens K, Huang SH, Pérez-Lara A, Romero-Sanchez G, Bhatnagar SR, Chatterjee A, Pusztaszeri MP, Spatz A, **Batist G**, Payabvash S, Haider SP, Mahajan A, Reinhold C, Forghani B, O'Sullivan B, Yu E, Forghani R. Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. *Cancers (Basel)*. 2021 Jul 24;13(15):3723. doi: 10.3390/cancers13153723. PMID: 34359623; PMCID: PMC8345201.
  13. Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, **Batist G**, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. *NPJ Precis Oncol*. 2021 Apr 28;5(1):33. doi: 10.1038/s41698-021-00171-6. PMID: 33911192; PMCID: PMC8080819.

### Christoph Borchers

1. Petrotchenko EV, **Borchers CH**. Protein Chemistry Combined with Mass Spectrometry for Protein Structure Determination. *Chem Rev*. 2021 Dec 30. doi: 10.1021/acs.chemrev.1c00302. Epub ahead of print. PMID: 34968047.
2. Gaspar VP, Ibrahim S, Zahedi RP, **Borchers CH**. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine. *J Mass Spectrom*. 2021 Nov;56(11):e4788. doi: 10.1002/jms.4788. Epub 2021 Nov 4. PMID: 34738286; PMCID: PMC8597589.
3. Bhowmick P, Roome S, **Borchers CH**, Goodlett DR, Mohammed Y. An Update on MRMAssayDB: A Comprehensive Resource for Targeted Proteomics Assays in the Community. *J Proteome Res*. 2021 Apr 2;20(4):2105-2115. doi: 10.1021/acs.jproteome.0c00961. Epub 2021 Mar 8. PMID: 33683131; PMCID: PMC8041396.
4. Percy AJ, **Borchers CH**. Detailed Method for Performing the ExSTA Approach in Quantitative Bottom-Up Plasma Proteomics. *Methods Mol Biol*. 2021;2228:353-384. doi: 10.1007/978-1-0716-1024-4\_25. PMID: 33950503.
5. Michaud SA, Pětrošová H, Jackson AM, McGuire JC, Sinclair NJ, Ganguly M, Flenniken AM, Nutter LMJ, McKerlie C, Schibli D, Smith D, **Borchers CH**. Process and Workflow for Preparation of Disparate Mouse Tissues for Proteomic Analysis. *J Proteome Res*. 2021 Jan 1;20(1):305-316. doi: 10.1021/acs.jproteome.0c00399. Epub 2020 Nov 5. PMID: 33151080.
6. Laselva O, Qureshi Z, Zeng ZW, Petrotchenko EV, Ramjeesingh M, Hamilton CM, Huan LJ, **Borchers CH**, Pomès R, Young R, Bear CE. Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator. *iScience*. 2021 May 15;24(6):102542. doi: 10.1016/j.isci.2021.102542. PMID: 34142049; PMCID: PMC8184517.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

7. Mohammed Y, Michaud SA, Pětrošová H, Yang J, Ganguly M, Schibli D, Flenniken AM, Nutter LMJ, Adissu HA, Lloyd KCK, McKerlie C, **Borchers CH**. Proteotyping of knockout mouse strains reveals sex- and strain-specific signatures in blood plasma. *NPJ Syst Biol Appl*. 2021 May 28;7(1):25. doi: 10.1038/s41540-021-00184-8. PMID: 34050187; PMCID: PMC8163790.
8. Serpa JJ, Popov KI, Petrotchenko EV, Dokholyan NV, **Borchers CH**. Structure of prion  $\beta$ -oligomers as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations. *Proteomics*. 2021 Nov;21(21-22):e2000298. doi: 10.1002/pmic.202000298. Epub 2021 Sep 16. PMID: 34482645.
9. Tran JN, Günther OP, Sherwood KR, Fenninger F, Allan LL, Lan J, Sapir-Pichhadze R, Duquesnoy R, Claas F, Marsh SGE, McMaster WR, Keown PA; **Genome Canada Transplant Consortium**. High-throughput sequencing defines donor and recipient HLA B-cell epitope frequencies for prospective matching in transplantation. *Commun Biol*. 2021 May 14;4(1):583. doi: 10.1038/s42003-021-01989-3. PMID: 33990681; PMCID: PMC8121953.
10. Shahid I, Han J, Hardie D, Baig DN, Malik KA, **Borchers CH**, Mehnaz S. Profiling of antimicrobial metabolites of plant growth promoting *Pseudomonas* spp. isolated from different plant hosts. *3 Biotech*. 2021 Feb;11(2):48. doi: 10.1007/s13205-020-02585-8. Epub 2021 Jan 11. PMID: 33489669; PMCID: PMC7801537.
11. Mohammed Y, Bhowmick P, Michaud SA, Sickmann A, **Borchers CH**. Mouse Quantitative Proteomics Knowledgebase: reference protein concentration ranges in 20 mouse tissues using 5000 quantitative proteomics assays. *Bioinformatics*. 2021 Jan 23:btab018. doi: 10.1093/bioinformatics/btab018. Epub ahead of print. PMID: 33483739.
12. Gaither C, Popp R, Borchers SP, Skarphedinsson K, Eiriksson FF, Thorsteinsdóttir M, Mohammed Y, **Borchers CH**. Performance Assessment of a 125 Human Plasma Peptide Mixture Stored at Room Temperature for Multiple Reaction Monitoring-Mass Spectrometry. *J Proteome Res*. 2021 Sep 3;20(9):4292-4302. doi: 10.1021/acs.jproteome.1c00249. Epub 2021 Jul 16. PMID: 34270269.
13. Li FKK, Gale RT, Petrotchenko EV, **Borchers CH**, Brown ED, Strynadka NCJ. Crystallographic analysis of TarI and TarJ, a cytidyltransferase and reductase pair for CDP-ribitol synthesis in *Staphylococcus aureus* wall teichoic acid biogenesis. *J Struct Biol*. 2021 Jun;213(2):107733. doi: 10.1016/j.jsb.2021.107733. Epub 2021 Apr 2. PMID: 33819634.
14. Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc A, Mohammed Y, Buchanan M, Aguilar-Mahecha A, Pötz O, Chen MX, Spatz A, Basik M, Batist G, Zahedi RP, **Borchers CH**. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 $\alpha$  in cell lines and tumor tissues. *Analyst*. 2021 Oct 25;146(21):6566-6575. doi: 10.1039/d1an00165e. PMID: 34585690.

**Nathaniel Bouganim**

1. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; **IMpassion131 investigators**. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- triple-negative breast cancer. *Ann Oncol.* 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. PMID: 34219000.
2. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilan MA, Bindal P, Bishnoi R, **Bouganim N**, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshov DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Ann Oncol.* 2021 Jun;32(6):787-800. doi: 10.1016/j.annonc.2021.02.024. Epub 2021 Mar 19. PMID: 33746047; PMCID: PMC7972830.
  3. Rouette J, Elfassy N, **Bouganim N**, Yin H, Lasry N, Azoulay L. Evaluation of the quality of mammographic breast positioning: a quality improvement study. *CMAJ Open.* 2021 Jun 4;9(2):E607-E612. doi: 10.9778/cmajo.20200211. PMID: 34088731; PMCID: PMC8191588.
  4. Beltran-Bless A, Murshed M, Zakikhani M, Kuchuk I, **Bouganim N**, Robertson S, Kekre N, Vandermeer L, Li J, Addison CL, Rauch F, Clemons M, Kremer R. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients. *Bone Rep.* 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. PMID: 34841014; PMCID: PMC8605385.
  5. Leblanc A, Owen S, Fiset PO, Gomez Corrador AL, Isenberg J, **Bouganim N**. Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib. *JCO Precis Oncol.* 2021 Nov;5:802-807. doi: 10.1200/PO.20.00348. PMID: 34994612.
  6. Chu QS, **Bouganim N**, Fortier C, Zaknoen S, Stille JR, Kremer JD, Yuen E, Hui YH, de la Peña A, Lithio A, Smith PS, Batist G. Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors. *Invest New Drugs.* 2021 Aug;39(4):1001-1010. doi: 10.1007/s10637-020-01049-3. Epub 2021 Jan 22. PMID: 33479856.
  7. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, **Bouganim N**, Gao ZH, Chong G, Foulkes WD, Zogopoulos G. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet.* 2021 Sep 23:jmedgenet-

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print. PMID: 34556502.

### **Pnina Brodt**

1. Tsilimigras DI, **Brodt P**, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E, Pawlik TM. Liver metastases. *Nat Rev Dis Primers*. 2021 Apr 15;7(1):27. doi: 10.1038/s41572-021-00261-6. PMID: 33859205.
2. Ciner AT, Jones K, Muschel RJ, **Brodt P**. The unique immune microenvironment of liver metastases: Challenges and opportunities. *Semin Cancer Biol*. 2021 Jun;71:143-156. doi: 10.1016/j.semcancer.2020.06.003. Epub 2020 Jun 8. PMID: 32526354.
3. Hashimoto M, Konda JD, Perrino S, Celia Fernandez M, Lowy AM, **Brodt P**. Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment. *Mol Cancer Ther*. 2021 Dec;20(12):2469-2482. doi: 10.1158/1535-7163.MCT-20-0144. Epub 2021 Sep 22. PMID: 34552012; PMCID: PMC8677570.
4. Tsui J, Qi S, Perrino S, Leibovitch M, **Brodt P**. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells. *Biomolecules*. 2021 Apr 1;11(4):527. doi: 10.3390/biom11040527. PMID: 33916323; PMCID: PMC8065809.

### **Najwa Buhlaiga**

1. Frohlich M, **Buhlaiga N**, Wang H, Patenaude F, Sirois C, Sakr L. Systemic sarcoidosis mimicking metastatic renal cell carcinoma with subsequent cardiac involvement. *Respir Med Case Rep*. 2020 Dec 31;32:101334. doi: 10.1016/j.rmcr.2020.101334. PMID: 33457201; PMCID: PMC7797905.

### **Julia Burnier**

1. Bustamante P, Piquet L, Landreville S, **Burnier JV**. Uveal melanoma pathobiology: Metastasis to the liver. *Semin Cancer Biol*. 2021 Jun;71:65-85. doi: 10.1016/j.semcancer.2020.05.003. Epub 2020 May 22. PMID: 32450140.
2. Jin E, **Burnier JV**. Liquid Biopsy in Uveal Melanoma: Are We There Yet? *Ocul Oncol Pathol*. 2021 Mar;7(1):1-16. doi: 10.1159/000508613. Epub 2020 Jul 29. PMID: 33796511; PMCID: PMC7989728.
3. Alvarez PB, Laskaris A, Goyeneche AA, Chen Y, Telleria CM, **Burnier JV**. Anticancer effects of mifepristone on human uveal melanoma cells. *Cancer Cell Int*. 2021 Nov 17;21(1):607. doi: 10.1186/s12935-021-02306-y. PMID: 34789240; PMCID: PMC8597220.
4. López RR, Sánchez LM, Alazzam A, **Burnier JV**, Stiharu I, Nerguizian V. Numerical and Experimental Validation of Mixing Efficiency in Periodic Disturbance Mixers. *Micromachines (Basel)*. 2021 Sep 14;12(9):1102. doi: 10.3390/mi12091102. PMID: 34577745; PMCID: PMC8469598.
5. López RR, Ocampo I, Font de Rubinat PG, Sánchez LM, Alazzam A, Tsering T, Bergeron KF, Camacho-Léon S, **Burnier JV**, Mounier C, Stiharu I, Nerguizian V. Parametric Study of the Factors Influencing Liposome Physicochemical Characteristics in a Periodic Disturbance Mixer. *Langmuir*. 2021 Jul 20;37(28):8544-8556. doi: 10.1021/acs.langmuir.1c01005. Epub 2021 Jul 7. PMID: 34232664.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

6. Bustamante P, Tsering T, Coblentz J, Mastromonaco C, Abdouh M, Fonseca C, Proença RP, Blanchard N, Dugé CL, Andujar RAS, Youhnovska E, Burnier MN, Callejo SA, **Burnier JV**. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. *J Exp Clin Cancer Res*. 2021 Jun 16;40(1):196. doi: 10.1186/s13046-021-01984-w. PMID: 34134723; PMCID: PMC8207750.
7. López RR, G Font de Rubinat P, Sánchez LM, Tsering T, Alazzam A, Bergeron KF, Mounier C, **Burnier JV**, Stiharu I, Nerguizian V. The effect of different organic solvents in liposome properties produced in a periodic disturbance mixer: Transcutol®, a potential organic solvent replacement. *Colloids Surf B Biointerfaces*. 2021 Feb;198:111447. doi: 10.1016/j.colsurfb.2020.111447. Epub 2020 Nov 4. PMID: 33223347.
8. Subeha MR, Goyeneche AA, Bustamante P, Lisio MA, **Burnier JV**, Telleria CM. Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition. *Cancers (Basel)*. 2021 Dec 26;14(1):99. doi: 10.3390/cancers14010099. PMID: 35008264; PMCID: PMC8750028.

**Stephen Caplan**

1. Bienz M, Morin-Ben Abdallah S, Greenaway C, Pelletier JS, **Caplan S**, Knecht H. Severe Cystic Echinococcosis-Associated Immune Thrombocytopenic Purpura: A Case Report. *J Hematol*. 2021 Apr;10(2):71-75. doi: 10.14740/jh789. Epub 2021 Apr 27. PMID: 34007368; PMCID: PMC8110226.
2. Bazinet A, Heath J, Chong AS, Simo-Cheyrou ER, Worme S, Rivera Polo B, Foulkes WD, **Caplan S**, Johnson NA, Orthwein A, Mercier FE. Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline *CHEK2* variant. *Cold Spring Harb Mol Case Stud*. 2021 Jun 11;7(3):a006090. doi: 10.1101/mcs.a006090. PMID: 33986034; PMCID: PMC8208041.

**Annie Carbonneau**

1. Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, **Carbonneau A**, Ferrario C, Boileau JF. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol*. 2021 May;28(5):2621-2629. doi: 10.1245/s10434-020-09211-0. Epub 2020 Oct 23. PMID: 33095362.

**Prosanto Chaudhury**

1. Dumitra T, Ganescu O, Hu R, Fiore JF Jr, Kaneva P, Mayo N, Lee L, Liberman AS, **Chaudhury P**, Ferri L, Feldman LS. Association Between Patient Activation and Health Care Utilization After Thoracic and Abdominal Surgery. *JAMA Surg*. 2021 Jan 1;156(1):e205002. doi: 10.1001/jamasurg.2020.5002. Epub 2021 Jan 13. PMID: 33146682; PMCID: PMC7643038.
2. MacIsaac S, Ramanakumar AV, Saw C, Naessens V, Saberi N, Cantarovich M, Baran D, Paraskevas S, Tchervenkov J, **Chaudhury P**, Sandal S. Relative decrease in hemoglobin and outcomes in patients undergoing kidney transplantation surgery: A retrospective cohort study. *Am J Surg*. 2021 Oct;222(4):825-831. doi: 10.1016/j.amjsurg.2021.03.002. Epub 2021 Mar 5. PMID: 33707078.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

3. Wang Y, Golesworthy B, Cuggia A, Domecq C, **Chaudhury P**, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet.* 2021 Sep 23;jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print. PMID: 34556502.
4. Marino A, Bessissow A, Miller C, Valenti D, Boucher L, **Chaudhury P**, Barkun J, Forbes N, Khashab MA, Martel M, Chen YI. Modified endoscopic ultrasound-guided double-balloon-occluded gastroenterostomy bypass (M-EPASS): a pilot study. *Endoscopy.* 2022 Feb;54(2):170-172. doi: 10.1055/a-1392-4546. Epub 2021 Feb 16. PMID: 33592629.
5. Chen YI, Chatterjee A, Berger R, Kanber Y, Wyse J, Lam E, Gan I, Auger M, Kenshil S, Telford J, Donnellan F, Quinlan J, Lutzak G, Alshamsi F, Parent J, Waschke K, Alghamdi A, Barkun J, Metrakos P, **Chaudhury P**, Martel M, Dorreen A, Candido K, Miller C, Adam V, Barkun A, Zogopoulos G, Wong C. Endoscopic ultrasound (EUS)-guided fine needle biopsy alone vs. EUS-guided fine needle aspiration with rapid onsite evaluation in pancreatic lesions: a multicenter randomized trial. *Endoscopy.* 2022 Jan;54(1):4-12. doi: 10.1055/a-1375-9775. Epub 2021 Jan 27. PMID: 33506455.

**Victor Cohen**

1. Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, Agulnik J, **Cohen V**, Charbonneau C, Marcoux N, Blais N, Leigh NB, Bradbury PA, Liu G, Shepherd FA, Bahig H, Routy B, Sacher A, Elkrief A. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer.* 2021 Jan;142:83-91. doi: 10.1016/j.ejca.2020.10.008. Epub 2020 Nov 24. PMID: 33242835.
2. Agulnik JS, Kasymjanova G, Pepe C, Hurry M, Walton RN, Sakr L, **Cohen V**, Small D. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. *Curr Oncol.* 2021 Dec 7;28(6):5179-5191. doi: 10.3390/curroncol28060434. PMID: 34940073; PMCID: PMC8700535.
3. Kasymjanova G, Anwar A, **Cohen V**, Sultanem K, Pepe C, Sakr L, Friedmann J, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. *Curr Oncol.* 2021 Oct 20;28(6):4247-4255. doi: 10.3390/curroncol28060360. PMID: 34898542; PMCID: PMC8544580.

**Fabio Cury**

1. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, **Cury FL**, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2021 Jan 1;109(1):174-185. doi: 10.1016/j.ijrobp.2020.08.034. Epub 2020 Aug 27. PMID: 32861817; PMCID: PMC7736505.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Yan M, Gouveia AG, **Cury FL**, Moideen N, Bratti VF, Patrocinio H, Berlin A, Mendez LC, Moraes FY. Practical considerations for prostate hypofractionation in the developing world. *Nat Rev Urol*. 2021 Nov;18(11):669-685. doi: 10.1038/s41585-021-00498-6. Epub 2021 Aug 13. PMID: 34389825; PMCID: PMC8361822.
3. Daro-Faye M, Kassouf W, Souhami L, Marcq G, **Cury F**, Niazi T, Sargos P. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. *World J Urol*. 2021 May;39(5):1331-1343. doi: 10.1007/s00345-020-03440-4. Epub 2020 Sep 11. PMID: 32915313; PMCID: PMC7484608.
4. Marcq G, Souhami L, **Cury FL**, Salimi A, Aprikian A, Tanguay S, Vanhuysse M, Rajan R, Brimo F, Mansure JJ, Kassouf W. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. *Int J Radiat Oncol Biol Phys*. 2021 Jul 1;110(3):738-741. doi: 10.1016/j.ijrobp.2020.12.033. Epub 2021 Jan 6. PMID: 33421558.
5. Almarzouq A, Kool R, Al Bulushi Y, Marcq G, Souhami L, **Cury FL**, Brimo F, Chong J, Kassouf W. Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. *Urol Oncol*. 2021 Nov 30:S1078-1439(21)00482-8. doi: 10.1016/j.urolonc.2021.11.002. Epub ahead of print. PMID: 34862117.
6. Kool R, Marcq G, El-Achkar A, Mansure JJ, Vanhuysse M, Aprikian A, Tanguay S, **Cury FL**, Brimo F, Souhami L, Kassouf W. Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary? *Urol Oncol*. 2021 May;39(5):299.e7-299.e14. doi: 10.1016/j.urolonc.2020.10.001. Epub 2020 Oct 23. PMID: 33283758.
7. Khriguian J, Patrocinio H, Andonian S, Aprikian A, Kassouf W, Tanguay S, **Cury FL**. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. *Pract Radiat Oncol*. 2022 Jan-Feb;12(1):e34-e39. doi: 10.1016/j.prr.2021.07.006. Epub 2021 Sep 13. PMID: 34530170.
8. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, Rajan R, Aprikian A, Tanguay S, **Cury FL**, Brimo F, Souhami L, Kassouf W. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci*. 2021 Dec 23;36:26-33. doi: 10.1016/j.euros.2021.11.011. PMID: 35098169; PMCID: PMC8783035.

**Richard Dalfen**

1. Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, Srivastava A, Hébert S, Samson B, Lespérance B, Ko YJ, **Dalfen R**, St-Hilaire E, Sideris L, Couture F, Burkes R, Harb M, Camlioglu E, Gologan A, Pelsser V, Constantin A, Greenwood CMT, Tejpar S, Kavan P, Kleinman CL, Batist G. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. *Clin Transl Med*. 2021 Apr;11(4):e401. doi: 10.1002/ctm2.401. PMID: 33931971; PMCID: PMC8087915.
2. Elkrief A, Redstone G, Petruccioli L, Ali A, Thomas D, Fernandez M, Rousseau C, Aleynikova O, Anderson D, Ghitulescu G, Vasilevsky CA, **Dalfen R**, Langleben A, Liberman S, Kavan P, Alcindor T. Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

McGill University Department of Oncology. *BMJ Open Qual.* 2021 Mar;10(1):e000934. doi: 10.1136/bmjoc-2020-000934. PMID: 33685857; PMCID: PMC7942255.

### Marc David

1. Rais F, Tsui JMG, Daianska A, Faye MD, Lambert C, **David M**, Panet-Raymond V, Azoulay M, Saidi A, Hijal T. Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. *Radiother Oncol.* 2021 Sep;162:156-161. doi: 10.1016/j.radonc.2021.07.008. Epub 2021 Jul 15. PMID: 34273468.

### Sonia del Rincon

1. Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymiski T, Mazan M, Masiejczyk M, Faber J, Houry E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, **Del Rincón SV**. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. *J Clin Invest.* 2021 Apr 15;131(8):e140752. doi: 10.1172/JCI140752. PMID: 33690225; PMCID: PMC8262472.
2. Lee LJ, Papadopoli D, Jewer M, **Del Rincon S**, Topisirovic I, Lawrence MG, Postovit LM. Cancer Plasticity: The Role of mRNA Translation. *Trends Cancer.* 2021 Feb;7(2):134-145. doi: 10.1016/j.trecan.2020.09.005. Epub 2020 Oct 13. PMID: 33067172; PMCID: PMC8023421.
3. Huang F, Santinon F, Flores González RE, **Del Rincón SV**. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy. *Front Oncol.* 2021 Sep 16;11:756001. doi: 10.3389/fonc.2021.756001. PMID: 34604096; PMCID: PMC8481945.
4. Krisna SS, Goncalves C, Gagnon N, Huang F, Plourde D, Miller WH Jr, Fritz JH, **Del Rincon SV**. Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse. *STAR Protoc.* 2021 Jul 2;2(3):100627. doi: 10.1016/j.xpro.2021.100627. PMID: 34258591; PMCID: PMC8260876.
5. Guo Q, Bartish M, Gonçalves C, Huang F, Smith-Voudouris J, Krisna SS, Preston SEJ, Emond A, Li VZ, Duerr CU, Gui Y, Cleret-Buhot A, Thebault P, Lefrère H, Lenaerts L, Plourde D, Su J, Mindt BC, Hewgill SA, Cotechini T, Hindmarch CCT, Yang W, Houry E, Zhan Y, Narykina V, Wei Y, Floris G, Basik M, Amant F, Quail DF, Lapointe R, Fritz JH, **Del Rincon SV**, Miller WH Jr. The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. *Cancer Res.* 2021 Jul 15;81(14):3876-3889. doi: 10.1158/0008-5472.CAN-20-3143. Epub 2021 May 11. PMID: 33975880.
6. Rys RN, Wever CM, Geoffrion D, Goncalves C, Ghassemian A, Brailovski E, Ryan J, Stoica L, Hébert J, Petrogiannis-Halioitis T, Dmitrienko S, Frenkiel S, Staiger A, Ott G, Steidl C, Scott DW, Sesques P, **Del Rincon S**, Mann KK, Letai A, Johnson NA. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. *Cancers (Basel).* 2021 Feb 28;13(5):1002. doi: 10.3390/cancers13051002. PMID: 33670870; PMCID: PMC7957722.
7. Shorstova T, Su J, Zhao T, Dahabieh M, Leibovitch M, De Sa Tavares Russo M, Avizonis D, Rajkumar S, Watson IR, **Del Rincón SV**, Miller WH Jr, Foulkes WD, Witcher M. Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

and MAP Kinase Inhibition. *Mol Cancer Ther.* 2021 Jan;20(1):64-75. doi: 10.1158/1535-7163.MCT-20-0259. Epub 2020 Oct 21. PMID: 33087508.

8. Dahabieh MS, Huang F, Goncalves C, Flores González RE, Prabhu S, Bolt A, Di Pietro E, Khoury E, Heath J, Xu ZY, Rémy-Sarrazin J, Mann KK, Orthwein A, Boisvert FM, Braverman N, Miller WH, **Del Rincón SV**. Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance. *Autophagy.* 2021 Jun 21:1-19. doi: 10.1080/15548627.2021.1936932. Epub ahead of print. PMID: 34074205.
9. Sabbah M, Krayem M, Najem A, Sales F, Miller W, **Del Rincon S**, Awada A, Ghanem GE, Journe F. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. *Mol Cancer Res.* 2021 Jul;19(7):1221-1233. doi: 10.1158/1541-7786.MCR-20-1040. Epub 2021 Mar 19. PMID: 33741716.

### Slobodan Devic

1. Watson PGF, Popovic M, Liang L, Tomic N, **Devic S**, Seuntjens J. Clinical Implication of Dosimetry Formalisms for Electronic Low-Energy Photon Intraoperative Radiation Therapy. *Pract Radiat Oncol.* 2021 Jan-Feb;11(1):e114-e121. doi: 10.1016/j.prro.2020.07.005. Epub 2020 Aug 11. PMID: 32795615.

### Shirin Abbasinejad Enger

1. Kim SP, Juneau D, Cohalan C, **Enger SA**. Standardizing SPECT/CT dosimetry following radioembolization with yttrium-90 microspheres. *EJNMMI Phys.* 2021 Oct 30;8(1):71. doi: 10.1186/s40658-021-00413-3. PMID: 34716850; PMCID: PMC8557238.
2. Lecavalier-Barsoum M, Khosrow-Khavar F, Asiev K, Popovic M, Vuong T, **Enger SA**. Utilization of brachytherapy in Quebec, Canada. *Brachytherapy.* 2021 Nov-Dec;20(6):1282-1288. doi: 10.1016/j.brachy.2021.07.002. Epub 2021 Aug 20. PMID: 34420860.
3. DeCunha JM, Villegas F, Vallières M, Torres J, Camilleri-Broët S, **Enger SA**. Patient-specific microdosimetry: a proof of concept. *Phys Med Biol.* 2021 Sep 13;66(18). doi: 10.1088/1361-6560/ac1d1e. PMID: 34384070.
4. Morcos M, Viswanathan AN, **Enger SA**. On the impact of absorbed dose specification, tissue heterogeneities, and applicator heterogeneities on Monte Carlo-based dosimetry of Ir-192, Se-75, and Yb-169 in conventional and intensity-modulated brachytherapy for the treatment of cervical cancer. *Med Phys.* 2021 May;48(5):2604-2613. doi: 10.1002/mp.14802. Epub 2021 Mar 17. PMID: 33619739.
5. DeCunha JM, Poole CM, Vallières M, Torres J, Camilleri-Broët S, Rayes RF, Spicer JD, **Enger SA**. Development of patient-specific 3D models from histopathological samples for applications in radiation therapy. *Phys Med.* 2021 Jan;81:162-169. doi: 10.1016/j.ejmp.2020.12.009. Epub 2021 Jan 15. PMID: 33461029.
6. Morcos M, Antaki M, Viswanathan AN, **Enger SA**. A novel minimally invasive dynamic-shield, intensity-modulated brachytherapy system for the treatment of cervical cancer. *Med Phys.* 2021 Jan;48(1):71-79. doi: 10.1002/mp.14459. Epub 2020 Oct 22. PMID: 32916763.

### Khashayar Esfahani

1. **Esfahani K**, Henderson Berg MH, Zargham H, Billick R, Pehr K, Redpath M, Roshdy O, Miller WH. Narrowband ultraviolet B therapy for refractory immune-related lichenoid

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

dermatitis on PD-1 therapy: a case report. *J Immunother Cancer*. 2021 Mar;9(3):e001831. doi: 10.1136/jitc-2020-001831. PMID: 33771890; PMCID: PMC7996651.

**Michael Evans**

1. Ayala Alvarez DS, Watson PGF, Popovic M, Heng VJ, **Evans MDC**, Seuntjens J. Monte Carlo calculation of the TG-43 dosimetry parameters for the INTRABEAM source with spherical applicators. *Phys Med Biol*. 2021 Nov 5;66(21). doi: 10.1088/1361-6560/ac309f. PMID: 34663769.

**Marc Fabian**

1. Fakim H, **Fabian MR**. A Cell-Free System for Investigating Human MARF1 Endonuclease Activity. *Methods Mol Biol*. 2021;2209:333-345. doi: 10.1007/978-1-0716-0935-4\_21. PMID: 33201479.

**Cristiano Ferrario**

1. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, **Ferrario C**, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med*. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206.
2. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; **VISION Investigators**. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. PMID: 34161051; PMCID: PMC8446332.
3. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; **OlympiA Clinical Trial Steering Committee and Investigators**. Adjuvant Olaparib for Patients with *BRCA1*- or *BRCA2*-Mutated Breast Cancer. *N Engl J Med*. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. PMID: 34081848.
4. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; **KEYNOTE-361 Investigators**. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. PMID: 34051178.
5. Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, Carbonneau A, **Ferrario C**, Boileau JF. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol*. 2021 May;28(5):2621-2629. doi: 10.1245/s10434-020-09211-0. Epub 2020 Oct 23. PMID: 33095362.
6. Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, **Ferrario C**, Gotto GT, Fernandes R, Niazi T, Noonan KL, Saad F, Hotte SJ, Hew H, Chan KFY, Wyllie LP, Shayegan B. Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. *JNCI Cancer Spectr*. 2021 Oct 1;5(6):pkab082. doi: 10.1093/jncics/pkab082. PMID: 34926988; PMCID: PMC8678925.
  7. Saad F, Hotte SJ, Finelli A, Malone S, Niazi T, Noonan K, Shayegan B, So AI, Danielson B, Basappa NS, Cagiannos I, Canil C, Delouya G, Fernandes R, **Ferrario C**, Gotto GT, Hamilton RJ, Izzard JP, Kapoor A, Khalaf D, Kolinsky M, Lalani AK, Lavallée LT, Morash C, Morgan SC, Ong M, Pouliot F, Rendon RA, Yip S, Zardan A, Park-Wyllie L, Chi K. Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. *Can Urol Assoc J*. 2021 Oct;15(10):353-358. doi: 10.5489/cuaj.7347. PMID: 34125066; PMCID: PMC8525526.
  8. Durairaj C, Chakrabarti J, **Ferrario C**, Hirte HW, Babu S, Piha-Paul SA, Plotka A, Hoffman J, Shi H, Wang DD. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. *Clin Pharmacokinet*. 2021 Jul;60(7):921-930. doi: 10.1007/s40262-020-00983-y. Epub 2021 Mar 9. PMID: 33686631; PMCID: PMC8249284.
  9. Wallis CJD, Shayegan B, Morgan SC, Hamilton RJ, Cagiannos I, Basappa NS, **Ferrario C**, Gotto GT, Fernandes R, Roy S, Noonan KL, Niazi T, Hotte SJ, Saad F, Hew H, Chan KFY, Park-Wyllie L, Malone S. Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. *Cancers (Basel)*. 2021 Jun 7;13(11):2844. doi: 10.3390/cancers13112844. PMID: 34200349; PMCID: PMC8200983.
  10. Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, **Ferrario C**, Muñoz-Mateu M, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). *Eur J Cancer*. 2021 Aug;153:223-233. doi: 10.1016/j.ejca.2021.05.025. Epub 2021 Jun 29. PMID: 34214937.

**Lorenzo Ferri**

1. Andalib A, Bouchard P, Demyttenaere S, **Ferri LE**, Court O. Esophageal cancer after sleeve gastrectomy: a population-based comparative cohort study. *Surg Obes Relat Dis*. 2021 May;17(5):879-887. doi: 10.1016/j.soard.2020.12.011. Epub 2020 Dec 29. PMID: 33547014.
2. Ferreira V, Minnella EM, Awasthi R, Gamsa A, **Ferri L**, Mulder D, Sirois C, Spicer J, Schmid S, Carli F. Multimodal Prehabilitation for Lung Cancer Surgery: A Randomized Controlled Trial. *Ann Thorac Surg*. 2021 Nov;112(5):1600-1608. doi: 10.1016/j.athoracsur.2020.11.022. Epub 2020 Dec 13. PMID: 33321089.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

3. Al Lawati Y, Alkaaki A, Luis Ramírez García Luna J, Skothos E, Mueller C, Spicer J, Mulder D, **Ferri L**, Cools-Lartigue J. The Predictive Value of Inflammatory Biomarkers in Esophageal Anastomotic Leaks. *Ann Thorac Surg.* 2021 Dec;112(6):1790-1796. doi: 10.1016/j.athoracsur.2020.12.033. Epub 2021 Jan 10. PMID: 33440175.
4. Seitlinger J, Wollbrett C, Mazzella A, Schmid S, Guerrero F, Banga Nkomo D, Hassan M, Brindel A, Ruuth-Praz J, Schmitt P, Clément-Duchêne C, Douiri N, Reeb J, Prisciandaro E, Siat J, Spaggiari L, Ruffini E, Filosso P, **Ferri L**, Santelmo N, Spicer J, Renaud S. Safety and Feasibility of Thoracic Malignancy Surgery During the COVID-19 Pandemic. *Ann Thorac Surg.* 2021 Dec;112(6):1870-1876. doi: 10.1016/j.athoracsur.2020.12.001. Epub 2020 Dec 14. PMID: 33333085; PMCID: PMC7834157.
5. Nevo Y, Arjah S, Katz A, Ramírez García Luna JL, Spicer J, Cools-Lartigue J, Mueller C, Feldman L, **Ferri L**. ERAS 2.0: Continued Refinement of an Established Enhanced Recovery Protocol for Esophagectomy. *Ann Surg Oncol.* 2021 Sep;28(9):4850-4858. doi: 10.1245/s10434-021-09854-7. Epub 2021 Mar 27. PMID: 33774774.
6. Dumitra T, Ganescu O, Hu R, Fiore JF Jr, Kaneva P, Mayo N, Lee L, Liberman AS, Chaudhury P, **Ferri L**, Feldman LS. Association Between Patient Activation and Health Care Utilization After Thoracic and Abdominal Surgery. *JAMA Surg.* 2021 Jan 1;156(1):e205002. doi: 10.1001/jamasurg.2020.5002. Epub 2021 Jan 13. PMID: 33146682; PMCID: PMC7643038.
7. Kammili A, Kaneva P, Lee L, Cools-Lartigue J, **Ferri LE**, Mueller CL. Perioperative Transfusions for Gastroesophageal Cancers: Risk Factors and Short- and Long-Term Outcomes. *J Gastrointest Surg.* 2021 Jan;25(1):48-57. doi: 10.1007/s11605-020-04845-7. Epub 2020 Nov 6. PMID: 33159242.
8. Flores-Torres S, Peza-Chavez O, Kuasne H, Munguia-Lopez JG, Kort-Mascort J, **Ferri L**, Jiang T, Rajadurai CV, Park M, Sangwan V, Kinsella JM. Alginate-gelatin-Matrigel hydrogels enable the development and multigenerational passaging of patient-derived 3D bioprinted cancer spheroid models. *Biofabrication.* 2021 Mar 10;13(2). doi: 10.1088/1758-5090/abdb87. PMID: 33440351.
9. Shimonosono M, Tanaka K, Flashner S, Takada S, Matsuura N, Tomita Y, Sachdeva UM, Noguchi E, Sangwan V, **Ferri L**, Momen-Heravi F, Yoon AJ, Klein-Szanto AJ, Diehl JA, Nakagawa H. Alcohol Metabolism Enriches Squamous Cell Carcinoma Cancer Stem Cells That Survive Oxidative Stress via Autophagy. *Biomolecules.* 2021 Oct 7;11(10):1479. doi: 10.3390/biom11101479. PMID: 34680112; PMCID: PMC8533166.
10. Kouyoumdjian A, Trepanier M, Al Shehhi R, Cools-Lartigue J, **Ferri LE**, Lee L, Mueller CL. The Effect of Preoperative Anemia and Perioperative Transfusion on Surgical Outcomes After Gastrectomy for Gastric Cancer. *J Surg Res.* 2021 Mar;259:523-531. doi: 10.1016/j.jss.2020.10.003. Epub 2020 Nov 25. PMID: 33248671.
11. Donlon NE, Kammili A, Roopnarinesingh R, Davern M, Power R, King S, Chmelo J, Phillips AW, Donohoe CL, Ravi N, Lowery M, Mueller CL, Cools-Lartigue J, **Ferri LE**, Reynolds JV. FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma. *Ann Surg.* 2021 Nov 1;274(5):814-820. doi: 10.1097/SLA.0000000000005097. PMID: 34310355.
12. Ngamruengphong S, **Ferri L**, Aihara H, Draganov PV, Yang DJ, Perbtani YB, Jue TL, Munroe CA, Boparai ES, Mehta NA, Bhatt A, Kumta NA, Othman MO, Mercado M, Javid H, Aadam AA, Siegel A, James TW, Grimm IS, DeWitt JM, Novikov A, Schlachterman A, Kowalski T, Samarasena J, Hashimoto R, Chehade NEH, Lee J, Chang

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- K, Su B, Ujiki MB, Mehta A, Sharaiha RZ, Carr-Locke DL, Chen A, Chen M, Chen YI, Pourmousavi Khoshknab M, Wang R, Kerdsirichairat T, Tomizawa Y, von Renteln D, Kumbhari V, Khashab MA, Bechara R, Karasik M, Patel NJ, Fukami N, Nishimura M, Hanada Y, Wong Kee Song LM, Laszkowska M, Wang AY, Hwang JH, Friedland S, Sethi A, Kalloo AN. Efficacy of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasia in a Large Cohort in North America. *Clin Gastroenterol Hepatol*. 2021 Aug;19(8):1611-1619.e1. doi: 10.1016/j.cgh.2020.06.023. Epub 2020 Jun 18. PMID: 32565290.
13. Patel NM, Puri A, Sounderajah V, **Ferri L**, Griffiths E, Low D, Maynard N, Mueller C, Pera M, van Berge Henegouwen MI, Watson DI, Zaninotto G, Hanna GB, Markar SR; Para-Oesophageal hernia Symptom Tool (POST) Collaborative. Quality of life and symptom assessment in paraesophageal hernias: a systematic literature review of reporting standards. *Dis Esophagus*. 2021 Jul 12;34(7):doaa134. doi: 10.1093/dote/doaa134. PMID: 33434921.
  14. Kamarajah SK, Phillips AW, Griffiths EA, **Ferri L**, Hofstetter WL, Markar SR. Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis. *Ann Surg Oncol*. 2021 Dec;28(13):8485-8494. doi: 10.1245/s10434-021-10346-x. Epub 2021 Jul 13. PMID: 34255246; PMCID: PMC8591012.
  15. Vermeulen BD, van der Leeden B, Ali JT, Gudbjartsson T, Hermansson M, Low DE, Adler DG, Botha AJ, D'Journo XB, Eroglu A, **Ferri LE**, Gubler C, Haveman JW, Kaman L, Kozarek RA, Law S, Loske G, Lindenmann J, Park JH, Richardson JD, Salminen P, Song HY, Søreide JA, Spaander MCW, Tarascio JN, Tsai JA, Vanuytsel T, Rosman C, Siersema PD; Benign Esophageal Perforation Collaborative Group. Early diagnosis is associated with improved clinical outcomes in benign esophageal perforation: an individual patient data meta-analysis. *Surg Endosc*. 2021 Jul;35(7):3492-3505. doi: 10.1007/s00464-020-07806-y. Epub 2020 Jul 17. PMID: 32681374; PMCID: PMC8195755.
  16. Voeten DM, Gisbertz SS, Ruurda JP, Wilschut JA, **Ferri LE**, van Hillegersberg R, van Berge Henegouwen MI; Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group. Overall Volume Trends in Esophageal Cancer Surgery Results From the Dutch Upper Gastrointestinal Cancer Audit. *Ann Surg*. 2021 Sep 1;274(3):449-458. doi: 10.1097/SLA.0000000000004985. PMID: 34397452
  17. Kammili A, Cools-Lartigue J, Mulder D, Feldman LS, **Ferri LE**, Mueller CL. Transition from open to minimally invasive en bloc esophagectomy can be achieved without compromising surgical quality. *Surg Endosc*. 2021 Jun;35(6):3067-3076. doi: 10.1007/s00464-020-07696-0. Epub 2020 Jun 15. PMID: 32556773.
  18. Schmid S, Kaafarani M, Baldini G, Amir A, Costescu F, Shafiepour D, Cools-Lartigue J, Najmeh S, Sirois C, **Ferri L**, Mulder D, Spicer J. Implication of a novel postoperative recovery protocol to increase day 1 discharge rate after anatomic lung resection. *J Thorac Dis*. 2021 Nov;13(11):6399-6408. doi: 10.21037/jtd-21-965. PMID: 34992820; PMCID: PMC8662496
  19. Zhao H, Misariu AM, Ramirez-GarciaLuna JL, Nobel T, Mueller C, Cools-Lartigue J, Spicer J, Molena D, Bains M, Swisher S, Hofstetter W, **Ferri L**. Synchronous Esophageal and Lung Cancers-Is Combined Anatomic Resection Appropriate? *Ann Thorac Surg*. 2022 Apr;113(4):1354-1360. doi: 10.1016/j.athoracsur.2021.04.026. Epub 2021 Apr 24. PMID: 33905733.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

20. Sangwan V, Al-Marzouki L, Pal S, Stavrakos V, Alzahrani M, Antonatos D, Nevo Y, Camilleri-Broët S, Rayes R, Bourdeau F, Giannias B, Bertos N, Bailey S, Rousseau S, Cools-Lartigue J, Spicer JD, **Ferri L**. Inhibition of LPS-mediated TLR4 activation abrogates gastric adenocarcinoma-associated peritoneal metastasis. *Clin Exp Metastasis*. 2022 Apr;39(2):323-333. doi: 10.1007/s10585-021-10133-8. Epub 2021 Nov 12. PMID: 34767138.
21. Nevo Y, Calderone A, Kammili A, Boulila C, Renaud S, Cools-Lartigue J, Spicer J, Mueller C, **Ferri L**. Endoscopic pyloromyotomy in minimally invasive esophagectomy: a novel approach. *Surg Endosc*. 2022 Apr;36(4):2341-2348. doi: 10.1007/s00464-021-08511-0. Epub 2021 May 4. PMID: 33948713
22. Seitlinger J, Prieto M, Guerrera F, Streit A, Gauchotte G, Siat J, Falcoz PE, Massard G, **Ferri L**, Spicer J, Renaud S. Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes. *Clin Lung Cancer*. 2022 Jan;23(1):e29-e42. doi: 10.1016/j.clcc.2021.08.001. Epub 2021 Aug 22. PMID: 34583910.

**William Foulkes**

1. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. *Lancet Oncol*. 2021;22(7):1014-22. Epub 2021/06/11. doi: 10.1016/s1470-2045(21)00189-3. PubMed PMID: 34111421; PubMed Central PMCID: PMC8934577.
2. Ahuno ST, Doebley AL, Ahearn TU, Yarney J, Titiloye N, Hamel N, **et al**. Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. *NPJ Precis Oncol*. 2021;5(1):83. Epub 2021/09/19. doi: 10.1038/s41698-021-00219-7. PubMed PMID: 34535742; PubMed Central PMCID: PMC8448727.
3. Apellaniz-Ruiz M, McCluggage WG, **Foulkes WD**. DICER1-associated embryonal rhabdomyosarcoma and adenocarcinoma of the gynecologic tract: Pathology, molecular genetics, and indications for molecular testing. *Genes Chromosomes Cancer*. 2021;60(3):217-33. Epub 2020/11/03. doi: 10.1002/gcc.22913. PubMed PMID: 33135284.
4. Aronson M, Colas C, Shuen A, Hampel H, **Foulkes WD**, Baris Feldman H, **et al**. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. *J Med Genet*. 2022;59(4):318-27. Epub 2021/02/25. doi: 10.1136/jmedgenet-2020-107627. PubMed PMID: 33622763.
5. Bazinet A, Heath J, Chong AS, Simo-Cheyou ER, Worme S, Rivera Polo B, **et al**. Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. *Cold Spring Harb Mol Case Stud*. 2021;7(3). Epub 2021/05/15. doi: 10.1101/mcs.a006090. PubMed PMID: 33986034; PubMed Central PMCID: PMC8208041.
6. Bennett JA, Ordulu Z, Young RH, Pinto A, Van de Vijver K, Burandt E, **et al**. Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations. *Mod Pathol*. 2021;34(9):1750-62. Epub 2021/05/22. doi: 10.1038/s41379-021-00821-x. PubMed PMID: 34017064.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

7. Biswas K, Couillard M, Cavallone L, Burkett S, Stauffer S, Martin BK, et al. A novel mouse model of PMS2 founder mutation that causes mismatch repair defect due to aberrant splicing. *Cell Death Dis.* 2021;12(9):838. Epub 2021/09/08. doi: 10.1038/s41419-021-04130-8. PubMed PMID: 34489406; PubMed Central PMCID: PMC8421400.
8. Boni J, Idani A, Roca C, Feliubadaló L, Tomiak E, Weber E, **et al.** A decade of RAD51C and RAD51D germline variants in cancer. *Hum Mutat.* 2022;43(3):285-98. Epub 2021/12/20. doi: 10.1002/humu.24319. PubMed PMID: 34923718.
9. Chong AS, Apellaniz-Ruiz M, de Kock L, Bouron-Dal Soglio D, Doyle WR, Priest JR, **et al.** Likely foregut endoderm origin for a postzygotic mutation affecting the RNase IIIb domain of DICER1. *J Med Genet.* 2021. Epub 2021/09/22. doi: 10.1136/jmedgenet-2021-107887. PubMed PMID: 34544839.
10. Chong AS, Han H, Albrecht S, Weon YC, Park SK, **Foulkes WD.** DICER1 syndrome in a young adult with pituitary blastoma. *Acta Neuropathol.* 2021;142(6):1071-6. Epub 2021/10/23. doi: 10.1007/s00401-021-02378-0. PubMed PMID: 34677675.
11. Chong AS, Nikiforov YE, Condello V, Wald AI, Nikiforova MN, **Foulkes WD,** et al. Prevalence and Spectrum of DICER1 Mutations in Adult-onset Thyroid Nodules with Indeterminate Cytology. *J Clin Endocrinol Metab.* 2021;106(4):968-77. Epub 2021/01/19. doi: 10.1210/clinem/dgab025. PubMed PMID: 33460435.
12. Combrink HM, Oosthuizen J, Visser B, Chabilal N, Buccimazza I, **Foulkes WD,** et al. Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study. *Cancer Genet.* 2021;258-259:1-6. Epub 2021/07/05. doi: 10.1016/j.cancergen.2021.06.002. PubMed PMID: 34218100.
13. Condello V, Nikitski AV, **Foulkes WD,** Nikiforov YE. Letter to the Editor: Prevalence of WWP1 Gene Mutations in Patients with Thyroid Nodules. *Thyroid.* 2021;31(7):1147-8. Epub 2020/12/31. doi: 10.1089/thy.2020.0919. PubMed PMID: 33375877.
14. Cullinan N, Schiller I, Di Giuseppe G, Mamun M, Reichman L, Cacciotti C, **et al.** Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors. *J Clin Oncol.* 2021;39(29):3207-16. Epub 2021/08/13. doi: 10.1200/jco.21.00018. PubMed PMID: 34383599.
15. Durno C, Ercan AB, Bianchi V, Edwards M, Aronson M, Galati M, **et al.** Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. *J Clin Oncol.* 2021;39(25):2779-90. Epub 2021/05/05. doi: 10.1200/jco.20.02636. PubMed PMID: 33945292; PubMed Central PMCID: PMC8407605.
16. Elkholi IE, Di Iorio M, Fahiminiya S, Arcand SL, Han H, Nogué C, **et al.** Investigating the causal role of MRE11A p.E506\* in breast and ovarian cancer. *Sci Rep.* 2021;11(1):2409. Epub 2021/01/30. doi: 10.1038/s41598-021-81106-w. PubMed PMID: 33510186; PubMed Central PMCID: PMC844268.
17. Elkholi IE, **Foulkes WD,** Rivera B. MRN Complex and Cancer Risk: Old Bottles, New Wine. *Clin Cancer Res.* 2021;27(20):5465-71. Epub 2021/07/16. doi: 10.1158/1078-0432.Ccr-21-1509. PubMed PMID: 34261697.
18. Evans DG, Messiaen LM, **Foulkes WD,** Irving REA, Murray AJ, Perez-Becerril C, et al. Typical 22q11.2 deletion syndrome appears to confer a reduced risk of schwannoma. *Genet Med.* 2021;23(9):1779-82. Epub 2021/04/22. doi: 10.1038/s41436-021-01175-0. PubMed PMID: 33879870; PubMed Central PMCID: PMC8460436 competing interests.
19. Evans DG, Phillips KA, Milne RL, Fruscio R, Cybulski C, Gronwald J, **et al.** Survival from breast cancer in women with a BRCA2 mutation by treatment. *Br J Cancer.*

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 2021;124(9):1524-32. Epub 2021/02/19. doi: 10.1038/s41416-020-01164-1. PubMed PMID: 33597716; PubMed Central PMCID: PMC8076275 interest.
20. Fahiminiya S, Rivard GE, Scott P, Montpetit A, Bacot F, St-Louis J, **et al.** A full molecular picture of F8 intron 1 inversion created with optical genome mapping. *Haemophilia*. 2021;27(5):e638-e40. Epub 2021/07/08. doi: 10.1111/hae.14375. PubMed PMID: 34232555.
  21. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, **et al.** A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. *Genome Med*. 2021;13(1):186. Epub 2021/12/05. doi: 10.1186/s13073-021-00998-5. PubMed PMID: 34861889; PubMed Central PMCID: PMC8642877.
  22. **Foulkes WD.** The ten genes for breast (and ovarian) cancer susceptibility. *Nat Rev Clin Oncol*. 2021;18(5):259-60. Epub 2021/03/12. doi: 10.1038/s41571-021-00491-3. PubMed PMID: 33692540.
  23. **Foulkes WD,** Polak P. Li-Fraumeni Syndrome in the Cancer Genomics Era. *J Natl Cancer Inst*. 2021;113(12):1615-7. Epub 2021/07/10. doi: 10.1093/jnci/djab118. PubMed PMID: 34240211; PubMed Central PMCID: PMC8634324.
  24. Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, **et al.** Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. *JAMA Oncol*. 2021;7(12):1806-14. Epub 2021/10/08. doi: 10.1001/jamaoncol.2021.4536. PubMed PMID: 34617981; PubMed Central PMCID: PMC8498936.
  25. Holdhof D, Johann PD, Spohn M, Bockmayr M, Safaei S, Joshi P, **et al.** Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. *Acta Neuropathol*. 2021;141(2):291-301. Epub 2020/12/18. doi: 10.1007/s00401-020-02250-7. PubMed PMID: 33331994; PubMed Central PMCID: PMC847432.
  26. Kim SJ, Lubinski J, Huzarski T, Møller P, Armel S, Karlan BY, **et al.** Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. *Cancer Epidemiol Biomarkers Prev*. 2021;30(11):2038-43. Epub 2021/08/25. doi: 10.1158/1055-9965.Epi-21-0296. PubMed PMID: 34426412.
  27. Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, **Foulkes WD,** McKinnon W, et al. An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool. *Cancer*. 2021;127(17):3183-93. Epub 2021/06/03. doi: 10.1002/cncr.33654. PubMed PMID: 34077552.
  28. Lawrence J, Richer L, Arseneau J, Zeng X, Chong G, Weber E, **et al.** Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort. *Curr Oncol*. 2021;28(1):509-22. Epub 2021/01/21. doi: 10.3390/curroncol28010052. PubMed PMID: 33467402; PubMed Central PMCID: PMC803281.
  29. Liu APY, Kelsey MM, Sabbaghian N, Park SH, Deal CL, Esbenshade AJ, **et al.** Clinical Outcomes and Complications of Pituitary Blastoma. *J Clin Endocrinol Metab*. 2021;106(2):351-63. Epub 2020/11/26. doi: 10.1210/clinem/dgaa857. PubMed PMID: 33236116; PubMed Central PMCID: PMC823240.
  30. Matis TS, Zayed N, Labraki B, de Ladurantaye M, Matis TA, Camacho Valenzuela J, **et al.** Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families. *NPJ Breast Cancer*. 2021;7(1):109. Epub 2021/08/27.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- doi: 10.1038/s41523-021-00315-8. PubMed PMID: 34433815; PubMed Central PMCID: PMC8387362.
31. McCluggage WG, **Foulkes WD**. DICER1-sarcoma: an emerging entity. *Mod Pathol*. 2021;34(12):2096-7. Epub 2021/10/14. doi: 10.1038/s41379-021-00935-2. PubMed PMID: 34642426.
  32. McCluggage WG, **Foulkes WD**. DICER1-associated sarcomas: towards a unified nomenclature. *Mod Pathol*. 2021;34(6):1226-8. Epub 2020/06/24. doi: 10.1038/s41379-020-0602-4. PubMed PMID: 32572152.
  33. McCluggage WG, **Foulkes WD**. DICER1-associated sarcomas at different sites exhibit morphological overlap arguing for a unified nomenclature. *Virchows Arch*. 2021;479(2):431-3. Epub 2021/04/08. doi: 10.1007/s00428-021-03087-5. PubMed PMID: 33825038.
  34. McCluggage WG, Fu L, Mohler K, de Kock L, Sabbaghian N, Mindlin A, **et al**. An Unusual Enteric Yolk Sac Tumor: First Report of an Ovarian Germ Cell Tumor Associated With a Germline Pathogenic Variant in DICER1. *Int J Gynecol Pathol*. 2021. Epub 2021/08/13. doi: 10.1097/pgp.0000000000000818. PubMed PMID: 34380971.
  35. Mighton C, Smith AC, Mayers J, Tomaszewski R, Taylor S, Hume S, **et al**. Data sharing to improve concordance in variant interpretation across laboratories: results from the Canadian Open Genetics Repository. *J Med Genet*. 2021. Epub 2021/04/21. doi: 10.1136/jmedgenet-2021-107738. PubMed PMID: 33875564; PubMed Central PMCID: PMC8523590.
  36. Mutetwa T, Goudie C, **Foulkes WD**, Polak P. Companion Tumor Sequencing to Assess the Clinical Significance of Germline Sequencing in Children With Cancer. *JAMA Netw Open*. 2021;4(11):e2135135. Epub 2021/11/19. doi: 10.1001/jamanetworkopen.2021.35135. PubMed PMID: 34792595; PubMed Central PMCID: PMC8603075 form of funding to clinical lab outside the submitted work. No other disclosures were reported.
  37. Nadaf J, de Kock L, Chong AS, Korbonits M, Thorner P, Benlimame N, **et al**. Molecular characterization of DICER1-mutated pituitary blastoma. *Acta Neuropathol*. 2021;141(6):929-44. Epub 2021/03/02. doi: 10.1007/s00401-021-02283-6. PubMed PMID: 33644822.
  38. Niedziela M, Sabbaghian N, de Kock L, **Foulkes WD**. Intrathyroidal Thymus (Incidentaloma) Mimicking Thyroid Neoplasia in DICER1 Syndrome. *Eur Thyroid J*. 2021;10(3):257-61. Epub 2021/06/29. doi: 10.1159/000510004. PubMed PMID: 34178712; PubMed Central PMCID: PMC8215947.
  39. Nogué C, Chong AS, Grau E, Han H, Dorca E, Roca C, **et al**. DGCR8 and the six hit, three-step model of schwannomatosis. *Acta Neuropathol*. 2022;143(1):115-7. Epub 2021/11/26. doi: 10.1007/s00401-021-02387-z. PubMed PMID: 34821987.
  40. Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, **et al**. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. *Eur J Cancer*. 2021;146:30-47. Epub 2021/02/13. doi: 10.1016/j.ejca.2020.12.023. PubMed PMID: 33578357.
  41. Sherman ME, **Foulkes WD**. BRCA1/2 and Endometrial Cancer Risk: Implications for Management. *J Natl Cancer Inst*. 2021;113(9):1127-8. Epub 2021/03/13. doi: 10.1093/jnci/djab037. PubMed PMID: 33710310; PubMed Central PMCID: PMC8418424.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

42. Shorstova T, **Foulkes WD**, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. *Br J Cancer*. 2021;124(9):1478-90. Epub 2021/03/17. doi: 10.1038/s41416-021-01321-0. PubMed PMID: 33723398; PubMed Central PMCID: PMC8076232.
43. Shorstova T, Su J, Zhao T, Dahabieh M, Leibovitch M, De Sa Tavares Russo M, **et al**. Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. *Mol Cancer Ther*. 2021;20(1):64-75. Epub 2020/10/23. doi: 10.1158/1535-7163.Mct-20-0259. PubMed PMID: 33087508.
44. Stjepanovic N, Lubinski J, Moller P, Randall Armel S, **Foulkes WD**, Tung N, **et al**. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. 2021;187(2):515-23. Epub 2021/01/11. doi: 10.1007/s10549-020-06072-9. PubMed PMID: 33423179.
45. Tessier-Cloutier B, Kleinman CL, **Foulkes WD**. SWI/SNF-deficient undifferentiated malignancies: where to draw the line(†). *J Pathol*. 2022;256(2):139-42. Epub 2021/11/13. doi: 10.1002/path.5836. PubMed PMID: 34767264.
46. Thomas C, Soschinski P, Zwaig M, Oikonomopoulos S, Okonechnikov K, Pajtler KW, **et al**. The genetic landscape of choroid plexus tumors in children and adults. *Neuro Oncol*. 2021;23(4):650-60. Epub 2020/11/30. doi: 10.1093/neuonc/noaa267. PubMed PMID: 33249490; PubMed Central PMCID: PMC8041331.
47. Tischkowitz M, Balmaña J, **Foulkes WD**, James P, Ngeow J, Schmutzler R, **et al**. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(8):1416-23. Epub 2021/05/13. doi: 10.1038/s41436-021-01151-8. PubMed PMID: 33976419.
48. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, **et al**. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *N Engl J Med*. 2021;384(25):2394-405. Epub 2021/06/04. doi: 10.1056/NEJMoa2105215. PubMed PMID: 34081848.
49. Wang Y, Cuggia A, Pacis A, Boileau JC, Marcus VA, Gao ZH, **et al**. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale. *J Natl Compr Canc Netw*. 2021;19(8):883-7. Epub 2021/08/21. doi: 10.6004/jnccn.2021.7049. PubMed PMID: 34416708.
50. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, **et al**. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet*. 2021. Epub 2021/09/25. doi: 10.1136/jmedgenet-2021-108054. PubMed PMID: 34556502.
51. Xue Y, Morris JL, Yang K, Fu Z, Zhu X, Johnson F, **et al**. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to mitochondria. *Nat Commun*. 2021;12(1):5404. Epub 2021/09/15. doi: 10.1038/s41467-021-25260-9. PubMed PMID: 34518526; PubMed Central PMCID: PMC8438089.
52. Yoon JY, Apellaniz-Ruiz M, Chong AL, Slim Z, Salfinger SG, Clarke BA, **et al**. The Value of DICER1 Mutation Analysis in "Subtle" Diagnostically Challenging Embryonal Rhabdomyosarcomas of the Uterine Cervix. *Int J Gynecol Pathol*. 2021;40(5):435-40. Epub 2020/10/07. doi: 10.1097/pgp.0000000000000718. PubMed PMID: 33021556.
53. Yoon JY, de Kock L, Stewart CJR, McCluggage WG, **Foulkes WD**, Clarke BA, **et al**. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

and Endometrial Stromal Sarcoma. *Cancer Treat Res Commun.* 2021;27:100363. Epub 2021/04/11. doi: 10.1016/j.ctarc.2021.100363. PubMed PMID: 33838572.

**Eduardo Franco**

1. Andrade Pessoa Morales J, Marconi C, El-Zein M, Ravel J, da Silva Pinto GV, Silveira R, **et al.** Vaginal microbiome components as correlates of cervical human papillomavirus infection. *J Infect Dis.* 2021. Epub 2021/11/01. doi: 10.1093/infdis/jiab547. PubMed PMID: 34718662.
2. Bonjour M, Charvat H, **Franco EL**, Piñeros M, Clifford GM, Bray F, et al. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. *Lancet Public Health.* 2021;6(7):e510-e21. Epub 2021/04/18. doi: 10.1016/s2468-2667(21)00046-3. PubMed PMID: 33864738; PubMed Central PMCID: PMC8225515 from Merck, outside of the submitted work. ELF has a patent “Methylation markers in cervical cancer” pending to his university. The other authors declare no competing interests.
3. Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, **et al.** The IARC Perspective on Cervical Cancer Screening. *N Engl J Med.* 2021;385(20):1908-18. Epub 2021/11/11. doi: 10.1056/NEJMSr2030640. PubMed PMID: 34758259.
4. Cromwell I, Smith LW, van der Hoek K, Hedden L, Coldman AJ, Cook D, **et al.** Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. *Cancer Med.* 2021;10(9):2996-3003. Epub 2021/04/04. doi: 10.1002/cam4.3864. PubMed PMID: 33811457; PubMed Central PMCID: PMC8085916.
5. El-Zein M, Gotlieb W, Gilbert L, Hemmings R, Behr MA, **Franco EL.** Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertainning Intraepithelial Neoplasia by Immunostain Testing study. *Int J Cancer.* 2021;148(2):492-501. Epub 2020/08/12. doi: 10.1002/ijc.33250. PubMed PMID: 32781481.
6. El-Zein M, Khosrow-Khavar F, Burchell AN, Tellier PP, Eintracht S, McNamara E, **et al.** Association of Serum 25-Hydroxyvitamin D With Prevalence, Incidence, and Clearance of Vaginal HPV Infection in Young Women. *J Infect Dis.* 2021;224(3):492-502. Epub 2020/12/12. doi: 10.1093/infdis/jiaa758. PubMed PMID: 33306088; PubMed Central PMCID: PMC8328206.
7. Farah E, Ali R, Tope P, El-Zein M, **Franco EL**, McGill Task Force On Covid-And C. A Review of Canadian Cancer-Related Clinical Practice Guidelines and Resources during the COVID-19 Pandemic. *Curr Oncol.* 2021;28(2):1020-33. Epub 2021/03/07. doi: 10.3390/currenol28020100. PubMed PMID: 33669102; PubMed Central PMCID: PMC8025749.
8. **Franco EL**, Shinder GA, Volesky KD, Shapiro SB, MacCosham A. Lessons from an unparalleled disruption to cancer prevention and control. *Prev Med.* 2021;151:106686. Epub 2021/07/05. doi: 10.1016/j.ypmed.2021.106686. PubMed PMID: 34217423; PubMed Central PMCID: PMC8241683.
9. **Franco EL**, Shinder GA, Volesky KD, Shapiro SB, MacCosham A. A bold but morally necessary and attainable goal. *Prev Med.* 2021;144:106461. Epub 2021/03/09. doi: 10.1016/j.ypmed.2021.106461. PubMed PMID: 33678238.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

10. **Franco EL**, Shinder GA, Volesky KD, Shapiro SB, MacCosham A. The noblest among noble public health goals: Preventing suicide. *Prev Med.* 2021;152(Pt 1):106771. Epub 2021/09/21. doi: 10.1016/j.ypmed.2021.106771. PubMed PMID: 34538379.
11. Gottschlich A, van Niekerk D, Smith LW, Gondara L, Melnikow J, Cook DA, **et al.** Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. *Cancer Epidemiol Biomarkers Prev.* 2021;30(1):22-9. Epub 2020/10/22. doi: 10.1158/1055-9965.Epi-20-1177. PubMed PMID: 33082202; PubMed Central PMCID: PMCPMC8284866.
12. Goyette A, Yen GP, Racovitan V, Bhangu P, Kothari S, **Franco EL.** Evolution of Public Health Human Papillomavirus Immunization Programs in Canada. *Curr Oncol.* 2021;28(1):991-1007. Epub 2021/02/23. doi: 10.3390/curroncol28010097. PubMed PMID: 33617515; PubMed Central PMCID: PMCPMC7985769.
13. Grimes DR, Corry EMA, Malagón T, O'Riain C, **Franco EL**, Brennan DJ. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination. *JAMA Netw Open.* 2021;4(6):e2115321. Epub 2021/07/01. doi: 10.1001/jamanetworkopen.2021.15321. PubMed PMID: 34190993; PubMed Central PMCID: PMCPMC8246311 Canadian Institutes of Health Research, the Canadian Cancer Society, and Merck outside the submitted work and holding a self-registered patent pending for methylation markers at the Office of Innovation and Partnerships, McGill University. No other disclosures were reported.
14. Hurtado-Salgado E, Cárdenas-Cárdenas L, Salmerón J, Luna-Gordillo R, Ortiz-Panozo E, Allen-Leigh B, **et al.** Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level. *Int J Cancer.* 2022;150(9):1422-30. Epub 2021/12/19. doi: 10.1002/ijc.33905. PubMed PMID: 34921727.
15. Laurie C, El-Zein M, Coutlée F, de Pokomandy A, **Franco EL.** Carrageenan as a Preventive Agent Against Human Papillomavirus Infection: A Narrative Review. *Sex Transm Dis.* 2021;48(7):458-65. Epub 2021/01/13. doi: 10.1097/olq.0000000000001363. PubMed PMID: 33433173.
16. Laurie C, El-Zein M, **Franco EL**, Coutlée F. Assessment of the possible inhibitory effect of carrageenan in human papillomavirus DNA testing by polymerase chain reaction amplification. *J Med Virol.* 2021;93(11):6408-11. Epub 2021/03/25. doi: 10.1002/jmv.26963. PubMed PMID: 33760280.
17. Laurie C, El-Zein M, Tota JE, Khosrow-Khavar F, Tellier PP, Coutlée F, **et al.** Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. *Sex Transm Infect.* 2021. Epub 2021/06/19. doi: 10.1136/sextrans-2021-055009. PubMed PMID: 34140405.
18. Laurie C, Tota JE, El-Zein M, Tellier PP, Coutlée F, Burchell AN, **et al.** Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial. *Contemp Clin Trials.* 2021;110:106560. Epub 2021/09/07. doi: 10.1016/j.cct.2021.106560. PubMed PMID: 34487919.
19. Malagón T, **Franco EL.** Invited Commentary: Rethinking Cervical Cancer Elimination in Terms of Lifetime Risk Rather Than Arbitrarily Defined Age-Standardized Incidence Rates. *Am J Epidemiol.* 2021;190(4):515-8. Epub 2020/07/09. doi: 10.1093/aje/kwaa120. PubMed PMID: 32639520.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

20. Malagón T, MacCosham A, Burchell AN, El-Zein M, Tellier PP, Coutlée F, **et al.** Sex- and Type-specific Genital Human Papillomavirus Transmission Rates Between Heterosexual Partners: A Bayesian Reanalysis of the HITCH Cohort. *Epidemiology*. 2021;32(3):368-77. Epub 2021/02/25. doi: 10.1097/ede.0000000000001324. PubMed PMID: 33625158; PubMed Central PMCID: PMC8012224.
21. Malagón T, MacCosham A, Burchell AN, El-Zein M, Tellier PP, Coutlée F, **et al.** Proportion of incident genital human papillomavirus detections not attributable to transmission and potentially attributable to latent infections: Implications for cervical cancer screening. *Clin Infect Dis*. 2021. Epub 2021/12/02. doi: 10.1093/cid/ciab985. PubMed PMID: 34849640.
22. Malagón T, Volesky KD, **Franco EL.** Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis. *Int J Cancer*. 2021;148(11):2859-60. Epub 2021/02/11. doi: 10.1002/ijc.33510. PubMed PMID: 33567100.
23. Malagón T, Yong JHE, Tope P, Miller WH, Jr., **Franco EL.** Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada. *Int J Cancer*. 2022;150(8):1244-54. Epub 2021/11/30. doi: 10.1002/ijc.33884. PubMed PMID: 34843106.
24. Mullen CJR, Barr RD, Franco EL. Timeliness of diagnosis and treatment: the challenge of childhood cancers. *Br J Cancer*. 2021;125(12):1612-20. Epub 2021/09/03. doi: 10.1038/s41416-021-01533-4. PubMed PMID: 34471259; PubMed Central PMCID: PMC8651632.
25. Mullen CJR, Barr RD, **Franco EL.** Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers. *Br J Cancer*. 2021;125(8):1178. Epub 2021/09/18. doi: 10.1038/s41416-021-01548-x. PubMed PMID: 34531549; PubMed Central PMCID: PMC8505650.
26. Mullen CJR, Volesky KD, Greenwald ZR, El-Zein M, **Franco EL.** Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2021;30(12):2167-75. Epub 2021/09/23. doi: 10.1158/1055-9965.Epi-21-0548. PubMed PMID: 34548328.
27. Smith LW, Racey CS, Gondara L, Krajden M, Lee M, Martin RE, **et al.** Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. *BMJ Open*. 2021;11(10):e052084. Epub 2021/10/09. doi: 10.1136/bmjopen-2021-052084. PubMed PMID: 34620663; PubMed Central PMCID: PMC8499254.
28. Strang THR, Gottschlich A, Cook DA, Smith LW, Gondara L, **Franco EL,** et al. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. *Am J Obstet Gynecol*. 2021;225(5):511.e1-.e7. Epub 2021/06/04. doi: 10.1016/j.ajog.2021.05.038. PubMed PMID: 34081897; PubMed Central PMCID: PMC8578173.
29. Tomita LY, Horta BL, da Silva LLS, Malta MB, **Franco EL,** Cardoso MA. Fruits and vegetables and cervical cancer: a systematic review and meta-analysis. *Nutr Cancer*. 2021;73(1):62-74. Epub 2020/03/12. doi: 10.1080/01635581.2020.1737151. PubMed PMID: 32156167.
30. Trevisan A, Wissing MD, Dagenais C, Forest P, Ramanakumar AV, Burchell AN, **et al.** Development and evaluation of a new non-competitive Luminex immunoassay detecting



## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

antibodies against human papillomavirus types 6, 11, 16 and 18. *J Gen Virol.* 2021;102(5). Epub 2021/05/28. doi: 10.1099/jgv.0.001610. PubMed PMID: 34043499; PubMed Central PMCID: PMC8627678.

31. Waheed DE, Schiller J, Stanley M, **Franco EL**, Poljak M, Kjaer SK, et al. Human papillomavirus vaccination in adults: impact, opportunities and challenges - a meeting report. *BMC Proc.* 2021;15(Suppl 7):16. Epub 2021/08/14. doi: 10.1186/s12919-021-00217-4. PubMed PMID: 34384438; PubMed Central PMCID: PMC8359761.

### Carolyn Freeman

1. Sepulveda E, Patrick H, **Freeman CR**, Kildea J. Implementation of a DVH Registry to provide constraints and continuous quality monitoring for pediatric CSI treatment planning. *J Appl Clin Med Phys.* 2021 Jan;22(1):191-202. doi: 10.1002/acm2.13131. Epub 2020 Dec 14. PMID: 33315306; PMCID: PMC7856485.

### Jennifer Friedmann

1. Kasymjanova G, Anwar A, Cohen V, Sultanem K, Pepe C, Sakr L, **Friedmann J**, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. *Curr Oncol.* 2021 Oct 20;28(6):4247-4255. doi: 10.3390/curroncol28060360. PMID: 34898542; PMCID: PMC8544580.

### Vincent Giguère

1. Vernier M, **Giguère V**. Aging, senescence and mitochondria: the PGC-1/ERR axis. *J Mol Endocrinol.* 2021 Jan;66(1):R1-R14. doi: 10.1530/JME-20-0196. PMID: 33112791.
2. Scholtes C, **Giguère V**. Transcriptional Regulation of ROS Homeostasis by the ERR Subfamily of Nuclear Receptors. *Antioxidants (Basel).* 2021 Mar 12;10(3):437. doi: 10.3390/antiox10030437. PMID: 33809291; PMCID: PMC7999130.
3. Paquette M, Yan M, Ramírez-Reyes JMJ, El-Houjeiri L, Biondini M, Dufour CR, Jeong H, Pacis A, **Giguère V**, Estall JL, Siegel PM, Audet-Walsh É, Pause A. Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways. *Sci Rep.* 2021 Oct 28;11(1):21268. doi: 10.1038/s41598-021-99958-7. PMID: 34711912; PMCID: PMC8553785.
4. McGuirk S, Audet-Delage Y, Annis MG, Xue Y, Vernier M, Zhao K, St-Louis C, Minarieta L, Patten DA, Morin G, Greenwood CM, **Giguère V**, Huang S, Siegel PM, St-Pierre J. Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. *Elife.* 2021 Jun 28;10:e65150. doi: 10.7554/eLife.65150. PMID: 34181531; PMCID: PMC8238502.
5. Tran A, Scholtes C, Songane M, Champagne C, Galarneau L, Levasseur MP, Fodil N, Dufour CR, **Giguère V**, Saleh M. Estrogen-related receptor alpha (ERR $\alpha$ ) is a key regulator of intestinal homeostasis and protects against colitis. *Sci Rep.* 2021 Jul 23;11(1):15073. doi: 10.1038/s41598-021-94499-5. PMID: 34302001; PMCID: PMC8302669.

### Lucy Gilbert

1. Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, **Gilbert L**, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A,

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

- Sikorska M, Moore K, DiSilvestro P. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. *Eur J Cancer*. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. PMID: 34597975.
2. Oaknin A, Tinker AV, **Gilbert L**, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. *Future Oncol*. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24. PMID: 34427115.
  3. Marth C, Tarnawski R, Tyulyandina A, Pignata S, **Gilbert L**, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. *Int J Gynecol Cancer*. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. PMID: 34799418; PMCID: PMC8762038.
  4. Shallwani SM, Towers A, Newman A, Salvador S, Yung A, **Gilbert L**, Gotlieb WH, Zeng X, Thomas D. Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema. *Curr Oncol*. 2021 Jan 13;28(1):455-470. doi: 10.3390/curroncol28010048. PMID: 33450972; PMCID: PMC7903266.
  5. El-Zein M, Gotlieb W, **Gilbert L**, Hemmings R, Behr MA, Franco EL; STAIN-IT Study Group. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study. *Int J Cancer*. 2021 Jan 15;148(2):492-501. doi: 10.1002/ijc.33250. Epub 2020 Aug 24. PMID: 32781481.
  6. Grundy A, Sandhu S, Arseneau J, **Gilbert L**, Gotlieb WH, Aronson KJ, Koushik A. Lifetime caffeine intake and the risk of epithelial ovarian cancer. *Cancer Epidemiol*. 2022 Feb;76:102058. doi: 10.1016/j.canep.2021.102058. Epub 2021 Nov 17. PMID: 34800867.
  7. Alcindor T, Jung S, **Gilbert L**. Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report. *Curr Oncol*. 2021 Jun 10;28(3):2146-2149. doi: 10.3390/curroncol28030199. PMID: 34200874; PMCID: PMC8293099.

### Walter Gotlieb

1. Ahmed S, **Gotlieb WH**, Erez G, Loiselle CG. Perceptions of BELONG as a supportive e-platform used by women with gynecologic cancers. *Psychooncology*. 2022;31(1):152-6. Epub 2021/08/18. doi: 10.1002/pon.5785. PubMed PMID: 34402558.
2. Cyr MP, Dumoulin C, Bessette P, Pina A, **Gotlieb WH**, Lapointe-Milot K, et al. A Prospective Single-Arm Study Evaluating the Effects of a Multimodal Physical Therapy Intervention on Psychosexual Outcomes in Women With Dyspareunia After Gynecologic Cancer. *J Sex Med*. 2021;18(5):946-54. Epub 2021/05/02. doi: 10.1016/j.jsxm.2021.02.014. PubMed PMID: 33931347.
3. Cyr MP, Dumoulin C, Bessette P, Pina A, **Gotlieb WH**, Lapointe-Milot K, et al. Changes in pelvic floor morphometry and muscle function after multimodal physiotherapy for

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- gynaecological cancer survivors suffering from dyspareunia: a prospective interventional study. *Physiotherapy*. 2022;114:54-62. Epub 2022/01/31. doi: 10.1016/j.physio.2021.09.003. PubMed PMID: 35093737.
4. Cyr MP, Dumoulin C, Bessette P, Pina A, **Gotlieb WH**, Lapointe-Milot K, et al. Characterizing Pelvic Floor Muscle Function and Morphometry in Survivors of Gynecological Cancer Who Have Dyspareunia: A Comparative Cross-Sectional Study. *Phys Ther*. 2021;101(4). Epub 2021/02/02. doi: 10.1093/ptj/pzab042. PubMed PMID: 33522584.
  5. El-Zein M, **Gotlieb W**, Gilbert L, Hemmings R, Behr MA, Franco EL. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertainning Intraepithelial Neoplasia by Immunostain Testing study. *Int J Cancer*. 2021;148(2):492-501. Epub 2020/08/12. doi: 10.1002/ijc.33250. PubMed PMID: 32781481.
  6. Elkholi IE, Di Iorio M, Fahiminiya S, Arcand SL, Han H, Nogué C, **et al**. Investigating the causal role of MRE11A p.E506\* in breast and ovarian cancer. *Sci Rep*. 2021;11(1):2409. Epub 2021/01/30. doi: 10.1038/s41598-021-81106-w. PubMed PMID: 33510186; PubMed Central PMCID: PMC7844268.
  7. Feigenberg T, Cormier B, **Gotlieb WH**, Jegatheeswaran K, Helpman L, Kim SR, et al. Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology of Canada (GOC) community of practice (CoP). *Gynecol Oncol*. 2021;162(3):606-12. Epub 2021/06/30. doi: 10.1016/j.ygyno.2021.06.013. PubMed PMID: 34183164.
  8. Gomolin A, **Gotlieb W**, Lau S, Salvador S, Racovitan F, Abitbol J. Mandate to evaluate robotic surgery implementation: a 12-year retrospective analysis of impact and future implications. *J Robot Surg*. 2021. Epub 2021/11/07. doi: 10.1007/s11701-021-01327-z. PubMed PMID: 34741713.
  9. Grundy A, Sandhu S, Arseneau J, Gilbert L, **Gotlieb WH**, Aronson KJ, et al. Lifetime caffeine intake and the risk of epithelial ovarian cancer. *Cancer Epidemiol*. 2022;76:102058. Epub 2021/11/21. doi: 10.1016/j.canep.2021.102058. PubMed PMID: 34800867.
  10. Kessous R, Matanes E, Laskov I, Wainstock T, Abitbol J, Yasmeen A, **et al**. Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation. *Acta Obstet Gynecol Scand*. 2021;100(3):453-8. Epub 2020/10/14. doi: 10.1111/aogs.14023. PubMed PMID: 33048344.
  11. Kessous R, Wissing MD, Laskov I, Abitbol J, Bitharas J, Agnihotram VR, **et al**. Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. *Int J Cancer*. 2021;148(9):2304-12. Epub 2020/11/17. doi: 10.1002/ijc.33395. PubMed PMID: 33197273.
  12. Le Page C, Amuzu S, Rahimi K, **Gotlieb W**, Ragoussis J, Tonin PN. Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1 and BRCA2 mutation carriers. *Semin Cancer Biol*. 2021;77:110-26. Epub 2020/08/23. doi: 10.1016/j.semcancer.2020.08.005. PubMed PMID: 32827632.
  13. López-Ozuna VM, Kogan L, Hachim MY, Matanes E, Hachim IY, Mitric C, **et al**. Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer. *Front Oncol*. 2021;11:695404. Epub 2021/07/27. doi:

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 10.3389/fonc.2021.695404. PubMed PMID: 34307159; PubMed Central PMCID: PMC8292832.
14. Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O, **et al.** Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. *Am J Obstet Gynecol.* 2021;225(4):367.e1-e39. Epub 2021/06/01. doi: 10.1016/j.ajog.2021.05.034. PubMed PMID: 34058168.
  15. Matanes E, Cantor T, AlShehri E, Salvador S, Lau S, **Gotlieb W.** Surgical technique for sentinel lymph node sampling in endometrial cancer using the articulated HOOK monopolar instrument. *Int J Gynecol Cancer.* 2021. Epub 2021/09/09. doi: 10.1136/ijgc-2021-002840. PubMed PMID: 34493585.
  16. Matanes E, Eisenberg N, Amajoud Z, Gupta V, Yasmeen A, Ismail S, **et al.** Sentinel Lymph Node Sampling as an Alternative to Lymphadenectomy in Patients With Endometrial Cancer and Obesity. *J Obstet Gynaecol Can.* 2021;43(10):1136-44.e1. Epub 2021/05/14. doi: 10.1016/j.jogc.2021.04.014. PubMed PMID: 33984524.
  17. Matanes E, Eisenberg N, Lau S, Salvador S, Ferenczy A, Pelmus M, **et al.** Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes. *Gynecol Oncol.* 2021;162(2):256-61. Epub 2021/06/14. doi: 10.1016/j.ygyno.2021.05.040. PubMed PMID: 34119364.
  18. Matanes E, **Gotlieb WH.** Pathophysiological and anatomical basis of lymphatic transit of cancer cells and role of the lymphatic system: a review of published literature. *Chin Clin Oncol.* 2021;10(2):14. Epub 2021/02/08. doi: 10.21037/cco-20-205. PubMed PMID: 33548982.
  19. Matanes E, Gupta V, Kogan L, Racicot J, Salvador S, **Gotlieb WH,** et al. Surgical Technique for Sentinel Lymph Node Sampling in Presumed Early-stage Ovarian Cancer. *J Minim Invasive Gynecol.* 2021;28(8):1446. Epub 2021/01/03. doi: 10.1016/j.jmig.2020.12.030. PubMed PMID: 33387689.
  20. Matanes E, López-Ozuna VM, Oceau D, Baloch T, Racovitan F, Dhillon AK, **et al.** Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. *Front Oncol.* 2021;11:745981. Epub 2021/11/16. doi: 10.3389/fonc.2021.745981. PubMed PMID: 34778062; PubMed Central PMCID: PMC8578901.
  21. Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, **et al.** Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. *J Minim Invasive Gynecol.* 2021;28(5):947-56. Epub 2020/11/30. doi: 10.1016/j.jmig.2020.11.023. PubMed PMID: 33249269.
  22. Mitric C, How B, Matanes E, Amajoud Z, Zaaroura H, Nguyen HH, **et al.** Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: A pilot project. *Gynecol Oncol Rep.* 2021;37:100842. Epub 2021/08/18. doi: 10.1016/j.gore.2021.100842. PubMed PMID: 34401437; PubMed Central PMCID: PMC8355950.
  23. Schnitman G, Wang T, Kundu S, Turkdogan S, Gotlieb R, How J, **et al.** The role of digital patient education in maternal health: A systematic review. *Patient Educ Couns.* 2022;105(3):586-93. Epub 2021/06/30. doi: 10.1016/j.pec.2021.06.019. PubMed PMID: 34183217.
  24. Shallwani SM, Towers A, Newman A, Salvador S, Yung A, Gilbert L, **et al.** Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

Women with Gynecological Cancer at Risk of Lymphedema. *Curr Oncol.* 2021;28(1):455-70. Epub 2021/01/17. doi: 10.3390/curroncol28010048. PubMed PMID: 33450972; PubMed Central PMCID: PMC7903266.

25. Turkdogan S, Schnitman G, Wang T, Gotlieb R, How J, **Gotlieb WH**. Development of a Digital Patient Education Tool for Patients With Cancer During the COVID-19 Pandemic. *JMIR Cancer.* 2021;7(2):e23637. Epub 2021/06/09. doi: 10.2196/23637. PubMed PMID: 34101611; PubMed Central PMCID: PMC7903266.
26. Xue Y, Morris JL, Yang K, Fu Z, Zhu X, Johnson F, **et al**. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to mitochondria. *Nat Commun.* 2021;12(1):5404. Epub 2021/09/15. doi: 10.1038/s41467-021-25260-9. PubMed PMID: 34518526; PubMed Central PMCID: PMC7903266.

**Celia Greenwood**

1. Amuzu S, Carmona E, Mes-Masson AM, **Greenwood CMT**, Tonin PN, Ragoussis J. Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. *Cancers (Basel).* 2021;13(6). Epub 2021/04/04. doi: 10.3390/cancers13061296. PubMed PMID: 33803939; PubMed Central PMCID: PMC7998846.
2. Bazinet A, Rys RN, Barry A, **Greenwood CMT**, Young YK, Mendoza A, **et al**. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. *Leuk Lymphoma.* 2021;62(10):2352-9. Epub 2021/05/23. doi: 10.1080/10428194.2021.1919658. PubMed PMID: 34020575.
3. Bhagwat N, Barry A, Dickie EW, Brown ST, Devenyi GA, Hatano K, **et al**. Understanding the impact of preprocessing pipelines on neuroimaging cortical surface analyses. *Gigascience.* 2021;10(1). Epub 2021/01/23. doi: 10.1093/gigascience/giaa155. PubMed PMID: 33481004; PubMed Central PMCID: PMC7821710.
4. Caillon A, Zhao K, Klein KO, **Greenwood CMT**, Lu Z, Paradis P, **et al**. High Systolic Blood Pressure at Hospital Admission Is an Important Risk Factor in Models Predicting Outcome of COVID-19 Patients. *Am J Hypertens.* 2021;34(3):282-90. Epub 2021/01/03. doi: 10.1093/ajh/hpaa225. PubMed PMID: 33386395; PubMed Central PMCID: PMC7799245.
5. Douard E, Zeribi A, Schramm C, Tamer P, Loum MA, Nowak S, **et al**. Effect Sizes of Deletions and Duplications on Autism Risk Across the Genome. *Am J Psychiatry.* 2021;178(1):87-98. Epub 2020/09/12. doi: 10.1176/appi.ajp.2020.19080834. PubMed PMID: 32911998; PubMed Central PMCID: PMC7931740.
6. Escribe C, Lu T, Keller-Baruch J, Forgetta V, Xiao B, Richards JB, **et al**. Block coordinate descent algorithm improves variable selection and estimation in error-in-variables regression. *Genet Epidemiol.* 2021;45(8):874-90. Epub 2021/09/02. doi: 10.1002/gepi.22430. PubMed PMID: 34468045.
7. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, **et al**. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. *Genome Med.* 2021;13(1):186. Epub 2021/12/05. doi: 10.1186/s13073-021-00998-5. PubMed PMID: 34861889; PubMed Central PMCID: PMC7903266.
8. Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, **et al**. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. *Clin Transl Med.* 2021;11(4):e401. Epub 2021/05/02. doi:

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 10.1002/ctm2.401. PubMed PMID: 33931971; PubMed Central PMCID: PMC8087915.
9. Guma E, Bordignon PDC, Devenyi GA, Gallino D, Anastassiadis C, Cvetkovska V, **et al.** Early or Late Gestational Exposure to Maternal Immune Activation Alters Neurodevelopmental Trajectories in Mice: An Integrated Neuroimaging, Behavioral, and Transcriptional Study. *Biol Psychiatry*. 2021;90(5):328-41. Epub 2021/06/01. doi: 10.1016/j.biopsych.2021.03.017. PubMed PMID: 34053674.
  10. Huguet G, Schramm C, Douard E, Tamer P, Main A, Monin P, **et al.** Genome-wide analysis of gene dosage in 24,092 individuals estimates that 10,000 genes modulate cognitive ability. *Mol Psychiatry*. 2021;26(6):2663-76. Epub 2021/01/09. doi: 10.1038/s41380-020-00985-z. PubMed PMID: 33414497; PubMed Central PMCID: PMC8953148.
  11. Lu T, Cardenas A, Perron P, Hivert MF, Bouchard L, **Greenwood CMT.** Detecting cord blood cell type-specific epigenetic associations with gestational diabetes mellitus and early childhood growth. *Clin Epigenetics*. 2021;13(1):131. Epub 2021/06/28. doi: 10.1186/s13148-021-01114-5. PubMed PMID: 34174944; PubMed Central PMCID: PMC8236204.
  12. Lu T, Forgetta V, Keller-Baruch J, Nethander M, Bennett D, Forest M, **et al.** Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. *Genome Med*. 2021;13(1):16. Epub 2021/02/05. doi: 10.1186/s13073-021-00838-6. PubMed PMID: 33536041; PubMed Central PMCID: PMC87860212.
  13. Lu T, Forgetta V, Wu H, Perry JRB, Ong KK, **Greenwood CMT,** et al. A Polygenic Risk Score to Predict Future Adult Short Stature Among Children. *J Clin Endocrinol Metab*. 2021;106(7):1918-28. Epub 2021/04/01. doi: 10.1210/clinem/dgab215. PubMed PMID: 33788949; PubMed Central PMCID: PMC8266463.
  14. Lu T, Zhou S, Wu H, Forgetta V, **Greenwood CMT,** Richards JB. Individuals with common diseases but with a low polygenic risk score could be prioritized for rare variant screening. *Genet Med*. 2021;23(3):508-15. Epub 2020/10/29. doi: 10.1038/s41436-020-01007-7. PubMed PMID: 33110269.
  15. McGuirk S, Audet-Delage Y, Annis MG, Xue Y, Vernier M, Zhao K, **et al.** Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. *Elife*. 2021;10. Epub 2021/06/29. doi: 10.7554/eLife.65150. PubMed PMID: 34181531; PubMed Central PMCID: PMC8238502.
  16. Neumann A, Jolicoeur-Martineau A, Szekely E, Sallis HM, O'Donnell K, **Greenwood CMT,** et al. Combined polygenic risk scores of different psychiatric traits predict general and specific psychopathology in childhood. *J Child Psychol Psychiatry*. 2021. Epub 2021/08/15. doi: 10.1111/jcpp.13501. PubMed PMID: 34389974.
  17. Ng KP, Pascoal TA, Mathotaarachchi S, Chan YH, Jiang L, Therriault J, **et al.** Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. *Transl Neurodegener*. 2021;10(1):1. Epub 2021/01/05. doi: 10.1186/s40035-020-00225-y. PubMed PMID: 33390174; PubMed Central PMCID: PMC87780680.
  18. Szekely E, Neumann A, Sallis H, Jolicoeur-Martineau A, Verhulst FC, Meaney MJ, **et al.** Maternal Prenatal Mood, Pregnancy-Specific Worries, and Early Child Psychopathology: Findings From the DREAM BIG Consortium. *J Am Acad Child Adolesc Psychiatry*. 2021;60(1):186-97. Epub 2020/04/12. doi: 10.1016/j.jaac.2020.02.017. PubMed PMID: 32278003.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

19. Zeng Y, Zhao K, Oros Klein K, Shao X, Fritzler MJ, Hudson M, **et al.** Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals. *Genes (Basel)*. 2021;12(9). Epub 2021/09/29. doi: 10.3390/genes12091349. PubMed PMID: 34573331; PubMed Central PMCID: PMC8472734.
20. Zhao K, Oualkacha K, Lakhali-Chaieb L, Labbe A, Klein K, Ciampi A, **et al.** A novel statistical method for modeling covariate effects in bisulfite sequencing derived measures of DNA methylation. *Biometrics*. 2021;77(2):424-38. Epub 2020/05/22. doi: 10.1111/biom.13307. PubMed PMID: 32438470; PubMed Central PMCID: PMC8359306.
21. Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, **et al.** A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. *Nat Med*. 2021;27(4):659-67. Epub 2021/02/27. doi: 10.1038/s41591-021-01281-1. PubMed PMID: 33633408.

**Melissa Henry**

1. Alias A, Bertrand L, Bisson-Gervais V, **Henry M.** Suicide in obstructive lung, cardiovascular and oncological disease. *Prev Med*. 2021;152(Pt 1):106543. Epub 2021/09/21. doi: 10.1016/j.ypmed.2021.106543. PubMed PMID: 34538370.
2. Greenfield B, Jolicoeur-Martineau A, Brown M, Kandiyoti A, **Henry M**, Sasson T, et al. Frequent follow-up of suicidal youth assessed in the emergency room: Long-term trajectory and predictors of suicidality. *Prev Med*. 2021;152(Pt 1):106737. Epub 2021/09/21. doi: 10.1016/j.ypmed.2021.106737. PubMed PMID: 34538378.
3. **Henry M.** Suicide prevention: A multisectorial public health concern. *Prev Med*. 2021;152(Pt 1):106772. Epub 2021/09/21. doi: 10.1016/j.ypmed.2021.106772. PubMed PMID: 34538363; PubMed Central PMCID: PMC8864081.
4. **Henry M**, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, et al. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology*. 2022;31(2):185-97. Epub 2022/02/06. doi: 10.1002/pon.5803. PubMed PMID: 35122670.
5. **Henry M**, Sargi E, Frenkiel S, Hier M, Zeitouni A, Kost K, et al. Longitudinal study indicating antecedent psychosocial vulnerability as predictor of anxiety disorders post-treatment in people with head and neck cancer. *Psychooncology*. 2021;30(11):1910-9. Epub 2021/07/01. doi: 10.1002/pon.5760. PubMed PMID: 34190381.

**Michael Hier**

1. da Silva SD, Marchi FA, Su J, Yang L, Valverde L, Hier J, **et al.** Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype. *Cancers (Basel)*. 2021;13(1). Epub 2021/01/21. doi: 10.3390/cancers13010153. PubMed PMID: 33466385; PubMed Central PMCID: PMC847795342.
2. de Lima JM, Castellano LRC, Bonan PRF, de Medeiros ES, **Hier M**, Bijian K, et al. Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation. *Int J Biochem Cell Biol*. 2021;134:105964. Epub 2021/03/06. doi: 10.1016/j.biocel.2021.105964. PubMed PMID: 33667680.
3. Henry M, Arnovitz E, Frenkiel S, **Hier M**, Zeitouni A, Kost K, et al. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers:

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- A longitudinal study. *Psychooncology*. 2022;31(2):185-97. Epub 2022/02/06. doi: 10.1002/pon.5803. PubMed PMID: 35122670.
4. Henry M, Sargi E, Frenkiel S, **Hier M**, Zeitouni A, Kost K, et al. Longitudinal study indicating antecedent psychosocial vulnerability as predictor of anxiety disorders post-treatment in people with head and neck cancer. *Psychooncology*. 2021;30(11):1910-9. Epub 2021/07/01. doi: 10.1002/pon.5760. PubMed PMID: 34190381.
  5. Hier J, Avior G, Pusztaszeri M, Krasner JR, Alyouha N, Forest VI, **et al**. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review. *J Otolaryngol Head Neck Surg*. 2021;50(1):29. Epub 2021/04/30. doi: 10.1186/s40463-021-00500-6. PubMed PMID: 33910629; PubMed Central PMCID: PMCPMC8082804.
  6. Hier J, Vachon O, Bernstein A, Ibrahim I, Mlynarek A, **Hier M**, et al. Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy. *Sci Rep*. 2021;11(1):10012. Epub 2021/05/13. doi: 10.1038/s41598-021-89476-x. PubMed PMID: 33976322; PubMed Central PMCID: PMCPMC8113272.
  7. Lubov J, Labbé M, Sioufi K, Morand GB, **Hier MP**, Khanna M, et al. Prognostic factors of head and neck cutaneous squamous cell carcinoma: a systematic review. *J Otolaryngol Head Neck Surg*. 2021;50(1):54. Epub 2021/09/09. doi: 10.1186/s40463-021-00529-7. PubMed PMID: 34493343; PubMed Central PMCID: PMCPMC8425113.
  8. Mascarella MA, Muthukrishnan N, Maleki F, Kergoat MJ, Richardson K, Mlynarek A, **et al**. Above and Beyond Age: Prediction of Major Postoperative Adverse Events in Head and Neck Surgery. *Ann Otol Rhinol Laryngol*. 2021;34894211041222. Epub 2021/08/22. doi: 10.1177/00034894211041222. PubMed PMID: 34416844.
  9. Mascarella MA, Peeva M, Forest VI, Pusztaszeri MP, Avior G, Tamilya M, **et al**. Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy. *Clin Otolaryngol*. 2022;47(1):75-80. Epub 2021/09/13. doi: 10.1111/coa.13859. PubMed PMID: 34510770.
  10. Mohtashami S, Richardson K, Forest VI, Mlynarek A, Payne RJ, Tamilya M, **et al**. Thyroidectomy for Graves' Disease Predicts Postoperative Neck Hematoma and Hypocalcemia: A North American cohort study. *Ann Otol Rhinol Laryngol*. 2022;131(4):341-51. Epub 2021/06/02. doi: 10.1177/00034894211021288. PubMed PMID: 34060342; PubMed Central PMCID: PMCPMC8899812.
  11. Nguyen DL, Kay-Rivest E, Tewfik MA, **Hier M**, Lehmann A. Association of In-Ear Device Use With Communication Quality Among Individuals Wearing Personal Protective Equipment in a Simulated Operating Room. *JAMA Netw Open*. 2021;4(4):e216857. Epub 2021/04/20. doi: 10.1001/jamanetworkopen.2021.6857. PubMed PMID: 33871614; PubMed Central PMCID: PMCPMC8056284 Stryker, Mylan, and Novartis; nonfinancial support from Ondine Biomedical; and research support from Sanofi (for serving as the principal investigator [PI] for a randomized clinical trial [RCT]) and from AstraZeneca (for serving as the PI for an RCT) outside the submitted work. Dr Lehmann reported receiving grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) after manuscript submission and nonfinancial support (through borrowed communication equipment) from EERS Inc during the conduct of the study. No other disclosures were reported.
  12. Silver JA, Bogatchenko M, Pusztaszeri M, Forest VI, **Hier MP**, Yang JW, et al. BRAF V600E mutation is associated with aggressive features in papillary thyroid



## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

carcinomas  $\leq 1.5$  cm. *J Otolaryngol Head Neck Surg.* 2021;50(1):63. Epub 2021/11/08. doi: 10.1186/s40463-021-00543-9. PubMed PMID: 34742355; PubMed Central PMCID: PMC8572458.

### Tarek Hijal

1. Aguilar M, Qian PC, Boeck M, Bredfeldt J, Seuntjens J, **Hijal T**, et al. The Rapidly-Developing Area of Radiocardiography: Principles, Complications and Applications of Radiotherapy on the Heart. *Can J Cardiol.* 2021;37(11):1818-27. Epub 2021/07/26. doi: 10.1016/j.cjca.2021.07.011. PubMed PMID: 34303782.
2. Chu D, Schuster T, Lessard D, Mate K, Engler K, Ma Y, **et al.** Acceptability of a Patient Portal (Opal) in HIV Clinical Care: A Feasibility Study. *J Pers Med.* 2021;11(2). Epub 2021/03/07. doi: 10.3390/jpm11020134. PubMed PMID: 33669439; PubMed Central PMCID: PMC8167586.
3. Di Lalla V, Patrick H, Siriani-Ayoub N, Kildea J, **Hijal T**, Alfieri J. Satisfaction among Cancer Patients Undergoing Radiotherapy during the COVID-19 Pandemic: An Institutional Experience. *Curr Oncol.* 2021;28(2):1507-17. Epub 2021/05/01. doi: 10.3390/curroncol28020142. PubMed PMID: 33920247; PubMed Central PMCID: PMC8167586.
4. Engler K, Vicente S, Ma Y, **Hijal T**, Cox J, Ahmed S, et al. Implementation of an electronic patient-reported measure of barriers to antiretroviral therapy adherence with the Opal patient portal: Protocol for a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic. *PLoS One.* 2021;16(12):e0261006. Epub 2021/12/31. doi: 10.1371/journal.pone.0261006. PubMed PMID: 34969046; PubMed Central PMCID: PMC8717992 and Gilead. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
5. Gerard JJ, Bernier M, **Hijal T**, Kopek N, Pater P, Stosky J, et al. Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experiences. *Adv Radiat Oncol.* 2021;6(4):100702. Epub 2021/06/08. doi: 10.1016/j.adro.2021.100702. PubMed PMID: 34095614; PubMed Central PMCID: PMC8165547.
6. Houlding E, Mate KKV, Engler K, Ortiz-Paredes D, Pomey MP, Cox J, **et al.** Barriers to Use of Remote Monitoring Technologies Used to Support Patients With COVID-19: Rapid Review. *JMIR Mhealth Uhealth.* 2021;9(4):e24743. Epub 2021/03/27. doi: 10.2196/24743. PubMed PMID: 33769943; PubMed Central PMCID: PMC8059785.
7. Marta GN, Ramiah D, Kaidar-Person O, Kirby A, Coles C, Jagsi R, **et al.** The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. *Clin Oncol (R Coll Radiol).* 2021;33(5):322-30. Epub 2020/12/29. doi: 10.1016/j.clon.2020.12.008. PubMed PMID: 33358283.
8. Rais F, Tsui JMG, Daianska A, Faye MD, Lambert C, David M, **et al.** Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. *Radiother Oncol.* 2021;162:156-61. Epub 2021/07/18. doi: 10.1016/j.radonc.2021.07.008. PubMed PMID: 34273468.

### Arezu Jahani-Asl

1. Sharanek A, Burbank A, Hernandez-Corchado A, Madrigal A, Fatakdawala I, Najafabadi HS, Soleimani VD, **Jahani-Asl A.** Transcriptional control of brain tumor stem cells by a

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

carbohydrate binding protein. *Cell Rep.* 2021 Aug 31;36(9):109647. doi: 10.1016/j.celrep.2021.109647. PMID: 34469737.

**Nathalie Johnson**

1. Bazinet A, Heath J, Chong AS, Simo-Cheyrou ER, Worme S, Rivera Polo B, **et al.** Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. *Cold Spring Harb Mol Case Stud.* 2021;7(3). Epub 2021/05/15. doi: 10.1101/mcs.a006090. PubMed PMID: 33986034; PubMed Central PMCID: PMC8208041.
2. Bazinet A, Rys RN, Barry A, Greenwood CMT, Young YK, Mendoza A, **et al.** A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. *Leuk Lymphoma.* 2021;62(10):2352-9. Epub 2021/05/23. doi: 10.1080/10428194.2021.1919658. PubMed PMID: 34020575.
3. Korsos V, Vallée A, Rys R, Probst S, Dmitrienko S, Decaluwe H, **et al.** Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab. *Leuk Lymphoma.* 2021:1-5. Epub 2021/12/17. doi: 10.1080/10428194.2021.2012571. PubMed PMID: 34913822.
4. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, **Johnson NA**, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol.* 2021;22(4):512-24. Epub 2021/03/16. doi: 10.1016/s1470-2045(21)00005-x. PubMed PMID: 33721562.
5. Le-Nguyen A, Rys RN, Petrogiannis-Haliotis T, **Johnson NA.** Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma. *Cancer Rep (Hoboken).* 2022;5(1):e1432. Epub 2021/05/29. doi: 10.1002/cnr2.1432. PubMed PMID: 34047076; PubMed Central PMCID: PMC8789614.
6. Leveille E, **Johnson NA.** Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. *Cancers (Basel).* 2021;13(9). Epub 2021/05/06. doi: 10.3390/cancers13092167. PubMed PMID: 33946435; PubMed Central PMCID: PMC8125500.
7. Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, **et al.** A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. *Blood.* 2021;137(5):600-9. Epub 2021/02/05. doi: 10.1182/blood.2020006578. PubMed PMID: 33538797; PubMed Central PMCID: PMC87869186
8. Rys RN, Wever CM, Geoffrion D, Goncalves C, Ghassemian A, Brailovski E, **et al.** Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. *Cancers (Basel).* 2021;13(5). Epub 2021/03/07. doi: 10.3390/cancers13051002. PubMed PMID: 33670870; PubMed Central PMCID: PMC87957722.
9. Safavi S, Larouche A, Zahn A, Patenaude AM, Domanska D, Dionne K, **et al.** Erratum: The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID. *NAR Cancer.* 2021;3(1):zcaa045. Epub 2021/07/29. doi: 10.1093/narcan/zcaa045. PubMed PMID: 34316697; PubMed Central PMCID: PMC8210038.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Petr Kavan**

1. Carrier M, Blais N, Crowther M, **Kavan P**, Le Gal G, Moodley O, et al. Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. *Curr Oncol.* 2021;28(6):5434-51. Epub 2021/12/24. doi: 10.3390/curroncol28060453. PubMed PMID: 34940092; PubMed Central PMCID: PMCPMC8700468.
2. Elkrief A, Redstone G, Petruccielli L, Ali A, Thomas D, Fernandez M, **et al.** Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. *BMJ Open Qual.* 2021;10(1). Epub 2021/03/10. doi: 10.1136/bmjopen-2020-000934. PubMed PMID: 33685857; PubMed Central PMCID: PMCPMC7942255.
3. Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, **et al.** Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. *Clin Transl Med.* 2021;11(4):e401. Epub 2021/05/02. doi: 10.1002/ctm2.401. PubMed PMID: 33931971; PubMed Central PMCID: PMCPMC8087915.
4. Garant A, **Kavan P**, Martin AG, Azoulay L, Vendrely V, Lavoie C, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. *Radiother Oncol.* 2021;155:237-45. Epub 2020/11/22. doi: 10.1016/j.radonc.2020.11.008. PubMed PMID: 33220397.
5. Meyers BM, Vogel A, Marotta P, **Kavan P**, Kamboj L, Pan J, et al. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. *Can J Gastroenterol Hepatol.* 2021;2021:8811018. Epub 2021/03/09. doi: 10.1155/2021/8811018. PubMed PMID: 33681090

**John Kildea**

1. Castro AR, Arnaert A, Moffatt K, **Kildea J**, Bitzas V, Tsimicalis A. Developing an mHealth Application to Coordinate Nurse-Provided Respite Care Services for Families Coping With Palliative-Stage Cancer: Protocol for a User-Centered Design Study. *JMIR Res Protoc.* 2021;10(12):e34652. Epub 2021/12/14. doi: 10.2196/34652. PubMed PMID: 34898464; PubMed Central PMCID: PMCPMC8713105.
2. Chu D, Schuster T, Lessard D, Mate K, Engler K, Ma Y, **et al.** Acceptability of a Patient Portal (Opal) in HIV Clinical Care: A Feasibility Study. *J Pers Med.* 2021;11(2). Epub 2021/03/07. doi: 10.3390/jpm11020134. PubMed PMID: 33669439; PubMed Central PMCID: PMCPMC7920437.
3. Di Lalla V, Patrick H, Siriani-Ayoub N, **Kildea J**, Hijal T, Alfieri J. Satisfaction among Cancer Patients Undergoing Radiotherapy during the COVID-19 Pandemic: An Institutional Experience. *Curr Oncol.* 2021;28(2):1507-17. Epub 2021/05/01. doi: 10.3390/curroncol28020142. PubMed PMID: 33920247; PubMed Central PMCID: PMCPMC8167586.
4. Mathew F, Wang H, Montgomery L, **Kildea J**. Natural language processing and machine learning to assist radiation oncology incident learning. *J Appl Clin Med Phys.* 2021;22(11):172-84. Epub 2021/10/06. doi: 10.1002/acm2.13437. PubMed PMID: 34610206; PubMed Central PMCID: PMCPMC8598135.
5. Mohsen K, **Kildea J**, Lambert SD, Laizner AM. Exploring Cancer Patients' Perceptions of Accessing and Experience with Using the Educational Material in the Opal Patient Portal.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- Support Care Cancer. 2021;29(8):4365-74. Epub 2021/01/09. doi: 10.1007/s00520-020-05900-4. PubMed PMID: 33415366.
6. Montgomery L, Lund CM, Landry A, **Kildea J**. Towards the characterization of neutron carcinogenesis through direct action simulations of clustered DNA damage. *Phys Med Biol*. 2021;66(20). Epub 2021/09/24. doi: 10.1088/1361-6560/ac2998. PubMed PMID: 34555818.
  7. Naseri H, Kafi K, Skamene S, Tolba M, Faye MD, Ramia P, **et al**. Development of a generalizable natural language processing pipeline to extract physician-reported pain from clinical reports: Generated using publicly-available datasets and tested on institutional clinical reports for cancer patients with bone metastases. *J Biomed Inform*. 2021;120:103864. Epub 2021/07/16. doi: 10.1016/j.jbi.2021.103864. PubMed PMID: 34265451.
  8. Patrick HM, Souhami L, **Kildea J**. Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention. *Acta Oncol*. 2021;60(2):229-36. Epub 2020/09/30. doi: 10.1080/0284186x.2020.1825801. PubMed PMID: 32988249.
  9. Sepulveda E, Patrick H, Freeman CR, **Kildea J**. Implementation of a DVH Registry to provide constraints and continuous quality monitoring for pediatric CSI treatment planning. *J Appl Clin Med Phys*. 2021;22(1):191-202. Epub 2020/12/15. doi: 10.1002/acm2.13131. PubMed PMID: 33315306; PubMed Central PMCID: PMC7856485.

**Neil Kopek**

1. Gerard IJ, Bernier M, Hijal T, **Kopek N**, Pater P, Stosky J, Stroian G, Toscani B, Alfieri J. Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experiences. *Adv Radiat Oncol*. 2021 Apr 20;6(4):100702. doi: 10.1016/j.adro.2021.100702. PMID: 34095614; PMCID: PMC8165547.
2. Qu XM, Chen Y, Zaric GS, Senan S, Olson RA, Harrow S, John-Baptiste A, Gaede S, Mulroy LA, Schellenberg D, Senthil S, Swaminath A, **Kopek N**, Liu M, Warner A, Rodrigues GB, Palma DA, Louie AV. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. *Int J Radiat Oncol Biol Phys*. 2021 Apr 1;109(5):1176-1184. doi: 10.1016/j.ijrobp.2020.12.001. Epub 2020 Dec 10. PMID: 33309977.

**Antonis Koromilas**

1. Ghaddar N, Wang S, Woodvine B, Krishnamoorthy J, van Hoef V, Darini C, Kazimierczak U, Ah-Son N, Popper H, Johnson M, Officer L, Teodósio A, Brogginini M, Mann KK, Hatzoglou M, Topisirovic I, Larsson O, Le Quesne J, **Koromilas AE**. The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. *Nat Commun*. 2021 Jul 30;12(1):4651. doi: 10.1038/s41467-021-24661-0. PMID: 34330898; PMCID: PMC8324901.

**Christine Lambert**

1. Rais F, Tsui JMG, Daianska A, Faye MD, **Lambert C**, David M, Panet-Raymond V, Azoulay M, Saidi A, Hijal T. Extreme weekly locoregional hypofractionated radiation in

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

elderly women with non-metastatic breast cancer. *Radiother Oncol.* 2021 Sep;162:156-161. doi: 10.1016/j.radonc.2021.07.008. Epub 2021 Jul 15. PMID: 34273468.

### Pierre Laneuville

1. Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, **Laneuville P**, Delage R, Mollica L, Busque L, Szuber N. Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. *Am J Hematol.* 2021 Jun 1;96(6):E200-E203. doi: 10.1002/ajh.26159. Epub 2021 Mar 26. PMID: 33719144; PMCID: PMC8250202.
2. Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, **Laneuville P**, Lipton JH, Kamel-Reid S, Leber B. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. *Br J Haematol.* 2021 May;193(4):779-791. doi: 10.1111/bjh.17447. Epub 2021 Apr 20. PMID: 33876423.
3. Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, **Laneuville P**, Lipton JH, Kamel-Reid S, Leber B. BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. *Br J Haematol.* 2022 Jan;196(1):136-145. doi: 10.1111/bjh.17807. Epub 2021 Sep 8. PMID: 34496035.

### Adrian Langleben

1. Elkrief A, Redstone G, Petrucci L, Ali A, Thomas D, Fernandez M, Rousseau C, Aleynikova O, Anderson D, Ghitulescu G, Vasilevsky CA, Dalfen R, **Langleben A**, Liberman S, Kavan P, Alcindor T. Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. *BMJ Open Qual.* 2021 Mar;10(1):e000934. doi: 10.1136/bmjopen-2020-000934. PMID: 33685857; PMCID: PMC7942255.
2. Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson GA, Xu L, Piperdi B, Samkari A, Reck M; **KEYNOTE-598 Investigators**. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score  $\geq$  50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. *J Clin Oncol.* 2021 Jul 20;39(21):2327-2338. doi: 10.1200/JCO.20.03579. Epub 2021 Jan 29. PMID: 33513313.

### Susie Lau

1. Feigenberg T, Cormier B, Gotlieb WH, Jegatheeswaran K, Helpman L, Kim SR, **et al**. Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology of Canada (GOC) community of practice (CoP). *Gynecol Oncol.* 2021;162(3):606-12. Epub 2021/06/30. doi: 10.1016/j.ygyno.2021.06.013. PubMed PMID: 34183164.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Gomolin A, Gotlieb W, **Lau S**, Salvador S, Racovitan F, Abitbol J. Mandate to evaluate robotic surgery implementation: a 12-year retrospective analysis of impact and future implications. *J Robot Surg*. 2021. Epub 2021/11/07. doi: 10.1007/s11701-021-01327-z. PubMed PMID: 34741713.
3. Kessous R, Matanes E, Laskov I, Wainstock T, Abitbol J, Yasmeen A, **et al**. Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation. *Acta Obstet Gynecol Scand*. 2021;100(3):453-8. Epub 2020/10/14. doi: 10.1111/aogs.14023. PubMed PMID: 33048344.
4. Kessous R, Wissing MD, Laskov I, Abitbol J, Bitharas J, Agnihotram VR, **et al**. Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. *Int J Cancer*. 2021;148(9):2304-12. Epub 2020/11/17. doi: 10.1002/ijc.33395. PubMed PMID: 33197273.
5. López-Ozuna VM, Kogan L, Hachim MY, Matanes E, Hachim IY, Mitric C, **et al**. Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer. *Front Oncol*. 2021;11:695404. Epub 2021/07/27. doi: 10.3389/fonc.2021.695404. PubMed PMID: 34307159; PubMed Central PMCID: PMC8292832.
6. Matanes E, Cantor T, AlShehri E, Salvador S, **Lau S**, Gotlieb W. Surgical technique for sentinel lymph node sampling in endometrial cancer using the articulated HOOK monopolar instrument. *Int J Gynecol Cancer*. 2021. Epub 2021/09/09. doi: 10.1136/ijgc-2021-002840. PubMed PMID: 34493585.
7. Matanes E, Eisenberg N, Amajoud Z, Gupta V, Yasmeen A, Ismail S, **et al**. Sentinel Lymph Node Sampling as an Alternative to Lymphadenectomy in Patients With Endometrial Cancer and Obesity. *J Obstet Gynaecol Can*. 2021;43(10):1136-44.e1. Epub 2021/05/14. doi: 10.1016/j.jogc.2021.04.014. PubMed PMID: 33984524.
8. Matanes E, Eisenberg N, **Lau S**, Salvador S, Ferenczy A, Pelmus M, **et al**. Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes. *Gynecol Oncol*. 2021;162(2):256-61. Epub 2021/06/14. doi: 10.1016/j.ygyno.2021.05.040. PubMed PMID: 34119364.
9. Matanes E, Gupta V, Kogan L, Racicot J, Salvador S, Gotlieb WH, **et al**. Surgical Technique for Sentinel Lymph Node Sampling in Presumed Early-stage Ovarian Cancer. *J Minim Invasive Gynecol*. 2021;28(8):1446. Epub 2021/01/03. doi: 10.1016/j.jmig.2020.12.030. PubMed PMID: 33387689.
10. Matanes E, López-Ozuna VM, Oceau D, Baloch T, Racovitan F, Dhillon AK, **et al**. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. *Front Oncol*. 2021;11:745981. Epub 2021/11/16. doi: 10.3389/fonc.2021.745981. PubMed PMID: 34778062; PubMed Central PMCID: PMC8578901.
11. Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, **et al**. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. *J Minim Invasive Gynecol*. 2021;28(5):947-56. Epub 2020/11/30. doi: 10.1016/j.jmig.2020.11.023. PubMed PMID: 33249269.
12. Mitric C, How B, Matanes E, Amajoud Z, Zaaroura H, Nguyen HH, **et al**. Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: A pilot project. *Gynecol Oncol Rep*. 2021;37:100842. Epub 2021/08/18.

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

doi: 10.1016/j.gore.2021.100842. PubMed PMID: 34401437; PubMed Central PMCID: PMCPMC8355950.

### Magali Lecavalier-Barsoum

1. **Lecavalier-Barsoum M**, Khosrow-Khavar F, Asiev K, Popovic M, Vuong T, Enger SA. Utilization of brachytherapy in Quebec, Canada. *Brachytherapy*. 2021 Nov-Dec;20(6):1282-1288. doi: 10.1016/j.brachy.2021.07.002. Epub 2021 Aug 20. PMID: 34420860.

### Ives Levesque

1. Mazzoni LN, Bock M, **Levesque IR**, Lurie DJ, Palma G. New developments in MRI: System characterization, technical advances and radiotherapy applications. *Phys Med*. 2021 Oct;90:50-52. doi: 10.1016/j.ejmp.2021.09.001. Epub 2021 Sep 16. PMID: 34537500.
2. Fortier V, Fortin MA, Pater P, Souhami L, **Levesque IR**. A role for magnetic susceptibility in synthetic computed tomography. *Phys Med*. 2021 May;85:137-146. doi: 10.1016/j.ejmp.2021.05.001. Epub 2021 May 15. PMID: 34004446.
3. Xing S, **Levesque IR**. A simulation study of cell size and volume fraction mapping for tissue with two underlying cell populations using diffusion-weighted MRI. *Magn Reson Med*. 2021 Aug;86(2):1029-1044. doi: 10.1002/mrm.28694. Epub 2021 Feb 28. PMID: 33644889.
4. Fortier V, **Levesque IR**. Longitudinal relaxation in fat-water mixtures and its dependence on fat content at 3 T. *NMR Biomed*. 2022 Feb;35(2):e4629. doi: 10.1002/nbm.4629. Epub 2021 Oct 11. PMID: 34636097.

### Sender Liberman

1. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. *Br J Surg*. 2021;108(11):1274-92. Epub 2021/07/07. doi: 10.1093/bjs/znab183. PubMed PMID: 34227657; PubMed Central PMCID: PMCPMC8344569.
2. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. *Lancet*. 2021;397(10272):387-97. Epub 2021/01/25. doi: 10.1016/s0140-6736(21)00001-5. PubMed PMID: 33485461; PubMed Central PMCID: PMCPMC7846817.
3. Alnaki A, Garfinkle R, Almalki T, Pelsser V, Bonaffini P, Reinhold C, **et al**. Long-term Implications of Persistent Diverticulitis: A Retrospective Cohort Study of 915 Patients. *Dis Colon Rectum*. 2021;64(9):1112-9. Epub 2021/08/17. doi: 10.1097/dcr.0000000000001969. PubMed PMID: 34397559.
4. Atoui S, Coca-Martinez M, Mahmoud I, Carli F, **Liberman AS**. Exercise intervention in cancer patients with sleep disturbances scheduled for elective surgery: Systematic review. *Int J Surg*. 2021;93:106069. Epub 2021/09/01. doi: 10.1016/j.ijssu.2021.106069. PubMed PMID: 34464753.
5. Balvardi S, Pecorelli N, Castelino T, Niculiseanu P, Alhashemi M, **Liberman AS**, et al. Impact of Facilitation of Early Mobilization on Postoperative Pulmonary Outcomes After Colorectal Surgery: A Randomized Controlled Trial. *Ann Surg*. 2021;273(5):868-75. Epub 2020/04/24. doi: 10.1097/sla.0000000000003919. PubMed PMID: 32324693.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

6. Carli F, Awasthi R, Gillis C, Baldini G, Bessissow A, **Lieberman AS**, et al. Integrating Prehabilitation in the Preoperative Clinic: A Paradigm Shift in Perioperative Care. *Anesth Analg.* 2021;132(5):1494-500. Epub 2021/03/17. doi: 10.1213/ane.0000000000005471. PubMed PMID: 33724962.
7. Dumitra T, Ganescu O, Hu R, Fiore JF, Jr., Kaneva P, Mayo N, **et al.** Association Between Patient Activation and Health Care Utilization After Thoracic and Abdominal Surgery. *JAMA Surg.* 2021;156(1):e205002. Epub 2020/11/05. doi: 10.1001/jamasurg.2020.5002. PubMed PMID: 33146682; PubMed Central PMCID: PMC7643038 fees from Shionogi outside the submitted work. Dr Lee reports grants from Johnson & Johnson outside the submitted work. Dr Lieberman reports personal fees from Merck, Servier, and Ipsen outside the submitted work. No other disclosures were reported.
8. Garfinkle R, Abou-Khalil M, Salama E, Marinescu D, Pang A, Morin N, **et al.** Development and Validation of a Clinical Risk Score for Intensive Care Resource Utilization After Colon Cancer Surgery: a Practical Guide to the Selection of Patients During COVID-19. *J Gastrointest Surg.* 2021;25(1):252-9. Epub 2020/06/05. doi: 10.1007/s11605-020-04665-9. PubMed PMID: 32495141; PubMed Central PMCID: PMC7269615.
9. Gillis C, Fenton TR, Gramlich L, Sajobi TT, Culos-Reed SN, Bousquet-Dion G, **et al.** Older frail prehabilitated patients who cannot attain a 400 m 6-min walking distance before colorectal surgery suffer more postoperative complications. *Eur J Surg Oncol.* 2021;47(4):874-81. Epub 2020/10/13. doi: 10.1016/j.ejso.2020.09.041. PubMed PMID: 33041092.
10. Lee L, Eustache J, Baldini G, **Lieberman AS**, Charlebois P, Stein B, et al. Enhanced Recovery 2.0 - Same Day Discharge With Mobile App Follow-Up After Minimally Invasive Colorectal Surgery. *Ann Surg.* 2021. Epub 2021/06/07. doi: 10.1097/sla.0000000000004962. PubMed PMID: 34091514.

**Carmen Loisel**

1. Nicoll I, Lockwood G, Longo CJ, **Loiselle CG**, Fitch MI. Relationships between Canadian adult cancer survivors' annual household income and emotional/practical concerns, help-seeking and unmet needs. *Health Soc Care Community.* 2021 Aug 12. doi: 10.1111/hsc.13536. Epub ahead of print. PMID: 34390067.
2. Moon J, Monton O, Smith A, Garfinkle R, Zhao K, Zelkowitz P, **Loiselle CG**, Fiore JF Jr, Sender Lieberman A, Morin N, Faria J, Ghitulescu G, Vasilevsky CA, Bhatnagar SR, Boutros M. Interactive online informational and peer support application for patients with low anterior resection syndrome: patient survey and protocol for a multicentre randomized controlled trial. *Colorectal Dis.* 2021 May;23(5):1248-1257. doi: 10.1111/codi.15602. Epub 2021 Apr 2. PMID: 33638278.
3. Ahmed S, Gotlieb WH, Erez G, **Loiselle CG**. Perceptions of BELONG as a supportive e-platform used by women with gynecologic cancers. *Psychooncology.* 2022 Jan;31(1):152-156. doi: 10.1002/pon.5785. Epub 2021 Aug 17. PMID: 34402558.
4. Fitch MI, Nicoll I, Lockwood G, **Loiselle CG**, Longo CJ, Newton L, Strohschein FJ. Exploring the relationships between income and emotional/practical concerns and help-seeking by older adult cancer survivors: A secondary analysis. *J Geriatr Oncol.* 2022 Apr;13(3):337-345. doi: 10.1016/j.jgo.2021.11.007. Epub 2021 Nov 12. PMID: 34776383.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Richard Margolese**

1. Wong SM, Basik M, Florianova L, **Margolese R**, Dumitra S, Muanza T, Carbonneau A, Ferrario C, Boileau JF. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol*. 2021 May;28(5):2621-2629. doi: 10.1245/s10434-020-09211-0. Epub 2020 Oct 23. PMID: 33095362.
2. Tejera D, Rana M, Basik M, Boileau JF, **Margolese R**, Prakash I, Meguerditchian AN, Muanza T, Monette J, Wong SM. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat*. 2021 Dec;190(3):491-501. doi: 10.1007/s10549-021-06393-3. Epub 2021 Sep 20. PMID: 34542772.

**Luke McCaffrey**

1. Al-Masri M, Paliotti K, Tran R, Halaoui R, Lelarge V, Chatterjee S, **et al**. Architectural control of metabolic plasticity in epithelial cancer cells. *Commun Biol*. 2021;4(1):371. Epub 2021/03/21. doi: 10.1038/s42003-021-01899-4. PubMed PMID: 33742081; PubMed Central PMCID: PMC7979883.
2. Boghdady CM, Kalashnikov N, Mok S, **McCaffrey L**, Moraes C. Revisiting tissue tensegrity: Biomaterial-based approaches to measure forces across length scales. *APL Bioeng*. 2021;5(4):041501. Epub 2021/10/12. doi: 10.1063/5.0046093. PubMed PMID: 34632250; PubMed Central PMCID: PMC798487350.
3. Ear J, Abd El-Hafeez AA, Roy S, Ngo T, Rajapakse N, Choi J, **et al**. A long isoform of GIV/Girdin contains a PDZ-binding module that regulates localization and G-protein binding. *J Biol Chem*. 2021;296:100493. Epub 2021/03/07. doi: 10.1016/j.jbc.2021.100493. PubMed PMID: 33675748; PubMed Central PMCID: PMC798042451.
4. Wang LT, Proulx M, Kim AD, Lelarge V, **McCaffrey L**. A proximity proteomics screen in three-dimensional spheroid cultures identifies novel regulators of lumen formation. *Sci Rep*. 2021;11(1):22807. Epub 2021/11/25. doi: 10.1038/s41598-021-02178-2. PubMed PMID: 34815476; PubMed Central PMCID: PMC798610992.
5. Wang LT, Rajah A, Brown CM, **McCaffrey L**. CD13 orients the apical-basal polarity axis necessary for lumen formation. *Nat Commun*. 2021;12(1):4697. Epub 2021/08/06. doi: 10.1038/s41467-021-24993-x. PubMed PMID: 34349123; PubMed Central PMCID: PMC798338993.

**Ari Meguerditchian**

1. Tejera D, Rana M, Basik M, Boileau JF, Margolese R, Prakash I, **Meguerditchian AN**, Muanza T, Monette J, Wong SM. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat*. 2021 Dec;190(3):491-501. doi: 10.1007/s10549-021-06393-3. Epub 2021 Sep 20. PMID: 34542772.
2. Kurteva S, Tamblyn R, Khosrow-Khavar F, **Meguerditchian AN**. Postoperative duration of opioid use and acute healthcare services use in cancer patients hospitalized for thoracic surgery. *J Surg Oncol*. 2021 Sep;124(3):431-440. doi: 10.1002/jso.26504. Epub 2021 Apr 24. PMID: 33893741.

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

### David Melnychuk

1. Panet F, Tétreault-Langlois M, Morin V, Sultanem K, **Melnichuk D**, Panasci L. The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. *Cancer Rep (Hoboken)*. 2021 Aug 18:e1531. doi: 10.1002/cnr2.1531. Epub ahead of print. PMID: 34409769.

### Sarkis Meterissian

1. GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. *Lancet*. 2021 Jan 30;397(10272):387-397. doi: 10.1016/S0140-6736(21)00001-5. Epub 2021 Jan 21. Erratum in: *Lancet*. 2021 Mar 6;397(10277):880. PMID: 33485461; PMCID: PMC7846817.
2. Di Lena É, Hopkins B, Wong SM, **Meterissian S**. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study. *Surgery*. 2022 Mar;171(3):666-672. doi: 10.1016/j.surg.2021.10.033. Epub 2021 Oct 22. PMID: 34862071; PMCID: PMC8531248.

### Nicholas Meti

1. Cheung MC, Franco BB, **Meti N**, Thawer A, Tahmasebi H, Shankar A, et al. Delivery of Virtual Care in Oncology: Province-Wide Interprofessional Consensus Statements Using a Modified Delphi Process. *Curr Oncol*. 2021;28(6):5332-45. Epub 2021/12/24. doi: 10.3390/currencol28060445. PubMed PMID: 34940084; PubMed Central PMCID: PMC8700064.
2. Lagree A, Mohebpour M, **Meti N**, Saednia K, Lu FI, Slodkowska E, et al. A review and comparison of breast tumor cell nuclei segmentation performances using deep convolutional neural networks. *Sci Rep*. 2021;11(1):8025. Epub 2021/04/15. doi: 10.1038/s41598-021-87496-1. PubMed PMID: 33850222; PubMed Central PMCID: PMC8044238.
3. Lesley GC, Tahmasebi H, **Meti N**, Wright FC, Thawer A, Cheung M, et al. Cancer Treatment During COVID-19: A Qualitative Analysis of Patient-Perceived Risks and Experiences with Virtual Care. *J Patient Exp*. 2021;8:23743735211039328. Epub 2021/09/07. doi: 10.1177/23743735211039328. PubMed PMID: 34485693; PubMed Central PMCID: PMC8411616.
4. Malone E, Barua R, **Meti N**, Li X, Fazelzad R, Hansen AR. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review. *Cancer Med*. 2021;10(15):5031-40. Epub 2021/06/30. doi: 10.1002/cam4.4086. PubMed PMID: 34184416; PubMed Central PMCID: PMC8335827.
5. **Meti N**, Kelly D, Allen MJ, Lanys A, Fazelzad R, Ramjeesingh R, et al. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. *Cancer Treat Rev*. 2021;101:102310. Epub 2021/11/11. doi: 10.1016/j.ctrv.2021.102310. PubMed PMID: 34757307.
6. **Meti N**, Sadeghi-Naini A, Tran WT. Reply to A. Pfof et al. *JCO Clin Cancer Inform*. 2021;5:656-7. Epub 2021/06/11. doi: 10.1200/cci.21.00059. PubMed PMID: 34110932.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

7. **Meti N**, Saednia K, Lagree A, Tabbarah S, Mohebpour M, Kiss A, et al. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features. *JCO Clin Cancer Inform.* 2021;5:66-80. Epub 2021/01/14. doi: 10.1200/cci.20.00078. PubMed PMID: 33439725.
8. **Meti N**, Tahmasebi H, Leahey A, Boudreau A, Thawer A, Stewart J, et al. SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience. *Curr Oncol.* 2021;28(1):278-82. Epub 2021/01/10. doi: 10.3390/currenol28010032. PubMed PMID: 33419159; PubMed Central PMCID: PMC7903264.
9. Saleh RR, Nadler MB, Desnoyers A, **Meti N**, Fazelzad R, Amir E. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. *Cancer Treat Rev.* 2021;100:102283. Epub 2021/09/17. doi: 10.1016/j.ctrv.2021.102283. PubMed PMID: 34530283.
10. Tabariès S, Annis MG, Lazaris A, Petrillo SK, Huxham J, Abdellatif A, **et al.** Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. *Commun Biol.* 2021;4(1):657. Epub 2021/06/04. doi: 10.1038/s42003-021-02189-9. PubMed PMID: 34079064; PubMed Central PMCID: PMC7903264.
11. Tran WT, Sadeghi-Naini A, Lu FI, Gandhi S, Meti N, Brackstone M, **et al.** Computational Radiology in Breast Cancer Screening and Diagnosis Using Artificial Intelligence. *Can Assoc Radiol J.* 2021;72(1):98-108. Epub 2020/09/01. doi: 10.1177/0846537120949974. PubMed PMID: 32865001.

**Catalin Mihalcioiu**

1. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, **Mihalcioiu C**, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. *Nat Med.* 2021 Aug;27(8):1432-1441. doi: 10.1038/s41591-021-01406-6. Epub 2021 Jul 8. PMID: 34239137.
2. Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, **Mihalcioiu C**, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. *J Immunother Cancer.* 2021 Oct;9(10):e003272. doi: 10.1136/jitc-2021-003272. PMID: 34599031; PMCID: PMC8488725.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Wilson Miller**

1. Guo Q, Bartish M, Gonçalves C, Huang F, Smith-Voudouris J, Krisna SS, **et al.** The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. *Cancer Res.* 2021;81(14):3876-89. Epub 2021/05/13. doi: 10.1158/0008-5472.Can-20-3143. PubMed PMID: 33975880.
2. Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, **et al.** Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. *J Clin Invest.* 2021;131(8). Epub 2021/03/11. doi: 10.1172/jci140752. PubMed PMID: 33690225; PubMed Central PMCID: PMCPCMC8262472.
3. Italiano A, **Miller WH, Jr.**, Blay JY, Gietema JA, Bang YJ, Mileskin LR, **et al.** Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. *Invest New Drugs.* 2021;39(6):1587-97. Epub 2021/06/29. doi: 10.1007/s10637-021-01141-2. PubMed PMID: 34180037; PubMed Central PMCID: PMCPCMC8541972.
4. Krisna SS, Goncalves C, Gagnon N, Huang F, Plourde D, **Miller WH, Jr.**, **et al.** Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse. *STAR Protoc.* 2021;2(3):100627. Epub 2021/07/15. doi: 10.1016/j.xpro.2021.100627. PubMed PMID: 34258591; PubMed Central PMCID: PMCPCMC8260876.
5. Maio M, Carlino MS, Joshua AM, McWhirter E, Ribas A, Ascierto PA, **et al.** KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. *Eur J Cancer.* 2022;160:1-11. Epub 2021/11/22. doi: 10.1016/j.ejca.2021.09.024. PubMed PMID: 34801354.
6. Malagón T, Yong JHE, Tope P, **Miller WH, Jr.**, Franco EL. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada. *Int J Cancer.* 2022;150(8):1244-54. Epub 2021/11/30. doi: 10.1002/ijc.33884. PubMed PMID: 34843106.
7. Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, **et al.** Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. *Nat Commun.* 2021;12(1):5022. Epub 2021/08/14. doi: 10.1038/s41467-021-25285-0. PubMed PMID: 34385448; PubMed Central PMCID: PMCPCMC8360951.
8. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, **et al.** Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. *J Immunother Cancer.* 2021;9(1). Epub 2021/01/21. doi: 10.1136/jitc-2020-001931. PubMed PMID: 33468556; PubMed Central PMCID: PMCPCMC7817383.
9. Shorstova T, Su J, Zhao T, Dahabieh M, Leibovitch M, De Sa Tavares Russo M, **et al.** Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. *Mol Cancer Ther.* 2021;20(1):64-75. Epub 2020/10/23. doi: 10.1158/1535-7163.Mct-20-0259. PubMed PMID: 33087508.
10. Thawer A, **Miller WH, Jr.**, Gregorio N, Claveau J, Rajagopal S, Savage KJ, **et al.** Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. *Curr Oncol.* 2021;28(5):3537-53. Epub 2021/10/01. doi: 10.3390/currenol28050304. PubMed PMID: 34590600; PubMed Central PMCID: PMCPCMC8482100.
11. Zhou S, Sikorski D, Xu H, Zubarev A, Chergui M, Lagacé F, **et al.** Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. *Cancers (Basel).*

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2021;13(9). Epub 2021/06/03. doi: 10.3390/cancers13092282. PubMed PMID: 34068774; PubMed Central PMCID: PMC8126223.

**Elliot Mitmaker**

1. Suurd DPD, Visscher WP, Vorselaars WCM, van Beek DJ, Spiering W, Borel Rinkes IHM, Valk GD, Vriens MR; **International CONNsortium Study Group**. A simplified primary aldosteronism surgical outcome score is a useful prediction model when target organ damage is unknown - Retrospective cohort study. *Ann Med Surg (Lond)*. 2021 Apr 20;65:102333. doi: 10.1016/j.amsu.2021.102333. PMID: 33996063; PMCID: PMC8091869.

**Thierry Muanza**

1. Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, **Muanza T**, Carbonneau A, Ferrario C, Boileau JF. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol*. 2021 May;28(5):2621-2629. doi: 10.1245/s10434-020-09211-0. Epub 2020 Oct 23. PMID: 33095362.
2. Tejera D, Rana M, Basik M, Boileau JF, Margolese R, Prakash I, Meguerditchian AN, **Muanza T**, Monette J, Wong SM. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat*. 2021 Dec;190(3):491-501. doi: 10.1007/s10549-021-06393-3. Epub 2021 Sep 20. PMID: 34542772.

**Alain Nepveu**

1. Ramdzan ZM, Vickridge E, Faraco CCF, **Nepveu A**. CUT Domain Proteins in DNA Repair and Cancer. *Cancers (Basel)*. 2021 Jun 12;13(12):2953. doi: 10.3390/cancers13122953. PMID: 34204734; PMCID: PMC8231510.
2. Ramdzan ZM, Vickridge E, Li L, Faraco CCF, Djerir B, Leduy L, Maréchal A, **Nepveu A**. CUT Domains Stimulate Pol  $\beta$  Enzymatic Activities to Accelerate Completion of Base Excision Repair. *J Mol Biol*. 2021 Feb 19;433(4):166806. doi: 10.1016/j.jmb.2020.166806. Epub 2021 Jan 13. PMID: 33450246.

**Tamim Niazi**

1. Chaddad A, Kucharczyk MJ, Cheddad A, Clarke SE, Hassan L, Ding S, **et al**. Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. *Cancers (Basel)*. 2021;13(3). Epub 2021/02/05. doi: 10.3390/cancers13030552. PubMed PMID: 33535569; PubMed Central PMCID: PMC8126223.
2. Chaussé G, Ben-Ezra N, Stoopler M, Levett JY, **Niazi T**, Anidjar M, et al. Diagnostic performance of (18)F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis. *Can Urol Assoc J*. 2021;15(6):173-8. Epub 2020/11/20. doi: 10.5489/cuaj.6817. PubMed PMID: 33212005; PubMed Central PMCID: PMC8195586. The remaining authors report no competing personal or financial interests related to this work.
3. Cheung P, Patel S, North SA, Sahgal A, Chu W, Soliman H, **et al**. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. *Eur Urol*.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 2021;80(6):693-700. Epub 2021/08/18. doi: 10.1016/j.eururo.2021.07.026. PubMed PMID: 34399998.
4. Daro-Faye M, Kassouf W, Souhami L, Marcq G, Cury F, **Niazi T**, et al. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. *World J Urol.* 2021;39(5):1331-43. Epub 2020/09/12. doi: 10.1007/s00345-020-03440-4. PubMed PMID: 32915313; PubMed Central PMCID: PMC7484608.
  5. Fervaha G, Izzard JP, Tripp DA, Aghel N, Shayegan B, Klotz L, **et al.** Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. *Can Urol Assoc J.* 2021;15(6):181-6. Epub 2020/11/20. doi: 10.5489/cuaj.6912. PubMed PMID: 33212008; PubMed Central PMCID: PMC8195585 Gopaul has served on advisory boards for Bayer and TerSera and has received honoraria from AstraZeneca. The remaining authors report no competing personal or financial interests related to this work.
  6. Giraud N, Benziane-Ouaritini N, Schick U, Beauval JB, Chaddad A, **Niazi T**, et al. Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach? *Front Oncol.* 2021;11:781040. Epub 2021/12/10. doi: 10.3389/fonc.2021.781040. PubMed PMID: 34881187; PubMed Central PMCID: PMC8647553.
  7. Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, **et al.** Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. *Can Urol Assoc J.* 2021;15(2):E90-e6. Epub 2020/08/28. doi: 10.5489/cuaj.6779. PubMed PMID: 32853135; PubMed Central PMCID: PMC7864716
  8. Khriouan J, Tsui JMG, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, **et al.** The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. *J Urol.* 2021;205(6):1648-54. Epub 2021/02/13. doi: 10.1097/ju.0000000000001646. PubMed PMID: 33577365.
  9. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, **et al.** Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. *Circulation.* 2021;144(16):1295-307. Epub 2021/08/31. doi: 10.1161/circulationaha.121.056810. PubMed PMID: 34459214.
  10. Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, **et al.** 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J.* 2021;15(2):E81-e90. Epub 2021/02/09. doi: 10.5489/cuaj.7074. PubMed PMID: 33556313; PubMed Central PMCID: PMC7864710
  11. Saad F, Hotte SJ, Finelli A, Malone S, **Niazi T**, Noonan K, et al. Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. *Can Urol Assoc J.* 2021;15(10):353-8. Epub 2021/06/15. doi: 10.5489/cuaj.7347. PubMed PMID: 34125066; PubMed Central PMCID: PMC8525526
  12. Sargos P, Faye MD, Bacci M, Supiot S, Latorzeff I, Azria D, **et al.** Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review. *Front Oncol.* 2021;11:666962. Epub 2021/07/06. doi: 10.3389/fonc.2021.666962. PubMed PMID: 34221983; PubMed Central PMCID: PMC8242201.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

13. Sargos P, Leduc N, Giraud N, Gandaglia G, Roumiguié M, Ploussard G, **et al.** Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy. *Front Oncol.* 2020;10:607923. Epub 2021/03/02. doi: 10.3389/fonc.2020.607923. PubMed PMID: 33643910; PubMed Central PMCID: PMC7906005.
14. Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, **et al.** Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. *JNCI Cancer Spectr.* 2021;5(6). Epub 2021/12/21. doi: 10.1093/jncics/pkab082. PubMed PMID: 34926988; PubMed Central PMCID: PMC78925.
15. Wallis CJD, Shayegan B, Morgan SC, Hamilton RJ, Cagiannos I, Basappa NS, **et al.** Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. *Cancers (Basel).* 2021;13(11). Epub 2021/07/03. doi: 10.3390/cancers13112844. PubMed PMID: 34200349; PubMed Central PMCID: PMC8200983.

**Alexandre Orthwein**

1. Bazinet A, Heath J, Chong AS, Simo-Cheyoun ER, Worme S, Rivera Polo B, **et al.** Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. *Cold Spring Harb Mol Case Stud.* 2021;7(3). Epub 2021/05/15. doi: 10.1101/mcs.a006090. PubMed PMID: 33986034; PubMed Central PMCID: PMC8208041.
2. Boni J, Idani A, Roca C, Feliubadaló L, Tomiak E, Weber E, **et al.** A decade of RAD51C and RAD51D germline variants in cancer. *Hum Mutat.* 2022;43(3):285-98. Epub 2021/12/20. doi: 10.1002/humu.24319. PubMed PMID: 34923718.
3. Dahabieh MS, Huang F, Goncalves C, Flores González RE, Prabhu S, Bolt A, **et al.** Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance. *Autophagy.* 2021;1-19. Epub 2021/06/03. doi: 10.1080/15548627.2021.1936932. PubMed PMID: 34074205.
4. Heath J, Cheyoun ES, Findlay S, Luo VM, Carpio EP, Lee J, **et al.** POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep.* 2022;23(1):e51041. Epub 2021/11/11. doi: 10.15252/embr.202051041. PubMed PMID: 34758190; PubMed Central PMCID: PMC8728601.
5. Matis TS, Zayed N, Labraki B, de Ladurantaye M, Matis TA, Camacho Valenzuela J, **et al.** Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families. *NPJ Breast Cancer.* 2021;7(1):109. Epub 2021/08/27. doi: 10.1038/s41523-021-00315-8. PubMed PMID: 34433815; PubMed Central PMCID: PMC8387362.

**Scott Owen**

1. Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, **et al.** Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer.* 2021;142:83-91. Epub 2020/11/27. doi: 10.1016/j.ejca.2020.10.008. PubMed PMID: 33242835.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Leblanc A, **Owen S**, Fiset PO, Gomez Corrador AL, Isenberg J, Bouganim N. Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib. *JCO Precis Oncol.* 2021;5:802-7. Epub 2022/01/08. doi: 10.1200/po.20.00348. PubMed PMID: 34994612.

**Lawrence Panasci**

1. Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; **PERUSE investigators**. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. *Ann Oncol.* 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. PMID: 34224826.
2. Panet F, Tétreault-Langlois M, Morin V, Sultanem K, Melnychuk D, **Panasci L**. The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. *Cancer Rep (Hoboken).* 2021 Aug 18:e1531. doi: 10.1002/cnr.2.1531. Epub ahead of print. PMID: 34409769.

**Valerie Panet-Raymond**

1. Rais F, Tsui JMG, Daianska A, Faye MD, Lambert C, David M, **Panet-Raymond V**, Azoulay M, Saidi A, Hijal T. Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. *Radiother Oncol.* 2021 Sep;162:156-161. doi: 10.1016/j.radonc.2021.07.008. Epub 2021 Jul 15. PMID: 34273468.
2. Vakilian S, Thébaut J, Ruo R, Marcovitz S, **Panet-Raymond V**, Shenouda G, Sultanem K, Souhami L. Examination of the Dose-Effect Relationship of Radiation-Induced Hypopituitarism: Results of a Case-Control Study. *Adv Radiat Oncol.* 2021 Apr 15;6(4):100693. doi: 10.1016/j.adro.2021.100693. PMID: 34141955; PMCID: PMC8184512.
3. Patil N, Somasundaram E, Waite KA, Lathia JD, Machtay M, Gilbert MR, Connor JR, Rubin JB, Berens ME, Buerki RA, Choi S, Sloan AE, Penas-Prado M, Ashby LS, Blumenthal DT, Werner-Wasik M, Hunter GK, Flickinger JC, Wendland MM, **Panet-Raymond V**, Robins HI, Pugh SL, Mehta MP, Barnholtz-Sloan JS. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. *J Neurooncol.* 2021 Dec;155(3):363-372. doi: 10.1007/s11060-021-03886-5. Epub 2021 Nov 10. PMID: 34761331; PMCID: PMC8651582.

**Morag Park**

1. Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, **et al**. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. *JCI Insight.* 2021;6(4). Epub 2021/01/21. doi: 10.1172/jci.insight.138382. PubMed PMID: 33470989; PubMed Central PMCID: PMC7934920.
2. Dankner M, Caron M, Al-Saadi T, Yu W, Ouellet V, Ezzeddine R, **et al**. Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. *Neuro Oncol.* 2021;23(9):1470-80. Epub 2021/01/13.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- doi: 10.1093/neuonc/noab002. PubMed PMID: 33433612; PubMed Central PMCID: PMC8408858.
3. El-Houjeiri L, Biondini M, Paquette M, Kuasne H, Pacis A, **Park M**, et al. Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. *J Clin Invest.* 2021;131(22). Epub 2021/11/16. doi: 10.1172/jci144871. PubMed PMID: 34779410; PubMed Central PMCID: PMC8592551.
  4. Flores-Torres S, Peza-Chavez O, Kuasne H, Munguia-Lopez JG, Kort-Mascort J, Ferri L, **et al.** Alginate-gelatin-Matrigel hydrogels enable the development and multigenerational passaging of patient-derived 3D bioprinted cancer spheroid models. *Biofabrication.* 2021;13(2). Epub 2021/01/14. doi: 10.1088/1758-5090/abdb87. PubMed PMID: 33440351.
  5. Fukano M, **Park M**, Deblois G. Metabolic Flexibility Is a Determinant of Breast Cancer Heterogeneity and Progression. *Cancers (Basel).* 2021;13(18). Epub 2021/09/29. doi: 10.3390/cancers13184699. PubMed PMID: 34572926; PubMed Central PMCID: PMC8467722.
  6. Ghanbari F, Fortier AM, **Park M**, Philip A. Cholesterol-Induced Metabolic Reprogramming in Breast Cancer Cells Is Mediated via the ERR $\alpha$  Pathway. *Cancers (Basel).* 2021;13(11). Epub 2021/06/03. doi: 10.3390/cancers13112605. PubMed PMID: 34073320; PubMed Central PMCID: PMC8198778.
  7. Goyette MA, Elkhohi IE, Apcher C, Kuasne H, Rothlin CV, Muller WJ, **et al.** Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1 $\alpha$  levels. *Proc Natl Acad Sci U S A.* 2021;118(29). Epub 2021/07/17. doi: 10.1073/pnas.2023868118. PubMed PMID: 34266948; PubMed Central PMCID: PMC8307381.
  8. Kuzmin E, Monlong J, Martinez C, Kuasne H, Kleinman CL, Ragoussis J, **et al.** Inferring Copy Number from Triple-Negative Breast Cancer Patient Derived Xenograft scRNAseq Data Using scCNA. *Methods Mol Biol.* 2021;2381:285-303. Epub 2021/10/01. doi: 10.1007/978-1-0716-1740-3\_16. PubMed PMID: 34590283.
  9. Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, **et al.** Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. *Nat Mater.* 2021;20(4):548-59. Epub 2020/12/02. doi: 10.1038/s41563-020-00849-5. PubMed PMID: 33257795; PubMed Central PMCID: PMC8005404.
  10. Sung VYC, Knight JF, Johnson RM, Stern YE, Saleh SM, Savage P, **et al.** Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. *NPJ Breast Cancer.* 2021;7(1):36. Epub 2021/03/28. doi: 10.1038/s41523-021-00238-4. PubMed PMID: 33772015; PubMed Central PMCID: PMC817997957.
  11. Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, **et al.** STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. *Nat Commun.* 2021;12(1):3299. Epub 2021/06/05. doi: 10.1038/s41467-021-23396-2. PubMed PMID: 34083537; PubMed Central PMCID: PMC8175605.
  12. Xue Y, Morris JL, Yang K, Fu Z, Zhu X, Johnson F, **et al.** SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

mitochondria. *Nat Commun.* 2021;12(1):5404. Epub 2021/09/15. doi: 10.1038/s41467-021-25260-9. PubMed PMID: 34518526; PubMed Central PMCID: PMC8438089.

### William Parker

1. Rahma OE, Yothers G, Hong TS, Russell MM, You YN, **Parker W**, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, Moxley KM, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2021 Aug 1;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683. PMID: 34196693; PMCID: PMC8251652.
2. Jalal S, **Parker W**, Ferguson D, Nicolaou S. Exploring the Role of Artificial Intelligence in an Emergency and Trauma Radiology Department. *Can Assoc Radiol J.* 2021 Feb;72(1):167-174. doi: 10.1177/0846537120918338. Epub 2020 Apr 20. PMID: 32309989.
3. Glide-Hurst CK, Lee P, Yock AD, Olsen JR, Cao M, Siddiqui F, **Parker W**, Doemer A, Rong Y, Kishan AU, Benedict SH, Li XA, Erickson BA, Sohn JW, Xiao Y, Wuthrick E. Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology. *Int J Radiat Oncol Biol Phys.* 2021 Mar 15;109(4):1054-1075. doi: 10.1016/j.ijrobp.2020.10.021. Epub 2020 Oct 24. PMID: 33470210; PMCID: PMC8290862.
4. **Parker W**, Jaremko JL, Cicero M, Azar M, El-Emam K, Gray BG, Hurrell C, Lavoie-Cardinal F, Desjardins B, Lum A, Sheremeta L, Lee E, Reinhold C, Tang A, Bromwich R. Canadian Association of Radiologists White Paper on De-identification of Medical Imaging: Part 2, Practical Considerations. *Can Assoc Radiol J.* 2021 Feb;72(1):25-34. doi: 10.1177/0846537120967345. Epub 2020 Nov 3. PMID: 33140663.
5. **Parker W**, Jaremko JL, Cicero M, Azar M, El-Emam K, Gray BG, Hurrell C, Lavoie-Cardinal F, Desjardins B, Lum A, Sheremeta L, Lee E, Reinhold C, Tang A, Bromwich R. Canadian Association of Radiologists White Paper on De-Identification of Medical Imaging: Part 1, General Principles. *Can Assoc Radiol J.* 2021 Feb;72(1):13-24. doi: 10.1177/0846537120967349. Epub 2020 Nov 3. PMID: 33138621.

### François Patenaude

1. Canil C, Kapoor A, Basappa NS, Bjarnason G, Bossé D, Dudani S, Graham J, Gray S, Hansen AR, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, **Patenaude F**, Soulières D, Thana M, Winkvist E, Wood LA, Reaume MN, Maloni R, Hotte SJ; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. *Can Urol Assoc J.* 2021 Apr;15(4):84-97. doi: 10.5489/cuaj.7245. PMID: 33830005; PMCID: PMC8021420.
2. Frohlich M, Buhlaiga N, Wang H, **Patenaude F**, Sirois C, Sakr L. Systemic sarcoidosis mimicking metastatic renal cell carcinoma with subsequent cardiac involvement. *Respir Med Case Rep.* 2020 Dec 31;32:101334. doi: 10.1016/j.rmcr.2020.101334. PMID: 33457201; PMCID: PMC7797905.
3. Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR, Graham J, Soulières D, Reaume MN, Lalani AA, Castonguay V, Bjarnason GA, **Patenaude F**,

**Gerald Bronfman Department of Oncology Annual Report 2021**  
**Publications**

- Breau RH, Pouliot F, Kapoor A, Wood LA. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. *Clin Genitourin Cancer*. 2021 Dec 10:S1558-7673(21)00232-9. doi: 10.1016/j.clgc.2021.12.003. Epub ahead of print. PMID: 35115252.
4. Cheung P, Patel S, North SA, Sahgal A, Chu W, Soliman H, Ahmad B, Winquist E, Niazi T, **Patenaude F**, Lim G, Heng DYC, Dubey A, Czaykowski P, Wong RKS, Swaminath A, Morgan SC, Mangat R, Keshavarzi S, Bjarnason GA. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. *Eur Urol*. 2021 Dec;80(6):693-700. doi: 10.1016/j.eururo.2021.07.026. Epub 2021 Aug 13. PMID: 34399998.

**Piotr Pater**

1. Fortier V, Fortin MA, **Pater P**, Souhami L, Levesque IR. A role for magnetic susceptibility in synthetic computed tomography. *Phys Med*. 2021 May;85:137-146. doi: 10.1016/j.ejmp.2021.05.001. Epub 2021 May 15. PMID: 34004446.
2. Gerard IJ, Bernier M, Hijal T, Kopek N, **Pater P**, Stosky J, Stroian G, Toscani B, Alfieri J. Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experiences. *Adv Radiat Oncol*. 2021 Apr 20;6(4):100702. doi: 10.1016/j.adro.2021.100702. PMID: 34095614; PMCID: PMC8165547.

**Horacio Patrocinio**

1. Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, **Patrocinio H**, Berlin A, Mendez LC, Moraes FY. Practical considerations for prostate hypofractionation in the developing world. *Nat Rev Urol*. 2021 Nov;18(11):669-685. doi: 10.1038/s41585-021-00498-6. Epub 2021 Aug 13. PMID: 34389825; PMCID: PMC8361822.
2. Khriguian J, **Patrocinio H**, Andonian S, Aprikian A, Kassouf W, Tanguay S, Cury FL. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. *Pract Radiat Oncol*. 2022 Jan-Feb;12(1):e34-e39. doi: 10.1016/j.ppro.2021.07.006. Epub 2021 Sep 13. PMID: 34530170.

**Jerry Pelletier**

1. Abusarah J, Cui Y, El-Hachem N, El-Kadiry AE, Hammond-Martel I, Wurtele H, **et al**. TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity. *Mol Cancer Ther*. 2021;20(1):37-49. Epub 2020/10/23. doi: 10.1158/1535-7163.Mct-20-0333. PubMed PMID: 33087510.
2. Abusarah J, Khodayarian F, El-Hachem N, Salame N, Olivier M, Balood M, **et al**. Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice. *Cell Rep Med*. 2021;2(12):100455. Epub 2022/01/15. doi: 10.1016/j.xcrm.2021.100455. PubMed PMID: 35028603; PubMed Central PMCID: PMC8714858.
3. Chu J, Robert F, **Pelletier J**. Trans-spliced mRNA products produced from circRNA expression vectors. *Rna*. 2021;27(6):676-82. Epub 2021/03/26. doi: 10.1261/rna.078261.120. PubMed PMID: 33762403; PubMed Central PMCID: PMC8127989.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

4. Lin YH, Wang H, Fiore A, Förster M, Tung LT, Belle JI, **et al.** Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma. *J Cell Mol Med.* 2021;25(14):7089-94. Epub 2021/06/12. doi: 10.1111/jcmm.16554. PubMed PMID: 34114734; PubMed Central PMCID: PMC8278115.
5. Naineni SK, Liang J, Hull K, Cencic R, Zhu M, Northcote P, **et al.** Functional mimicry revealed by the crystal structure of an eIF4A:RNA complex bound to the interfacial inhibitor, desmethyl pateamine A. *Cell Chem Biol.* 2021;28(6):825-34.e6. Epub 2021/01/08. doi: 10.1016/j.chembiol.2020.12.006. PubMed PMID: 33412110; PubMed Central PMCID: PMC8626061.
6. **Pelletier J**, Schmeing TM, Sonenberg N. The multifaceted eukaryotic cap structure. *Wiley Interdiscip Rev RNA.* 2021;12(2):e1636. Epub 2020/12/11. doi: 10.1002/wrna.1636. PubMed PMID: 33300197.
7. Sénéchal P, Robert F, Cencic R, Yanagiya A, Chu J, Sonenberg N, **et al.** Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse. *Cell Mol Life Sci.* 2021;78(19-20):6709-19. Epub 2021/09/25. doi: 10.1007/s00018-021-03940-5. PubMed PMID: 34559254.
8. Shen L, Pugsley L, Cencic R, Wang H, Robert F, Naineni SK, **et al.** A forward genetic screen identifies modifiers of rocaglate responsiveness. *Sci Rep.* 2021;11(1):18516. Epub 2021/09/18. doi: 10.1038/s41598-021-97765-8. PubMed PMID: 34531456; PubMed Central PMCID: PMC8445955.
9. Skofler C, Kleinegger F, Krassnig S, Birkl-Toeglhofer AM, Singer G, Till H, **et al.** Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma. *Cells.* 2021;10(2). Epub 2021/02/06. doi: 10.3390/cells10020301. PubMed PMID: 33540613; PubMed Central PMCID: PMC87912938.

**Carmela Pepe**

1. Kasymjanova G, Anwar A, Cohen V, Sultanem K, **Pepe C**, Sakr L, Friedmann J, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. *Curr Oncol.* 2021 Oct 20;28(6):4247-4255. doi: 10.3390/curroncol28060360. PMID: 34898542; PMCID: PMC8544580.
2. Agulnik JS, Kasymjanova G, **Pepe C**, Hurry M, Walton RN, Sakr L, Cohen V, Small D. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. *Curr Oncol.* 2021 Dec 7;28(6):5179-5191. doi: 10.3390/curroncol28060434. PMID: 34940073; PMCID: PMC8700535.

**Michael Pollak**

1. Cho BA, Iyengar NM, Zhou XK, Morrow M, Giri DD, Verma A, **et al.** Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. *Carcinogenesis.* 2021;42(10):1281-92. Epub 2021/07/28. doi: 10.1093/carcin/bgab066. PubMed PMID: 34314488; PubMed Central PMCID: PMC8546933.
2. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, **et al.** IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. *JNCI Cancer Spectr.* 2021;5(1). Epub 2021/01/12. doi: 10.1093/jncics/pkaa074. PubMed PMID: 33426464; PubMed Central PMCID: PMC87785047.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

3. Igelmann S, Lessard F, Uchenunu O, Bouchard J, Fernandez-Ruiz A, Rowell MC, **et al.** A hydride transfer complex reprograms NAD metabolism and bypasses senescence. *Mol Cell.* 2021;81(18):3848-65.e19. Epub 2021/09/22. doi: 10.1016/j.molcel.2021.08.028. PubMed PMID: 34547241.
4. Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, **et al.** Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. *NPJ Breast Cancer.* 2021;7(1):18. Epub 2021/03/03. doi: 10.1038/s41523-021-00226-8. PubMed PMID: 33649363; PubMed Central PMCID: PMC7921427 Morrow receives consulting fees from Genomic Health. The remaining authors declare no competing interests.
5. Iyengar NM, Zhou XK, Mendieta H, Giri DD, El-Hely O, Winston L, **et al.** Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. *Cancer Prev Res (Phila).* 2021;14(5):541-50. Epub 2021/03/03. doi: 10.1158/1940-6207.Capr-20-0507. PubMed PMID: 33648942; PubMed Central PMCID: PMC8102399.
6. Ma C, Wang Y, Wilson KM, Mucci LA, Stampfer MJ, **Pollak M**, et al. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. *JNCI Cancer Spectr.* 2022;6(1). Epub 2022/01/21. doi: 10.1093/jncics/pkab091. PubMed PMID: 35047751; PubMed Central PMCID: PMC8763370.
7. Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, **et al.** Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. *J Cancer Prev.* 2021;26(4):309-17. Epub 2022/01/21. doi: 10.15430/jcp.2021.26.4.309. PubMed PMID: 35047458; PubMed Central PMCID: PMC8749317.
8. Papadopoli D, **Pollak M**, Topisirovic I. The role of GSK3 in metabolic pathway perturbations in cancer. *Biochim Biophys Acta Mol Cell Res.* 2021;1868(8):119059. Epub 2021/05/15. doi: 10.1016/j.bbamcr.2021.119059. PubMed PMID: 33989699.
9. Papadopoli D, Uchenunu O, Palia R, Chekkal N, Hulea L, Topisirovic I, **et al.** Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. *Neoplasia.* 2021;23(4):391-9. Epub 2021/03/31. doi: 10.1016/j.neo.2021.02.003. PubMed PMID: 33784591; PubMed Central PMCID: PMC8027095.
10. Rosendahl AH, Björner S, Ygland Rödström M, Jirström K, Borgquist S, Ingvar C, **et al.** Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. *Front Oncol.* 2021;11:626058. Epub 2021/03/27. doi: 10.3389/fonc.2021.626058. PubMed PMID: 33767994; PubMed Central PMCID: PMC7986849.
11. Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Cohen SJ, Gill S, **et al.** Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. *JNCI Cancer Spectr.* 2021;5(5). Epub 2021/09/07. doi: 10.1093/jncics/pkab070. PubMed PMID: 34485815; PubMed Central PMCID: PMC8410141.
12. Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, **et al.** STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. *Nat Commun.* 2021;12(1):3299. Epub 2021/06/05. doi: 10.1038/s41467-021-23396-2. PubMed PMID: 34083537; PubMed Central PMCID: PMC8175605.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

13. Wong SM, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, **et al.** Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer*. 2022;128(7):1365-72. Epub 2021/12/18. doi: 10.1002/cncr.34065. PubMed PMID: 34919263.
14. Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, **et al.** A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. *Nat Med*. 2021;27(4):659-67. Epub 2021/02/27. doi: 10.1038/s41591-021-01281-1. PubMed PMID: 33633408.

**Marija Popovic**

1. Ayala Alvarez DS, Watson PGF, **Popovic M**, Heng VJ, Evans MDC, Seuntjens J. Monte Carlo calculation of the TG-43 dosimetry parameters for the INTRABEAM source with spherical applicators. *Phys Med Biol*. 2021 Nov 5;66(21). doi: 10.1088/1361-6560/ac309f. PMID: 34663769.
2. Lecavalier-Barsoum M, Khosrow-Khavar F, Asiev K, **Popovic M**, Vuong T, Enger SA. Utilization of brachytherapy in Quebec, Canada. *Brachytherapy*. 2021 Nov-Dec;20(6):1282-1288. doi: 10.1016/j.brachy.2021.07.002. Epub 2021 Aug 20. PMID: 34420860.
3. Watson PGF, **Popovic M**, Liang L, Tomic N, Devic S, Seuntjens J. Clinical Implication of Dosimetry Formalisms for Electronic Low-Energy Photon Intraoperative Radiation Therapy. *Pract Radiat Oncol*. 2021 Jan-Feb;11(1):e114-e121. doi: 10.1016/j.prro.2020.07.005. Epub 2020 Aug 11. PMID: 32795615.

**Ipshita Prakash**

1. **Prakash I**, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Hyslop T, Fayanju OM. Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. *Breast Cancer Res Treat*. 2021 Apr;186(2):535-550. doi: 10.1007/s10549-020-06012-7. Epub 2020 Nov 18. PMID: 33206290; PMCID: PMC7994184.
2. Tejera D, Rana M, Basik M, Boileau JF, Margolese R, **Prakash I**, Meguerditchian AN, Muanza T, Monette J, Wong SM. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat*. 2021 Dec;190(3):491-501. doi: 10.1007/s10549-021-06393-3. Epub 2021 Sep 20. PMID: 34542772.
3. Wong SM, Ajjamada L, Weiss AC, **Prakash I**, Skamene S, Boileau JF, Pollak MN, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer*. 2022 Apr 1;128(7):1365-1372. doi: 10.1002/cncr.34065. Epub 2021 Dec 17. PMID: 34919263.

**Raghu Rajan**

1. Marcq G, Souhami L, Cury FL, Salimi A, Aprikian A, Tanguay S, Vanhuysse M, **Rajan R**, Brimo F, Mansure JJ, Kassouf W. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. *Int J Radiat Oncol Biol Phys*.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2021 Jul 1;110(3):738-741. doi: 10.1016/j.ijrobp.2020.12.033. Epub 2021 Jan 6. PMID: 33421558.

2. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, **Rajan R**, Aprikian A, Tanguay S, Cury FL, Brimo F, Souhami L, Kassouf W. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci.* 2021 Dec 23;36:26-33. doi: 10.1016/j.euros.2021.11.011. PMID: 35098169; PMCID: PMC8783035.

**Paul Ramia**

1. **Ramia P**, Ollaik F, Hilal L, Jalbout W, AlJaroudi W, Al Ahmad A, Sfeir P, Jurjus A, Refaat M, Youssef B. Stereotactic Radiosurgery for Atrioventricular Node Ablation in Swine: A Study on Efficacy and Dosimetric Evaluation of Organs at Risk. *Cureus.* 2021 Oct 14;13(10):e18785. doi: 10.7759/cureus.18785. PMID: 34804652; PMCID: PMC8592376.
2. Naseri H, Kafi K, Skamene S, Tolba M, Faye MD, **Ramia P**, Khriuguian J, Kildea J. Development of a generalizable natural language processing pipeline to extract physician-reported pain from clinical reports: Generated using publicly-available datasets and tested on institutional clinical reports for cancer patients with bone metastases. *J Biomed Inform.* 2021 Aug;120:103864. doi: 10.1016/j.jbi.2021.103864. Epub 2021 Jul 12. PMID: 34265451.
3. Abou Heidar N, El-Doueihi R, Merhe A, **Ramia P**, Bustros G, Yacoubian A, Jaafar R, Nasr R. The role of pre-biopsy mpMRI in lymph node staging for prostate cancer. *Urologia.* 2022 Feb;89(1):64-69. doi: 10.1177/03915603211016805. Epub 2021 May 13. PMID: 33985388.
4. Kayali M, Jaoude JA, **Ramia P**, Assi H, Geara F, Poortmans P, Zeidan YH. Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited. *Ecancermedicalscience.* 2021 Mar 1;15:1194. doi: 10.3332/ecancer.2021.1194. PMID: 33889203; PMCID: PMC8043677.

**Stéphane Richard**

1. Cai T, Cinkornpumin JK, Yu Z, Villarreal OD, Pastor WA, **Richard S**. Deletion of RBMX RGG/RG motif in Shashi-XLID syndrome leads to aberrant p53 activation and neuronal differentiation defects. *Cell Rep.* 2021;36(2):109337. Epub 2021/07/15. doi: 10.1016/j.celrep.2021.109337. PubMed PMID: 34260915.
2. Cai T, Yu Z, Wang Z, Liang C, **Richard S**. Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication. *J Biol Chem.* 2021;297(1):100821. Epub 2021/05/25. doi: 10.1016/j.jbc.2021.100821. PubMed PMID: 34029587; PubMed Central PMCID: PMC8141346.
3. Dominici C, Sgarloto N, Yu Z, Sesma-Sanz L, Masson JY, **Richard S**, et al. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. *Clin Epigenetics.* 2021;13(1):54. Epub 2021/03/12. doi: 10.1186/s13148-021-01037-1. PubMed PMID: 33691794; PubMed Central PMCID: PMC8141346.
4. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, et al. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep.* 2022;23(1):e51041. Epub 2021/11/11. doi: 10.15252/embr.202051041. PubMed PMID: 34758190; PubMed Central PMCID: PMC8728601.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

5. Lee JS, Lamarche-Vane N, **Richard S**. Microexon alternative splicing of small GTPase regulators: Implication in central nervous system diseases. *Wiley Interdiscip Rev RNA*. 2022;13(2):e1678. Epub 2021/06/23. doi: 10.1002/wrna.1678. PubMed PMID: 34155820.
6. Qiao A, Zhou J, Xu S, Ma W, Boriboun C, Kim T, **et al**. Sam68 promotes hepatic gluconeogenesis via CRTC2. *Nat Commun*. 2021;12(1):3340. Epub 2021/06/09. doi: 10.1038/s41467-021-23624-9. PubMed PMID: 34099657; PubMed Central PMCID: PMC8185084.
7. Xu J, **Richard S**. Cellular pathways influenced by protein arginine methylation: Implications for cancer. *Mol Cell*. 2021;81(21):4357-68. Epub 2021/10/08. doi: 10.1016/j.molcel.2021.09.011. PubMed PMID: 34619091; PubMed Central PMCID: PMC8571027.

**Stephen Robbins**

1. Peirsman A, Blondeel E, Ahmed T, Anckaert J, Audenaert D, Boterberg T, Buzas K, Carragher N, Castellani G, Castro F, Dangles-Marie V, Dawson J, De Tullio P, De Vlieghere E, Dedeyne S, Depypere H, Diosdi A, Dmitriev RI, Dolznig H, Fischer S, Gespach C, Goossens V, Heino J, Hendrix A, Horvath P, Kunz-Schughart LA, Maes S, Mangodt C, Mestdagh P, Michlíková S, Oliveira MJ, Pampaloni F, Piccinini F, Pinheiro C, Rahn J, **Robbins SM**, Siljamäki E, Steigemann P, Sys G, Takayama S, Tesei A, Tulkens J, Van Waeyenberge M, Vandesompele J, Wagemans G, Weindorfer C, Yigit N, Zablowsky N, Zanoni M, Blondeel P, De Wever O. MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity. *Nat Methods*. 2021 Nov;18(11):1294-1303. doi: 10.1038/s41592-021-01291-4. Epub 2021 Nov 1. PMID: 34725485; PMCID: PMC8566242.

**Zeev Rosberger**

1. Henry M, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, **et al**. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology*. 2022;31(2):185-97. Epub 2022/02/06. doi: 10.1002/pon.5803. PubMed PMID: 35122670.
2. Henry M, Sargi E, Frenkiel S, Hier M, Zeitouni A, Kost K, **et al**. Longitudinal study indicating antecedent psychosocial vulnerability as predictor of anxiety disorders post-treatment in people with head and neck cancer. *Psychooncology*. 2021;30(11):1910-9. Epub 2021/07/01. doi: 10.1002/pon.5760. PubMed PMID: 34190381.
3. Kruglova K, Gelgoot EN, Chan P, Lo K, **Rosberger Z**, Bélanger E, et al. Risky Business: Increasing Fertility Knowledge of Men in the General Public Using the Mobile Health Application Infertility XY. *Am J Mens Health*. 2021;15(5):15579883211049027. Epub 2021/10/27. doi: 10.1177/15579883211049027. PubMed PMID: 34697968; PubMed Central PMCID: PMC8552396.
4. McBride E, Tatar O, **Rosberger Z**, Rockliffe L, Marlow LAV, Moss-Morris R, et al. Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed method systematic review with meta-analysis. *Health Psychol Rev*. 2021;15(3):395-429. Epub 2020/05/26. doi: 10.1080/17437199.2020.1762106. PubMed PMID: 32449477.
5. O'Connell SBL, Gelgoot EN, Grunberg PH, Schinazi J, Da Costa D, Dennis CL, **et al**. 'I felt less alone knowing I could contribute to the forum': psychological distress and use of



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

an online infertility peer support forum. *Health Psychol Behav Med.* 2021;9(1):128-48. Epub 2021/06/10. doi: 10.1080/21642850.2021.1884556. PubMed PMID: 34104553; PubMed Central PMCID: PMC8158233.

6. Rodin D, Dare AJ, Booker R, Booth C, Bryant H, Ginsburg O, **et al.** Transforming Canada's role in global cancer control. *Lancet Oncol.* 2021;22(9):e400-e9. Epub 2021/09/04. doi: 10.1016/s1470-2045(21)00374-0. PubMed PMID: 34478676.

**April Rose**

1. Kelly D, **Rose AAN**, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. *Cancers (Basel).* 2021 Jul 20;13(14):3640. doi: 10.3390/cancers13143640. PMID: 34298857; PMCID: PMC8306971.
2. Muniz TP, Sorotsky H, Kanjanapan Y, **Rose AAN**, Araujo DV, Fortuna A, Ghazarian D, Kamil ZS, Pugh T, Mah M, Thiagarajah M, Torti D, Spreafico A, Hogg D. Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-Like Melanoma. *J Invest Dermatol.* 2021 Oct;141(10):2470-2479. doi: 10.1016/j.jid.2021.03.016. Epub 2021 Apr 6. PMID: 33831431.
3. **Rose AAN**, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. *J Immunother Cancer.* 2021 Jan;9(1):e001642. doi: 10.1136/jitc-2020-001642. PMID: 33483342; PMCID: PMC7831745.
4. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, **Rose AAN**, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schandendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. *J Immunother Cancer.* 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931. Erratum in: *J Immunother Cancer.* 2021 Oct;9(10): Erratum in: *J Immunother Cancer.* 2022 Mar;10(3): PMID: 33468556; PMCID: PMC7817383.
5. Nadler MB, **Rose AAN**, Prince R, Eng L, Lott A, Grant RC, Jones JM, Enright K. Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement Initiative. *JCO Oncol Pract.* 2021 Apr;17(4):e593-e602. doi: 10.1200/OP.20.00432. Epub 2020 Dec 8. PMID: 33290162.

**Nader Sadeghi**

1. Henry M, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, **et al.** Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology.* 2022;31(2):185-97. Epub 2022/02/06. doi: 10.1002/pon.5803. PubMed PMID: 35122670.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Henry M, Sargi E, Frenkiel S, Hier M, Zeitouni A, Kost K, **et al.** Longitudinal study indicating antecedent psychosocial vulnerability as predictor of anxiety disorders post-treatment in people with head and neck cancer. *Psychooncology*. 2021;30(11):1910-9. Epub 2021/07/01. doi: 10.1002/pon.5760. PubMed PMID: 34190381.
3. Hier J, Avior G, Pusztaszeri M, Krasner JR, Alyouha N, Forest VI, **et al.** Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review. *J Otolaryngol Head Neck Surg*. 2021;50(1):29. Epub 2021/04/30. doi: 10.1186/s40463-021-00500-6. PubMed PMID: 33910629; PubMed Central PMCID: PMCPCMC8082804.
4. Lee E, Gorelik D, Crowder HR, Badger C, Schottler J, Li NW, **et al.** Swallowing Function Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Carcinoma: A 2-Year Follow-up. *Otolaryngol Head Neck Surg*. 2021:1945998211057430. Epub 2021/11/10. doi: 10.1177/01945998211057430. PubMed PMID: 34752157.
5. Mascarella MA, Muthukrishnan N, Maleki F, Kergoat MJ, Richardson K, Mlynarek A, **et al.** Above and Beyond Age: Prediction of Major Postoperative Adverse Events in Head and Neck Surgery. *Ann Otol Rhinol Laryngol*. 2021:34894211041222. Epub 2021/08/22. doi: 10.1177/00034894211041222. PubMed PMID: 34416844.
6. Mianroodi AA, Mohtashami S, Romero N, Fuson A, Joshi A, **Sadeghi N.** Autologous Free Dermal-Fat-Fascial Graft for Parotidectomy Defects: A Case Series. *Ann Otol Rhinol Laryngol*. 2021;130(10):1171-80. Epub 2021/03/05. doi: 10.1177/0003489421999542. PubMed PMID: 33657862; PubMed Central PMCID: PMCPCMC8385583.
7. Mohtashami S, Richardson K, Forest VI, Mlynarek A, Payne RJ, Tamilya M, **et al.** Thyroidectomy for Graves' Disease Predicts Postoperative Neck Hematoma and Hypocalcemia: A North American cohort study. *Ann Otol Rhinol Laryngol*. 2022;131(4):341-51. Epub 2021/06/02. doi: 10.1177/00034894211021288. PubMed PMID: 34060342; PubMed Central PMCID: PMCPCMC8899812.

**Asma Saidi**

1. Rais F, Tsui JMG, Daianska A, Faye MD, Lambert C, David M, Panet-Raymond V, Azoulay M, **Saidi A**, Hijal T. Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. *Radiother Oncol*. 2021 Sep;162:156-161. doi: 10.1016/j.radonc.2021.07.008. Epub 2021 Jul 15. PMID: 34273468.

**Ramy Saleh**

1. Restuti RD, Priyono H, **Saleh RR**, Sriyana AA. Clinical and intraoperative findings for dangerous chronic suppurative otitis media in paediatric cases. *Pan Afr Med J*. 2021 Nov 21;40:174. doi: 10.11604/pamj.2021.40.174.22291. PMID: 35018207; PMCID: PMC8720231.
2. **Saleh RR**, Nadler MB, Desnoyers A, Meti N, Fazelzad R, Amir E. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. *Cancer Treat Rev*. 2021 Nov;100:102283. doi: 10.1016/j.ctrv.2021.102283. Epub 2021 Aug 28. PMID: 34530283.
3. Sternschuss M, Yerushalmi R, **Saleh RR**, Amir E, Goldvaser H. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. *J Cancer Res Clin Oncol*. 2021 Nov;147(11):3369-3379. doi: 10.1007/s00432-021-03591-w. Epub 2021 Mar 21. PMID: 33745080.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Monica Serban**

1. **Serban M**, Fokdal L, Nielsen SK, Hokland SB, Hansen AT, Spejlborg H, Rylander S, Petric P, Lindegaard JC, Tanderup K. Characterization of combined intracavitary/interstitial brachytherapy including oblique needles in locally advanced cervix cancer. *Brachytherapy*. 2021 Jul-Aug;20(4):796-806. doi: 10.1016/j.brachy.2021.03.019. Epub 2021 May 14. PMID: 33994344.
2. **Serban M**, de Leeuw AAC, Tanderup K, Jürgenliemk-Schulz IM. Vaginal dose-surface maps in cervical cancer brachytherapy: Methodology and preliminary results on correlation with morbidity. *Brachytherapy*. 2021 May-Jun;20(3):565-575. doi: 10.1016/j.brachy.2021.02.004. Epub 2021 Mar 17. PMID: 33741274.
3. Wang LM, Jung S, **Serban M**, Chatterjee A, Lee S, Jeyaseelan K, El Naqa I, Seuntjens J, Ybarra N. Comparison of quantitative and qualitative scoring approaches for radiation-induced pulmonary fibrosis as applied to a preliminary investigation into the efficacy of mesenchymal stem cell delivery methods in a rat model. *BJR Open*. 2021 Jul 5;2(1):20210006. doi: 10.1259/bjro.20210006. PMID: 34381940; PMCID: PMC8320116.
4. Heng VJ, **Serban M**, Seuntjens J, Renaud MA. Ion chamber and film-based quality assurance of mixed electron-photon radiation therapy. *Med Phys*. 2021 Sep;48(9):5382-5395. doi: 10.1002/mp.15081. Epub 2021 Jul 29. PMID: 34224144.

**Jan Seuntjens**

1. Aguilar M, Qian PC, Boeck M, Bredfeldt J, **Seuntjens J**, Hijal T, et al. The Rapidly-Developing Area of Radiocardiology: Principles, Complications and Applications of Radiotherapy on the Heart. *Can J Cardiol*. 2021;37(11):1818-27. Epub 2021/07/26. doi: 10.1016/j.cjca.2021.07.011. PubMed PMID: 34303782.
2. Ayala Alvarez DS, Watson PGF, Popovic M, Heng VJ, Evans MDC, **Seuntjens J**. Monte Carlo calculation of the TG-43 dosimetry parameters for the INTRABEAM source with spherical applicators. *Phys Med Biol*. 2021;66(21). Epub 2021/10/20. doi: 10.1088/1361-6560/ac309f. PubMed PMID: 34663769.
3. Chatterjee A, Vallières M, Forghani R, **Seuntjens J**. Investigating the impact of the CT Hounsfield unit range on radiomic feature stability using dual energy CT data. *Phys Med*. 2021;88:272-7. Epub 2021/07/31. doi: 10.1016/j.ejmp.2021.07.023. PubMed PMID: 34329921.
4. Côté B, Keszi F, Bancheri J, Sarfehnia A, **Seuntjens J**, Renaud J. Feasibility of operating a millimeter-scale graphite calorimeter for absolute dosimetry of small-field photon beams in the clinic. *Med Phys*. 2021;48(11):7476-92. Epub 2021/09/23. doi: 10.1002/mp.15244. PubMed PMID: 34549805.
5. Heng VJ, Serban M, **Seuntjens J**, Renaud MA. Ion chamber and film-based quality assurance of mixed electron-photon radiation therapy. *Med Phys*. 2021;48(9):5382-95. Epub 2021/07/06. doi: 10.1002/mp.15081. PubMed PMID: 34224144.
6. Mirzakhani L, Bassalow R, Zaks D, Huntzinger C, **Seuntjens J**. IAEA-AAPM TRS-483-based reference dosimetry of the new RefleXion biology-guided radiotherapy (BgRT) machine. *Med Phys*. 2021;48(4):1884-92. Epub 2020/12/10. doi: 10.1002/mp.14631. PubMed PMID: 33296515.
7. Morin O, Vallières M, Braunstein S, Ginart JB, Upadhaya T, Woodruff HC, **et al**. An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication. *Nat Cancer*.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 2021;2(7):709-22. Epub 2022/02/06. doi: 10.1038/s43018-021-00236-2. PubMed PMID: 35121948.
8. Patel PS, Vyravanathan S, Milne E, Bezjak A, Wouters BG, Bennewith K, **et al.** Strategic Training in Transdisciplinary Radiation Science for the 21st Century (STARS21): 15-Year Evaluation of an Innovative Research Training Program. *Int J Radiat Oncol Biol Phys.* 2021;110(3):656-66. Epub 2021/01/14. doi: 10.1016/j.ijrobp.2021.01.010. PubMed PMID: 33440225.
  9. Petti PL, Rivard MJ, Alvarez PE, Bednarz G, Daniel Bourland J, DeWerd LA, **et al.** Recommendations on the practice of calibration, dosimetry, and quality assurance for gamma stereotactic radiosurgery: Report of AAPM Task Group 178. *Med Phys.* 2021;48(7):e733-e70. Epub 2021/03/11. doi: 10.1002/mp.14831. PubMed PMID: 33690912.
  10. Wang LM, Jung S, Serban M, Chatterjee A, Lee S, Jeyaseelan K, **et al.** Comparison of quantitative and qualitative scoring approaches for radiation-induced pulmonary fibrosis as applied to a preliminary investigation into the efficacy of mesenchymal stem cell delivery methods in a rat model. *BJR Open.* 2021;2(1):20210006. Epub 2021/08/13. doi: 10.1259/bjro.20210006. PubMed PMID: 34381940; PubMed Central PMCID: PMC8320116.
  11. Watson PGF, Popovic M, Liang L, Tomic N, Devic S, **Seuntjens J.** Clinical Implication of Dosimetry Formalisms for Electronic Low-Energy Photon Intraoperative Radiation Therapy. *Pract Radiat Oncol.* 2021;11(1):e114-e21. Epub 2020/08/17. doi: 10.1016/j.prro.2020.07.005. PubMed PMID: 32795615.
  12. Yabsantia S, Suriyapee S, Phaisangittisakul N, Oonsiri S, Sanghangthum T, Mirzakhani L, **et al.** Determination of field output correction factors of radiophotoluminescence glass dosimeter and CC01 ionization chamber and validation against IAEA-AAPM TRS-483 code of practice. *Phys Med.* 2021;88:167-74. Epub 2021/07/20. doi: 10.1016/j.ejmp.2021.07.004. PubMed PMID: 34280729.

**George Shenouda**

1. Carsuzaa F, Lapeyre M, Gregoire V, Maingon P, Beddok A, Marcy PY, Salleron J, Coutte A, Racadot S, Pointreau Y, Graff P, Beadle B, Benezery K, Biau J, Calugaru V, Castelli J, Chua M, Di Rito A, Dore M, Ghadjar P, Huguet F, Jardel P, Johansen J, Kimple R, Kregli M, Laskar S, Mcdowell L, Nichols A, Tribius S, Valduvico I, Hu C, Liem X, Moya-Plana A, D'onofrio I, Parvathaneni U, Takiar V, Orlandi E, Psyrra A, **Shenouda G**, Sher D, Steuer C, Shan Sun X, Tao Y, Thomson D, Tsai MH, Vulquin N, Gorphe P, Mehanna H, Yom SS, Bourhis J, Thariat J. Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. *Radiother Oncol.* 2021 Jul;160:140-147. doi: 10.1016/j.radonc.2021.04.026. Epub 2021 May 11. PMID: 33984351.
2. Vakilian S, Thébaut J, Ruo R, Marcovitz S, Panet-Raymond V, **Shenouda G**, Sultanem K, Souhami L. Examination of the Dose-Effect Relationship of Radiation-Induced Hypopituitarism: Results of a Case-Control Study. *Adv Radiat Oncol.* 2021 Apr 15;6(4):100693. doi: 10.1016/j.adro.2021.100693. PMID: 34141955; PMCID: PMC8184512.
3. Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, **Shenouda G**,

## Gerald Bronfman Department of Oncology Annual Report 2021 Publications

Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M; NRG Oncology Group. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. *Oral Oncol.* 2021 May;116:105241. doi: 10.1016/j.oraloncology.2021.105241. Epub 2021 Feb 25. PMID: 33640577; PMCID: PMC8144062.

4. Kish JA, Zhang Q, Langer CJ, Nguyen-Tân PF, Rosenthal DI, Weber RS, List MA, Wong SJ, Garden AS, Hu K, Trotti AM, Bonner JA, Jones CU, Yom SS, Thorstad W, Schultz CJ, Ridge JA, **Shenouda G**, Harris J, Le QT. The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. *J Geriatr Oncol.* 2021 Jul;12(6):937-944. doi: 10.1016/j.jgo.2021.03.011. Epub 2021 Apr 2. PMID: 33814339; PMCID: PMC8829803.
5. Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, **Shenouda G**, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. *Head Neck.* 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 3. PMID: 34729846; PMCID: PMC8783635.

### Chaim Shustik

1. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, **Shustik C**, Kastiritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. *J Clin Oncol.* 2022 Jan 1;40(1):52-62. doi: 10.1200/JCO.21.00838. Epub 2021 Oct 4. PMID: 34606378; PMCID: PMC8683240.
2. Cornell RF, Baz R, Richter JR, Rossi A, Vogl DT, Chen C, **Shustik C**, Alvarez MJ, Shen Y, Unger TJ, Ben-Shahar O, Wang H, Baloglu E, Senapedis W, Ma X, Landesman Y, Bai X, Bader J, Xu H, Marshall T, Chang H, Walker CJ, Shah J, Shacham S, Kauffman MG, Hofmeister CC. A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. *Am J Hematol.* 2022 Feb 1;97(2):E54-E58. doi: 10.1002/ajh.26420. Epub 2021 Nov 30. PMID: 34817872.

### Shireen Sirhan

1. Nguyen E, Harnois M, Busque L, **Sirhan S**, Assouline S, Chamaki I, Olney H, Mollica L, Szuber N. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. *Blood Cancer J.* 2021 Apr 15;11(4):75. doi: 10.1038/s41408-021-00463-x. PMID: 33859172; PMCID: PMC8050282.
2. Simpson-Poirier K, Harnois M, Olney HJ, **Sirhan S**, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N. Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. *Am J Hematol.* 2021 Jun 1;96(6):E200-E203. doi: 10.1002/ajh.26159. Epub 2021 Mar 26. PMID: 33719144; PMCID: PMC8250202.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Sonia Skamene**

1. Shi DD, Balboni TA, Krishnan MS, Spektor A, Huynh MA, Shiloh RY, **Skamene S**, Zaslowski-Dude C, Hertan LM. Quantitative-qualitative analyses of patient-reported pain response after palliative radiation therapy. *Support Care Cancer*. 2021 Jul;29(7):3707-3714. doi: 10.1007/s00520-020-05887-y. Epub 2020 Nov 16. PMID: 33196866.
2. Naseri H, Kafi K, **Skamene S**, Tolba M, Faye MD, Ramia P, Khriouan J, Kildea J. Development of a generalizable natural language processing pipeline to extract physician-reported pain from clinical reports: Generated using publicly-available datasets and tested on institutional clinical reports for cancer patients with bone metastases. *J Biomed Inform*. 2021 Aug;120:103864. doi: 10.1016/j.jbi.2021.103864. Epub 2021 Jul 12. PMID: 34265451.
3. Wong SM, Ajjamada L, Weiss AC, Prakash I, **Skamene S**, Boileau JF, Pollak MN, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer*. 2022 Apr 1;128(7):1365-1372. doi: 10.1002/cncr.34065. Epub 2021 Dec 17. PMID: 34919263.

**Luis Souhami**

1. Almarzouq A, Kool R, Al Bulushi Y, Marcq G, **Souhami L**, Cury FL, et al. Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. *Urol Oncol*. 2021. Epub 2021/12/05. doi: 10.1016/j.urolonc.2021.11.002. PubMed PMID: 34862117.
2. Daro-Faye M, Kassouf W, **Souhami L**, Marcq G, Cury F, Niazi T, et al. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. *World J Urol*. 2021;39(5):1331-43. Epub 2020/09/12. doi: 10.1007/s00345-020-03440-4. PubMed PMID: 32915313; PubMed Central PMCID: PMC7484608.
3. Fortier V, Fortin MA, Pater P, **Souhami L**, Levesque IR. A role for magnetic susceptibility in synthetic computed tomography. *Phys Med*. 2021;85:137-46. Epub 2021/05/19. doi: 10.1016/j.ejmp.2021.05.001. PubMed PMID: 34004446.
4. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, **et al**. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. *Int J Radiat Oncol Biol Phys*. 2022;112(2):294-303. Epub 2021/09/05. doi: 10.1016/j.ijrobp.2021.08.031. PubMed PMID: 34481017; PubMed Central PMCID: PMC748315.
5. Kool R, Marcq G, El-Achkar A, Mansure JJ, Vanhuysse M, Aprikian A, **et al**. Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary? *Urol Oncol*. 2021;39(5):299.e7-.e14. Epub 2020/12/08. doi: 10.1016/j.urolonc.2020.10.001. PubMed PMID: 33283758.
6. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, Rajan R, **et al**. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci*. 2022;36:26-33. Epub 2022/02/01. doi: 10.1016/j.euros.2021.11.011. PubMed PMID: 35098169; PubMed Central PMCID: PMC783035.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

7. Marcq G, **Souhami L**, Cury FL, Salimi A, Aprikian A, Tanguay S, et al. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. *Int J Radiat Oncol Biol Phys.* 2021;110(3):738-41. Epub 2021/01/10. doi: 10.1016/j.ijrobp.2020.12.033. PubMed PMID: 33421558.
8. Marcq G, **Souhami L**, Kassouf W. In Reply to Khalifa and Sargos. *Int J Radiat Oncol Biol Phys.* 2021;110(3):917-8. Epub 2021/06/06. doi: 10.1016/j.ijrobp.2021.01.057. PubMed PMID: 34089689.
9. Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, **et al.** Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. *Eur J Cancer.* 2021;143:64-74. Epub 2020/12/07. doi: 10.1016/j.ejca.2020.10.023. PubMed PMID: 33279855.
10. Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, **et al.** Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. *Int J Radiat Oncol Biol Phys.* 2021;111(3):732-40. Epub 2021/04/27. doi: 10.1016/j.ijrobp.2021.04.013. PubMed PMID: 33901566.
11. Patrick HM, **Souhami L**, Kildea J. Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention. *Acta Oncol.* 2021;60(2):229-36. Epub 2020/09/30. doi: 10.1080/0284186x.2020.1825801. PubMed PMID: 32988249.
12. Vakilian S, Thébaut J, Ruo R, Marcovitz S, Panet-Raymond V, Shenouda G, **et al.** Examination of the Dose-Effect Relationship of Radiation-Induced Hypopituitarism: Results of a Case-Control Study. *Adv Radiat Oncol.* 2021;6(4):100693. Epub 2021/06/19. doi: 10.1016/j.adro.2021.100693. PubMed PMID: 34141955; PubMed Central PMCID: PMC8184512.
13. Vassilakopoulou M, Won M, Curran WJ, **Souhami L**, Prados MD, Langer CJ, et al. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. *Oncology.* 2021;99(9):580-8. Epub 2021/05/07. doi: 10.1159/000516168. PubMed PMID: 33957633; PubMed Central PMCID: PMC8491475.

**Alan Spatz**

1. Cheung CC, Smith AC, Albadine R, Bigras G, Bojarski A, Couture C, **et al.** Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. *Lung Cancer.* 2021;160:127-35. Epub 2021/09/12. doi: 10.1016/j.lungcan.2021.08.003. PubMed PMID: 34509095.
2. Ezer N, Wang H, Corredor AG, Fiset PO, Baig A, van Kempen LC, **et al.** Integrating NGS-derived mutational profiling in the diagnosis of multiple lung adenocarcinomas. *Cancer Treat Res Commun.* 2021;29:100484. Epub 2021/11/14. doi: 10.1016/j.ctarc.2021.100484. PubMed PMID: 34773797.
3. Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc A, Mohammed Y, **et al.** A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 $\alpha$  in cell lines and tumor tissues. *Analyst.* 2021;146(21):6566-75. Epub 2021/09/30. doi: 10.1039/d1an00165e. PubMed PMID: 34585690.
4. Ibrahim S, Lan C, Chabot C, Mitsa G, Buchanan M, Aguilar-Mahecha A, **et al.** Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- Controversy. *Anal Chem.* 2021;93(31):10816-24. Epub 2021/07/30. doi: 10.1021/acs.analchem.1c00975. PubMed PMID: 34324311.
5. Liu X, Maleki F, Muthukrishnan N, Ovens K, Huang SH, Pérez-Lara A, **et al.** Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. *Cancers (Basel).* 2021;13(15). Epub 2021/08/08. doi: 10.3390/cancers13153723. PubMed PMID: 34359623; PubMed Central PMCID: PMCPMC8345201.
  6. Oughton M, Brukner I, Eintracht S, Papadakis AI, **Spatz A**, Resendes A. Importance of Adequate qPCR Controls in Infection Control. *Diagnostics (Basel).* 2021;11(12). Epub 2021/12/25. doi: 10.3390/diagnostics11122373. PubMed PMID: 34943608; PubMed Central PMCID: PMCPMC8700483.

**Barry Stein**

1. Balvardi S, Pecorelli N, Castelino T, Niculiseanu P, Alhashemi M, Liberman AS, **et al.** Impact of Facilitation of Early Mobilization on Postoperative Pulmonary Outcomes After Colorectal Surgery: A Randomized Controlled Trial. *Ann Surg.* 2021;273(5):868-75. Epub 2020/04/24. doi: 10.1097/sla.0000000000003919. PubMed PMID: 32324693.
2. Eustache J, Latimer EA, Liberman S, Charlebois P, **Stein B**, Fiore JF, Jr., et al. A Mobile Phone App Improves Patient-Physician Communication And Reduces Emergency Department Visits After Colorectal Surgery. *Dis Colon Rectum.* 2021. Epub 2021/12/22. doi: 10.1097/dcr.0000000000002187. PubMed PMID: 34933314.
3. Lee L, Eustache J, Baldini G, Liberman AS, Charlebois P, **Stein B**, et al. Enhanced Recovery 2.0 - Same Day Discharge With Mobile App Follow-Up After Minimally Invasive Colorectal Surgery. *Ann Surg.* 2021. Epub 2021/06/07. doi: 10.1097/sla.0000000000004962. PubMed PMID: 34091514.
4. Lee L, Trepanier M, Renaud J, Liberman S, Charlebois P, **Stein B**, et al. Patients' preferences for sphincter preservation versus abdominoperineal resection for low rectal cancer. *Surgery.* 2021;169(3):623-8. Epub 2020/08/29. doi: 10.1016/j.surg.2020.07.020. PubMed PMID: 32854970.
5. Leung V, Baldini G, Liberman S, Charlebois P, **Stein B**, Fiore JF, Jr., et al. Trajectory of gastrointestinal function after laparoscopic colorectal surgery within an enhanced recovery pathway. *Surgery.* 2022;171(3):607-14. Epub 2021/12/01. doi: 10.1016/j.surg.2021.08.062. PubMed PMID: 34844751.

**Gabriela Stroian**

1. Gerard IJ, Bernier M, Hijal T, Kopek N, Pater P, Stosky J, **Stroian G**, Toscani B, Alfieri J. Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experiences. *Adv Radiat Oncol.* 2021 Apr 20;6(4):100702. doi: 10.1016/j.adro.2021.100702. PMID: 34095614; PMCID: PMC8165547.

**Shelly Sud**

1. Marginean EC, Gotfrit J, Marginean H, Yokom DW, Bateman JJ, Daneshmand M, **Sud S**, Gown AM, Jonker D, Asmis T, Goodwin RA. Phosphorylated transducer and activator of transcription-3 (pSTAT3) immunohistochemical expression in paired primary and metastatic colorectal cancer. *Transl Oncol.* 2021 Feb;14(2):100996. doi: 10.1016/j.tranon.2020.100996. Epub 2020 Dec 17. PMID: 33341488; PMCID: PMC7750168.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Khalil Sultanem**

1. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, **Sultanem K**, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Odell M, Parker C, Wehrli B, Kwan K, Palma DA. Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial. *J Clin Oncol*. 2022 Mar 10;40(8):866-875. doi: 10.1200/JCO.21.01961. Epub 2022 Jan 7. PMID: 34995124.

**Michael Thirlwell**

1. Gotfrit J, Goodwin R, Asmis T, Hyde AJ, Alcindor T, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, **Thirlwell M**, Valdes M, Welch S, Vickers M. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. *Curr Oncol*. 2021 May 26;28(3):1988-2006. doi: 10.3390/currenconcol28030185. PMID: 34073199; PMCID: PMC8161825.
2. Ganz PA, Cecchini RS, Fehrenbacher L, Geyer CE Jr, Rastogi P, Crown JP, **Thirlwell MP**, Ellison DM, Boileau JF, Flynn PJ, Jeong JH, Mamounas EP, Wolmark N. NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. *NPJ Breast Cancer*. 2021 May 20;7(1):55. doi: 10.1038/s41523-021-00264-2. PMID: 34016989; PMCID: PMC8137688.

**Steven Tisseverasinghe**

1. **Tisseverasinghe S**, Marbán M, Crook J, Petrik D, Araujo C. Comparison between postoperative TRUS-CT fusion with MRI-CT fusion for postimplant quality assurance in prostate LDR permanent seed brachytherapy. *Brachytherapy*. 2021 Jul-Aug;20(4):849-856. doi: 10.1016/j.brachy.2021.03.005. Epub 2021 Apr 16. PMID: 33867295.
2. Sabloff M, **Tisseverasinghe S**, Babadagli ME, Samant R. Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on? *Curr Oncol*. 2021 Feb 14;28(1):903-917. doi: 10.3390/currenconcol28010089. PMID: 33617507; PMCID: PMC7985756.

**Nada Tomic**

1. Watson PGF, Popovic M, Liang L, **Tomic N**, Devic S, Seuntjens J. Clinical Implication of Dosimetry Formalisms for Electronic Low-Energy Photon Intraoperative Radiation Therapy. *Pract Radiat Oncol*. 2021 Jan-Feb;11(1):e114-e121. doi: 10.1016/j.prr.2020.07.005. Epub 2020 Aug 11. PMID: 32795615.

**Ivan Topisirovic**

1. Ghaddar N, Wang S, Woodvine B, Krishnamoorthy J, van Hoef V, Darini C, **et al**. The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. *Nat Commun*. 2021;12(1):4651. Epub 2021/08/01. doi:

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 10.1038/s41467-021-24661-0. PubMed PMID: 34330898; PubMed Central PMCID: PMC8324901.
2. Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, **et al.** Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. *J Clin Invest.* 2021;131(8). Epub 2021/03/11. doi: 10.1172/jci140752. PubMed PMID: 33690225; PubMed Central PMCID: PMC8262472.
  3. Igelmann S, Lessard F, Uchenunu O, Bouchard J, Fernandez-Ruiz A, Rowell MC, **et al.** A hydride transfer complex reprograms NAD metabolism and bypasses senescence. *Mol Cell.* 2021;81(18):3848-65.e19. Epub 2021/09/22. doi: 10.1016/j.molcel.2021.08.028. PubMed PMID: 34547241.
  4. Jobava R, Mao Y, Guan BJ, Hu D, Krokowski D, Chen CW, **et al.** Adaptive translational pausing is a hallmark of the cellular response to severe environmental stress. *Mol Cell.* 2021;81(20):4191-208.e8. Epub 2021/10/24. doi: 10.1016/j.molcel.2021.09.029. PubMed PMID: 34686314; PubMed Central PMCID: PMC8559772.
  5. Kaspar S, Oertlin C, Szczepanowska K, Kukat A, Senft K, Lucas C, **et al.** Adaptation to mitochondrial stress requires CHOP-directed tuning of ISR. *Sci Adv.* 2021;7(22). Epub 2021/05/28. doi: 10.1126/sciadv.abf0971. PubMed PMID: 34039602; PubMed Central PMCID: PMC8153728.
  6. Kusnadi EP, Timpone C, **Topisirovic I**, Larsson O, Furic L. Regulation of gene expression via translational buffering. *Biochim Biophys Acta Mol Cell Res.* 2022;1869(1):119140. Epub 2021/10/03. doi: 10.1016/j.bbamcr.2021.119140. PubMed PMID: 34599983.
  7. Lee BJ, Boyer JA, Burnett GL, Thottumkara AP, Tibrewal N, Wilson SL, **et al.** Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. *Nat Chem Biol.* 2021;17(10):1065-74. Epub 2021/06/26. doi: 10.1038/s41589-021-00813-7. PubMed PMID: 34168367.
  8. Lee BJ, Boyer JA, Burnett GL, Thottumkara AP, Tibrewal N, Wilson SL, **et al.** Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. *Nat Chem Biol.* 2021;17(11):1209. Epub 2021/10/08. doi: 10.1038/s41589-021-00905-4. PubMed PMID: 34616097.
  9. Lee BJ, Boyer JA, Burnett GL, Thottumkara AP, Tibrewal N, Wilson SL, **et al.** Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. *Nat Chem Biol.* 2021;17(8):925. Epub 2021/07/01. doi: 10.1038/s41589-021-00843-1. PubMed PMID: 34188221.
  10. Lee LJ, Papadopoli D, Jewer M, Del Rincon S, **Topisirovic I**, Lawrence MG, et al. Cancer Plasticity: The Role of mRNA Translation. *Trends Cancer.* 2021;7(2):134-45. Epub 2020/10/18. doi: 10.1016/j.trecan.2020.09.005. PubMed PMID: 33067172; PubMed Central PMCID: PMC8023421.
  11. Papadopoli D, Pollak M, **Topisirovic I**. The role of GSK3 in metabolic pathway perturbations in cancer. *Biochim Biophys Acta Mol Cell Res.* 2021;1868(8):119059. Epub 2021/05/15. doi: 10.1016/j.bbamcr.2021.119059. PubMed PMID: 33989699.
  12. Papadopoli D, Uchenunu O, Palia R, Chekkal N, Hulea L, **Topisirovic I**, et al. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. *Neoplasia.* 2021;23(4):391-9. Epub 2021/03/31. doi: 10.1016/j.neo.2021.02.003. PubMed PMID: 33784591; PubMed Central PMCID: PMC8027095.
  13. Tan C, Ginzberg MB, Webster R, Iyengar S, Liu S, Papadopoli D, **et al.** Cell size homeostasis is maintained by CDK4-dependent activation of p38 MAPK. *Dev Cell.*

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2021;56(12):1756-69.e7. Epub 2021/05/23. doi: 10.1016/j.devcel.2021.04.030. PubMed PMID: 34022133.

14. Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, **et al.** STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. *Nat Commun.* 2021;12(1):3299. Epub 2021/06/05. doi: 10.1038/s41467-021-23396-2. PubMed PMID: 34083537; PubMed Central PMCID: PMC8175605.

**Anna Towers**

1. Shallwani SM, **Towers A**, Newman A, Salvador S, Yung A, Gilbert L, Gotlieb WH, Zeng X, Thomas D. Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema. *Curr Oncol.* 2021 Jan 13;28(1):455-470. doi: 10.3390/curroncol28010048. PMID: 33450972; PMCID: PMC7903266.

**Michel Tremblay**

1. Bell S, McCarty V, Peng H, Jefri M, Hettige N, Antonyan L, **et al.** Lesch-Nyhan disease causes impaired energy metabolism and reduced developmental potential in midbrain dopaminergic cells. *Stem Cell Reports.* 2021;16(7):1749-62. Epub 2021/07/03. doi: 10.1016/j.stemcr.2021.06.003. PubMed PMID: 34214487; PubMed Central PMCID: PMC8282463.
2. Marchelletta RR, Krishnan M, Spalinger MR, Placone TW, Alvarez R, Sayoc-Becerra A, **et al.** T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling. *J Clin Invest.* 2021;131(17). Epub 2021/10/09. doi: 10.1172/jci138230. PubMed PMID: 34623320; PubMed Central PMCID: PMC8409587.
3. Spalinger MR, Shawki A, Chatterjee P, Canale V, Santos A, Sayoc-Becerra A, **et al.** Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive *Escherichia coli* by integrating bacterial uptake and lysosomal defence. *Gut.* 2022;71(1):89-99. Epub 2021/02/11. doi: 10.1136/gutjnl-2020-323636. PubMed PMID: 33563644; PubMed Central PMCID: PMC8666829.
4. Vinette V, Aubry I, Insull H, Uetani N, Hardy S, **Tremblay ML.** Protein tyrosine phosphatome metabolic screen identifies TC-PTP as a positive regulator of cancer cell bioenergetics and mitochondrial dynamics. *Faseb j.* 2021;35(7):e21708. Epub 2021/06/26. doi: 10.1096/fj.202100207R. PubMed PMID: 34169549.
5. Zolotarov Y, Ma C, González-Recio I, Hardy S, Franken GAC, Uetani N, **et al.** ARL15 modulates magnesium homeostasis through N-glycosylation of CNNMs. *Cell Mol Life Sci.* 2021;78(13):5427-45. Epub 2021/06/06. doi: 10.1007/s00018-021-03832-8. PubMed PMID: 34089346; PubMed Central PMCID: PMC8257531.

**James Man Git Tsui**

1. Rais F, **Tsui JMG**, Daianska A, Faye MD, Lambert C, David M, Panet-Raymond V, Azoulay M, Saidi A, Hijal T. Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. *Radiother Oncol.* 2021 Sep;162:156-161. doi: 10.1016/j.radonc.2021.07.008. Epub 2021 Jul 15. PMID: 34273468.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Khriguian J, **Tsui JMG**, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M, Niazi T. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. *J Urol*. 2021 Jun;205(6):1648-1654. doi: 10.1097/JU.0000000000001646. Epub 2021 Feb 12. PMID: 33577365.
3. **Tsui J**, Qi S, Perrino S, Leibovitch M, Brodt P. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells. *Biomolecules*. 2021 Apr 1;11(4):527. doi: 10.3390/biom11040527. PMID: 33916323; PMCID: PMC8065809.

**Josie Ursini-Siegel**

1. Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, Ahn R, Lewis K, Lebeau B, La Selva R, Sabourin V, Martínez C, Savage P, Kuasne H, Avizonis D, Santos Martínez N, Chabot C, Aguilar-Mahecha A, Goulet ML, Dankner M, Witcher M, Petrecca K, Basik M, Pollak M, Topisirovic I, Lin R, Siegel PM, Kleinman CL, Park M, St-Pierre J, **Ursini-Siegel J**. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. *Nat Commun*. 2021 Jun 3;12(1):3299. doi: 10.1038/s41467-021-23396-2. PMID: 34083537; PMCID: PMC8175605.
2. Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, **Ursini-Siegel J**. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. *JCI Insight*. 2021 Feb 22;6(4):e138382. doi: 10.1172/jci.insight.138382. PMID: 33470989; PMCID: PMC7934920.
3. Ahn R, **Ursini-Siegel J**. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. *Int J Mol Sci*. 2021 Mar 5;22(5):2608. doi: 10.3390/ijms22052608. PMID: 33807608; PMCID: PMC7961781.
4. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, Djerir B, Chen X, Morin T, Lebeau B, Karam M, Bagci H, Grapton D, **Ursini-Siegel J**, Côté JF, Witcher M, Richard S, Maréchal A, Orthwein A. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep*. 2022 Jan 5;23(1):e51041. doi: 10.15252/embr.202051041. Epub 2021 Nov 10. PMID: 34758190; PMCID: PMC8728601.

**Tsafir Vanounou**

1. Benzaquen E, Wang Y, Wiseman S, Rosenfeld V, Sideris L, Dubé P, Pelletier JS, **Vanounou T**. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study. *Can J Surg*. 2021 Mar 2;64(2):E111-E118. doi: 10.1503/cjs.001619. PMID: 33651573; PMCID: PMC8064255.

**Carol-Ann Vasilevsky**

1. Abou-Khalil M, Garfinkle R, Alqahtani M, Morin N, **Vasilevsky CA**, Boutros M. Diverting loop ileostomy versus total abdominal colectomy for clostridioides difficile colitis: outcomes beyond the index admission. *Surg Endosc*. 2021;35(6):3147-53. Epub 2020/07/01. doi: 10.1007/s00464-020-07755-6. PubMed PMID: 32601762.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

2. Alnaki A, Garfinkle R, Almalki T, Pelsser V, Bonaffini P, Reinhold C, **et al.** Long-term Implications of Persistent Diverticulitis: A Retrospective Cohort Study of 915 Patients. *Dis Colon Rectum.* 2021;64(9):1112-9. Epub 2021/08/17. doi: 10.1097/dcr.0000000000001969. PubMed PMID: 34397559.
3. Brissette V, Alnaki A, Garfinkle R, Lloyd M, Demian M, **Vasilevsky CA**, et al. The quality, suitability, content and readability of online health-related information regarding sexual dysfunction after rectal cancer surgery. *Colorectal Dis.* 2021;23(2):376-83. Epub 2021/01/07. doi: 10.1111/codi.15514. PubMed PMID: 33404140.
4. Elkrief A, Redstone G, Petruccielli L, Ali A, Thomas D, Fernandez M, **et al.** Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. *BMJ Open Qual.* 2021;10(1). Epub 2021/03/10. doi: 10.1136/bmjopen-2020-000934. PubMed PMID: 33685857; PubMed Central PMCID: PMCPCMC7942255.
5. Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, **et al.** Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. *Radiother Oncol.* 2021;155:237-45. Epub 2020/11/22. doi: 10.1016/j.radonc.2020.11.008. PubMed PMID: 33220397.
6. Garfinkle R, Abou-Khalil M, Salama E, Marinescu D, Pang A, Morin N, **et al.** Development and Validation of a Clinical Risk Score for Intensive Care Resource Utilization After Colon Cancer Surgery: a Practical Guide to the Selection of Patients During COVID-19. *J Gastrointest Surg.* 2021;25(1):252-9. Epub 2020/06/05. doi: 10.1007/s11605-020-04665-9. PubMed PMID: 32495141; PubMed Central PMCID: PMCPCMC7269615.
7. Garfinkle R, Dell'Aniello S, Bhatnagar S, Morin N, Ghitulescu G, Faria J, **et al.** Assessment of long-term bowel dysfunction after restorative proctectomy for neoplastic disease: A population-based cohort study. *Surgery.* 2021. Epub 2021/12/02. doi: 10.1016/j.surg.2021.10.068. PubMed PMID: 34848073.
8. Garfinkle R, Ky A, Singh A, Morin N, Ghitulescu G, Faria J, **et al.** Financial and occupational impact of low anterior resection syndrome in rectal cancer survivors. *Colorectal Dis.* 2021;23(7):1777-84. Epub 2021/03/17. doi: 10.1111/codi.15633. PubMed PMID: 33724620.
9. Garfinkle R, Salama E, Amar-Zifkin A, Morin N, Ghitulescu G, Faria J, **et al.** Observational versus antibiotic therapy for acute uncomplicated diverticulitis: A non-inferiority meta-analysis based on a Delphi consensus. *Surgery.* 2022;171(2):328-35. Epub 2021/08/05. doi: 10.1016/j.surg.2021.07.012. PubMed PMID: 34344525.
10. Moon J, Monton O, Smith A, Garfinkle R, Zhao K, Zelkowitz P, **et al.** Interactive online informational and peer support application for patients with low anterior resection syndrome: patient survey and protocol for a multicentre randomized controlled trial. *Colorectal Dis.* 2021;23(5):1248-57. Epub 2021/02/28. doi: 10.1111/codi.15602. PubMed PMID: 33638278.
11. Pang AJ, Harra Z, Chen L, Morin NA, Faria JJ, Ghitulescu GA, **et al.** Understanding the Burden of Colorectal Adenomas in Patients Younger Than 50 Years of Age: A Large Single-Center Retrospective Cohort Study. *Dis Colon Rectum.* 2021. Epub 2021/12/14. doi: 10.1097/dcr.0000000000002069. PubMed PMID: 34897208.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

**Antonio Vigano**

1. Sevryugin O, Kasvis P, Vigano M, **Vigano A**. Taste and smell disturbances in cancer patients: a scoping review of available treatments. *Support Care Cancer*. 2021 Jan;29(1):49-66. doi: 10.1007/s00520-020-05609-4. Epub 2020 Jul 30. PMID: 32734392.
2. Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, Cyr C, Eisenberg E, de Oliveira Silva RF, Frohlich E, Georgius P, Hogg M, Horsted TI, MacCallum CA, Müller-Vahl KR, O'Connell C, Sealey R, Seibolt M, Sihota A, Smith BK, Sulak D, **Vigano A**, Moulin DE. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. *J Cannabis Res*. 2021 Jul 2;3(1):22. doi: 10.1186/s42238-021-00073-1. PMID: 34215346; PMCID: PMC8252988.

**Té Vuong**

1. Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, **et al**. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. *Radiother Oncol*. 2021;155:237-45. Epub 2020/11/22. doi: 10.1016/j.radonc.2020.11.008. PubMed PMID: 33220397.
2. Lecavalier-Barsoum M, Khosrow-Khavar F, Asiev K, Popovic M, **Vuong T**, Enger SA. Utilization of brachytherapy in Quebec, Canada. *Brachytherapy*. 2021;20(6):1282-8. Epub 2021/08/24. doi: 10.1016/j.brachy.2021.07.002. PubMed PMID: 34420860.
3. Nguyen NP, Baumert BG, Oboite E, Motta M, Appalanaido GK, Arenas M, **et al**. Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group. *Gerontology*. 2021;67(4):379-85. Epub 2021/03/31. doi: 10.1159/000514451. PubMed PMID: 33784693; PubMed Central PMCID: PMC8089416.
4. Sargos P, Faye MD, Bacci M, Supiot S, Latorzeff I, Azria D, **et al**. Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review. *Front Oncol*. 2021;11:666962. Epub 2021/07/06. doi: 10.3389/fonc.2021.666962. PubMed PMID: 34221983; PubMed Central PMCID: PMC8242201.
5. Stewart AJ, Van Limbergen EJ, Gerard JP, Appelt AL, Verhaegen F, Berbee M, **et al**. GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. *Clin Transl Radiat Oncol*. 2022;33:15-22. Epub 2022/03/05. doi: 10.1016/j.ctro.2021.12.004. PubMed PMID: 35243017; PubMed Central PMCID: PMC8885383.

**Michael Witcher**

1. Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, **et al**. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. *JCI Insight*. 2021;6(4). Epub 2021/01/21. doi: 10.1172/jci.insight.138382. PubMed PMID: 33470989; PubMed Central PMCID: PMC807934920.
2. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, **et al**. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep*. 2022;23(1):e51041. Epub 2021/11/11. doi: 10.15252/embr.202051041. PubMed PMID: 34758190; PubMed Central PMCID: PMC8728601.
3. Shorstova T, Foulkes WD, **Witcher M**. Achieving clinical success with BET inhibitors as anti-cancer agents. *Br J Cancer*. 2021;124(9):1478-90. Epub 2021/03/17. doi:

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

- 10.1038/s41416-021-01321-0. PubMed PMID: 33723398; PubMed Central PMCID: PMC8076232.
4. Shorstova T, Su J, Zhao T, Dahabieh M, Leibovitch M, De Sa Tavares Russo M, **et al.** Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. *Mol Cancer Ther.* 2021;20(1):64-75. Epub 2020/10/23. doi: 10.1158/1535-7163.Mct-20-0259. PubMed PMID: 33087508.
  5. Tawil N, Bassawon R, Meehan B, Nehme A, Montermini L, Gayden T, **et al.** Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. *Blood Adv.* 2021;5(6):1682-94. Epub 2021/03/16. doi: 10.1182/bloodadvances.2020002998. PubMed PMID: 33720339; PubMed Central PMCID: PMC87993100 interests.
  6. Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, **et al.** STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. *Nat Commun.* 2021;12(1):3299. Epub 2021/06/05. doi: 10.1038/s41467-021-23396-2. PubMed PMID: 34083537; PubMed Central PMCID: PMC8175605.

**Stephanie Wong**

1. Di Lena É, Hopkins B, **Wong SM**, Meterissian S. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study. *Surgery.* 2022;171(3):666-72. Epub 2021/12/05. doi: 10.1016/j.surg.2021.10.033. PubMed PMID: 34862071; PubMed Central PMCID: PMC8531248.
2. Jimenez RB, **Wong SM**, Johnson A, Lalani N, Hughes KS. The Association Between Cardiac Mortality and Adjuvant Radiation Therapy Among Older Patients With Stage I Estrogen Positive Breast Cancer: A Surveillance, Epidemiology, and End Results (SEER)-Based Study on Cardiac Mortality and Radiation Therapy. *Adv Radiat Oncol.* 2021;6(2):100633. Epub 2021/04/30. doi: 10.1016/j.adro.2020.100633. PubMed PMID: 33912735; PubMed Central PMCID: PMC8071719.
3. Suissa M, Yin H, Yu OHY, **Wong SM**, Azoulay L. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes. *Diabetes Care.* 2021;44(1):e9-e11. Epub 2020/11/08. doi: 10.2337/dc20-1073. PubMed PMID: 33158946.
4. Tejera D, Rana M, Basik M, Boileau JF, Margolese R, Prakash I, **et al.** Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat.* 2021;190(3):491-501. Epub 2021/09/21. doi: 10.1007/s10549-021-06393-3. PubMed PMID: 34542772.
5. **Wong SM**, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, **et al.** Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer.* 2022;128(7):1365-72. Epub 2021/12/18. doi: 10.1002/cncr.34065. PubMed PMID: 34919263.
6. **Wong SM**, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, **et al.** Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol.* 2021;28(5):2621-9. Epub 2020/10/24. doi: 10.1245/s10434-020-09211-0. PubMed PMID: 33095362.

**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

7. **Wong SM**, Boileau JF. ASO Author Reflections: Low Rates of Axillary Recurrence in Clinically Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Alone Following Pathologic Response to Neoadjuvant Chemotherapy. *Ann Surg Oncol.* 2021;28(5):2630-1. Epub 2020/10/31. doi: 10.1245/s10434-020-09259-y. PubMed PMID: 33123855.

**Norma Ybarra**

1. Wang LM, Jung S, Serban M, Chatterjee A, Lee S, Jeyaseelan K, El Naqa I, Seuntjens J, **Ybarra N**. Comparison of quantitative and qualitative scoring approaches for radiation-induced pulmonary fibrosis as applied to a preliminary investigation into the efficacy of mesenchymal stem cell delivery methods in a rat model. *BJR Open.* 2021 Jul 5;2(1):20210006. doi: 10.1259/bjro.20210006. PMID: 34381940; PMCID: PMC8320116.

**George Zogopoulos**

1. Chen YI, Chatterjee A, Berger R, Kanber Y, Wyse J, Lam E, **et al**. Endoscopic ultrasound (EUS)-guided fine needle biopsy alone vs. EUS-guided fine needle aspiration with rapid onsite evaluation in pancreatic lesions: a multicenter randomized trial. *Endoscopy.* 2022;54(1):4-12. Epub 2021/01/29. doi: 10.1055/a-1375-9775. PubMed PMID: 33506455.
2. Golan T, O'Kane GM, Denroche RE, Raitises-Gurevich M, Grant RC, Holter S, **et al**. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. *Gastroenterology.* 2021;160(6):2119-32.e9. Epub 2021/02/02. doi: 10.1053/j.gastro.2021.01.220. PubMed PMID: 33524400.
3. Gonda TA, Everett JN, Wallace M, Simeone DM. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium. *Gastroenterology.* 2021;161(6):1751-7. Epub 2021/08/30. doi: 10.1053/j.gastro.2021.08.036. PubMed PMID: 34454916.
4. Gonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, **et al**. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. *Gastrointest Endosc.* 2022;95(4):723-32.e7. Epub 2021/11/06. doi: 10.1016/j.gie.2021.10.025. PubMed PMID: 34736932.
5. Grant RC, Denroche R, Jang GH, Nowak KM, Zhang A, Borgida A, **et al**. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. *Gut.* 2021;70(10):1894-903. Epub 2020/09/17. doi: 10.1136/gutjnl-2020-320730. PubMed PMID: 32933947.
6. Hsu FC, Roberts NJ, Childs E, Porter N, Rabe KG, Borgida A, **et al**. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. *JAMA Oncol.* 2021;7(11):1664-8. Epub 2021/09/17. doi: 10.1001/jamaoncol.2021.3701. PubMed PMID: 34529012; PubMed Central PMCID: PMC8446906 patent for GNAS, the technology used in this study, which is licensed under an agreement between Thrive Earlier Detection (a subsidiary of Exact Sciences Corporation) and Johns Hopkins University. Dr Syngal reported a patent for PREMM model licensed to Myriad Genetics during the conduct of the study. Dr Klein reported consulting fees from Merck outside the submitted work. No other disclosures were reported.
7. Meti N, Kelly D, Allen MJ, Lanys A, Fazelzad R, Ramjeesingh R, **et al**. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. *Cancer Treat Rev.* 2021;101:102310. Epub 2021/11/11. doi: 10.1016/j.ctrv.2021.102310. PubMed PMID: 34757307.



**Gerald Bronfman Department of Oncology Annual Report 2021  
Publications**

8. Wang Y, Cuggia A, Pacis A, Boileau JC, Marcus VA, Gao ZH, **et al.** Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale. *J Natl Compr Canc Netw.* 2021;19(8):883-7. Epub 2021/08/21. doi: 10.6004/jnccn.2021.7049. PubMed PMID: 34416708.
9. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, **et al.** Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet.* 2021. Epub 2021/09/25. doi: 10.1136/jmedgenet-2021-108054. PubMed PMID: 34556502.
10. Zhang H, Corredor ALG, Messina-Pacheco J, Li Q, **Zogopoulos G**, Kaddour N, et al. REG3A/REG3B promotes acinar to ductal metaplasia through binding to EXTL3 and activating the RAS-RAF-MEK-ERK signaling pathway. *Commun Biol.* 2021;4(1):688. Epub 2021/06/09. doi: 10.1038/s42003-021-02193-z. PubMed PMID: 34099862; PubMed Central PMCID: PMC8184755.